













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 






Identifying and overcoming mechanisms of 
resistance to Wee1 kinase inhibitor (AZD1775) in 
high grade serous ovarian cancer 
 
 





Thesis presented for the degree of  
Doctor of Philosophy.  






I declare that this thesis is an original report of my research, has been written by me 
and has not been submitted for any previous degree. The experimental work is my own 
work, except where clearly stated. The collaborative work is indicated and 
acknowledged. The experiments were designed under the supervision of Professor 










Undertaking this Ph.D has been a life-changing experience for me and would not have 
been possible without the support and guidance of Professor David W. Melton. I would 
also like to thank Professor Charlie Gourley for his continuous support. Without either 
the project would not have been completed.  
In addition, I would like to extend my gratitude to my sponsors University of 
Edinburgh, UK (Edinburgh Global Research Scholarship and Principal’s Career 
Development Award) and National University of Sciences and Technology, Pakistan 
(Faculty Development Program) for funding my studies.  
I would also like to thank Dr. Mark J. O’Connor (Chief Scientist Oncology, Head of 
DNA Damage Response Biology, AstraZeneca) for his assistance. I am thankful to 
Drs. Anderson Wang and Elisabetta Leo and their teams at AstraZeneca for their help 
with the project.  
I am thankful to Drs. John P. Thomson and Graeme Grimes, Technical Services (HGU) 
and everyone at ECRC level 3 for their assistance, support and feedback. Lastly, I 
would like to say a special thanks to all members of Gourley lab, especially, Anne-
Marie, Barbara, Jess, Laura, Michael and Robb.  
I would not be here without my constants: my parents, my sister Michelle and my 
friends, particularly, Amna, Fahd, Nida, Rabia and Zehra who have kept me sane.  
I’d like to put here some words by Sir Muhammad Iqbal to describe my Ph.D. journey,  
 
Other worlds exist beyond the stars, more tests of love (passion) are yet to come 







Dedicated to everyone battling cancer. 
Table of contents                                                                                                                                v 
 
Table of Contents 
Declaration.............................................................................................................................. ii 
Acknowledgements ............................................................................................................... iii 
Table of Contents ................................................................................................................... v 
List of Figures ......................................................................................................................... x 
List of Tables ....................................................................................................................... xiii 
List of Appendices ............................................................................................................... xiv 
List of Abbreviations ........................................................................................................... xv 
Abstract ................................................................................................................................... 1 
Lay Summary ......................................................................................................................... 4 
Chapter 1 Introduction .......................................................................................................... 6 
1.1. Ovarian cancer .............................................................................................................. 6 
1.1.1. Types of ovarian cancer ......................................................................................... 6 
1.1.1. The epidemiology and risk factors of ovarian cancer ............................................ 6 
1.1.2. Grading and staging of ovarian cancer................................................................... 8 
1.1.3. Subtypes of epithelial ovarian cancer .................................................................... 9 
1.1.4. Molecular pathogenesis of epithelial ovarian cancer ........................................... 10 
1.2. High grade serous ovarian cancer ............................................................................... 11 
1.2.1. Molecular biology of high grade serous ovarian cancer ...................................... 11 
1.3. DNA damage repair pathways .................................................................................... 13 
1.4. Homologous recombination repair .............................................................................. 15 
1.4.1. Risks associated with mutations of HR pathway genes ....................................... 18 
1.5. Ovarian cancer treatment ............................................................................................ 19 
1.5.1. Surgical management of ovarian cancer .............................................................. 20 
1.5.2. Chemotherapy in ovarian cancer .......................................................................... 20 
1.5.2.1. Use of platinum agents .................................................................................. 21 
1.5.2.2. Use of Taxanes .............................................................................................. 22 
1.5.2.3. Combination therapy ..................................................................................... 23 
1.5.2.4. PARP inhibition ............................................................................................ 23 
1.6. Chemoresistance in ovarian cancer ............................................................................. 26 
1.6.1. Mechanisms of ovarian cancer chemoresistance ................................................. 26 
1.6.2. Resistance to current chemotherapies .................................................................. 26 
1.6.2.1. Platinum resistance ....................................................................................... 27 
1.6.2.2. PARP inhibitor resistance ............................................................................. 29 
Table of contents                                                                                                                                vi 
 
1.7. Targeting Wee1 kinase ............................................................................................... 33 
1.7.1. Cell cycle and DNA damage and repair checkpoints ........................................... 33 
1.7.2. Cell cycle control by Wee1 kinase ....................................................................... 34 
1.7.3. Wee1 kinase inhibition......................................................................................... 36 
1.7.4. Selectivity of Wee1 kinase inhibition .................................................................. 38 
1.7.5. Preclinical studies with Wee1 kinase inhibitor .................................................... 39 
1.7.6. Clinical studies with Wee1 inhibitor .................................................................... 41 
1.7.7. Other targets for G2-checkpoint abrogation ........................................................ 41 
1.8. Kinase inhibitor resistance .......................................................................................... 43 
1.8.1. Mechanisms of kinase inhibitor resistance .......................................................... 43 
1.8.2. Overcoming kinase inhibitor resistance ............................................................... 44 
1.9. Aims of thesis ............................................................................................................. 46 
Chapter 2 Materials and Methods ...................................................................................... 49 
2.1. Materials ..................................................................................................................... 49 
2.1.1. General Chemicals ............................................................................................... 49 
2.1.2. Drugs used and their concentrations .................................................................... 50 
2.1.3. Mammalian Cell Culture ...................................................................................... 50 
2.1.4. Cell Lines ............................................................................................................. 51 
2.1.5. Western Blotting .................................................................................................. 52 
2.1.5.1. Antibodies Used ............................................................................................ 53 
2.1.6. Kinase Activity Assay .......................................................................................... 54 
2.1.7. Drug Sensitivity Assays ....................................................................................... 54 
2.1.7.1. Growth Assay ................................................................................................ 54 
2.1.7.2. Viability Assay .............................................................................................. 55 
2.1.8. Propidium Iodide FACS Assay ............................................................................ 55 
2.1.9. DNA Extraction ................................................................................................... 55 
2.1.10. RNA Extraction.................................................................................................. 55 
2.1.11. Polymerase Chain Reaction ............................................................................... 56 
2.1.11.1. Primer Information ...................................................................................... 56 
2.1.12. RNA Sequencing................................................................................................ 57 
2.2. Methods....................................................................................................................... 58 
2.2.1. Mammalian Cell Culture ...................................................................................... 58 
2.2.1.1. Culturing ....................................................................................................... 58 
2.2.1.2. Cryopreservation of Cell Lines ..................................................................... 58 
2.2.1.3. Counting Cells .............................................................................................. 59 
Table of contents                                                                                                                                vii 
 
2.2.2. Drug Sensitivity Assays ....................................................................................... 59 
2.2.2.1. Growth Assay ................................................................................................ 59 
2.2.2.2. Viability Assay .............................................................................................. 60 
2.2.2.3. Calculation of IC50 values ............................................................................. 61 
2.2.3. Protein Assays ...................................................................................................... 61 
2.2.3.1. Western Blotting ........................................................................................... 61 
2.2.3.1.1. Preparation of Whole Cell Lysate from Cultured Cells ......................... 61 
2.2.3.1.2. Determination of Protein Concentration ................................................ 62 
2.2.3.1.3. Preparation of Samples for Loading into Gels ....................................... 62 
2.2.3.1.4. Transfer and Detection of Proteins ........................................................ 63 
2.2.3.2. Kinase Activity Assay ................................................................................... 63 
2.2.3.2.1. Preparation of Whole Cell Lysates ........................................................ 63 
2.2.3.2.2. Processing Reactions on Pamstation ...................................................... 64 
2.2.3.2.3. Differential Kinase Activity Analysis .................................................... 64 
2.2.4. Cell cycle FACS Assay ........................................................................................ 65 
2.2.5. DNA Analysis ...................................................................................................... 66 
2.2.5.1. DNA Extraction ............................................................................................ 66 
2.2.5.2. Polymerase Chain Reaction .......................................................................... 67 
2.2.5.3. Sanger DNA sequencing ............................................................................... 69 
2.2.5.4. Sequence analysis ......................................................................................... 70 
2.2.6. RNA Analysis ...................................................................................................... 70 
2.2.6.1. RNA Extraction............................................................................................. 70 
2.2.6.2. Quality control for RNA isolation................................................................. 72 
2.2.6.3. RNA Sequencing........................................................................................... 72 
2.2.6.3.1. Library Preparation ................................................................................ 73 
2.2.6.3.2. Library QC ............................................................................................. 74 
2.2.6.3.3. Sequencing ............................................................................................. 74 
2.2.6.3.4. Data Analysis ......................................................................................... 75 
2.2.6.3.5. QC for RNASeq data ............................................................................. 75 
Chapter 3 Analysis of High Grade Serous Cell lines for Sensitivity to Different Agents
 ............................................................................................................................................... 78 
3.1. Introduction ................................................................................................................. 78 
3.2. Selection of HGSOC cell line panel ........................................................................... 78 
3.3. Molecular characterisation of HGSOC cell lines ........................................................ 80 
3.4. Single agent treatment ................................................................................................. 83 
Table of contents                                                                                                                                viii 
 
3.5. Changes in sensitivity to DNA damaging agents in combination with AZD1775 ..... 86 
3.5.1. Cisplatin-AZD1775 combination treatment ......................................................... 86 
3.5.2. Olaparib-AZD1775 combination treatment ......................................................... 95 
3.6. Discussion ................................................................................................................. 102 
Chapter 4 Isolation and Characterisation of Resistant Clones ...................................... 106 
4.1. Introduction ............................................................................................................... 106 
4.2. Selection of resistant clones ...................................................................................... 106 
4.2.1. Generation of AZD1775 resistant clones from HR proficient and deficient cell 
lines .............................................................................................................................. 107 
4.2.2. Generation of olaparib resistant clones from HR proficient and deficient cell lines
 ..................................................................................................................................... 111 
4.3. Confirmation of resistance ........................................................................................ 113 
4.3.1. AZD1775 resistant clones .................................................................................. 113 
4.3.2. Olaparib resistant clones .................................................................................... 117 
4.4 Olaparib resistant clones remain sensitive to AZD1775 ............................................ 119 
4.5. Cell cycle analysis of AZD1775 resistant clones ...................................................... 121 
4.6. AZD1775 resistant clones have slower growth rates than their parents ................... 129 
4.7. Wee1 kinase gene mutation is not responsible for AZD1775 resistance in ES-2 and 
OVCAR8 ......................................................................................................................... 130 
4.8. Discussion ................................................................................................................. 133 
Chapter 5 Identification of Protein Expression Changes in Resistant Clones ............. 139 
5.1. Introduction ............................................................................................................... 139 
5.2. The resistance mechanism to AZD1775 in HGSOC is different to that found in SCLC
 ......................................................................................................................................... 140 
5.3. Reduced levels of total Cdk1 in ES-2 resistant clones .............................................. 142 
5.4. Changes in Wee1 and PKMYT1 kinase and Cdk1 phosphorylation levels .............. 145 
5.5. Target engagement by AZD1775 .............................................................................. 146 
5.6. Alterations in Cdc25C expression ............................................................................. 148 
5.7. Altered DNA damage response in AZD1775 resistant clones .................................. 149 
5.8. Other cell cycle alterations on treatment with AZD1775 ......................................... 152 
5.9. MDR1 overexpression not found in AZD1775- resistant clones .............................. 154 
5.10. Alterations in the kinome ........................................................................................ 155 
5.11. Changes in olaparib resistant clones ....................................................................... 161 
5.12. Discussion ............................................................................................................... 166 
Chapter 6 Changes in the Transcriptome of AZD1775 Resistant Clones ..................... 173 
6.1. Introduction ............................................................................................................... 173 
Table of contents                                                                                                                                ix 
 
6.2. RNASeq experiment ................................................................................................. 173 
6.3. Preliminary analysis of altered gene expression in resistant clones.......................... 174 
6.4. Altered expression of cell cycle and related pathway genes in resistant clones ....... 176 
6.5. Detailed analysis of altered cell cycle gene expression in resistant clones ............... 180 
6.6. Additional gene expression changes in AZD1775 resistant clones .......................... 189 
6.7. Comparison of kinome analysis and RNASeq data .................................................. 194 
6.8. Overcoming resistance to AZD1775 ......................................................................... 195 
6.9. Discussion ................................................................................................................. 198 
Chapter 7 Conclusion ........................................................................................................ 204 
7.1. HGSOC cell line responses to different chemotherapeutic agents ........................... 204 
7.2. Resistance in HGSOC ............................................................................................... 204 
7.3. Mechanisms of resistance ......................................................................................... 205 
7.3.1. Olaparib resistance ............................................................................................. 205 
7.3.2. AZD1775 resistance ........................................................................................... 206 
7.3.2.1. Changes in the AZD1775 targeted pathways .............................................. 206 
7.3.2.2. Wee1 kinase ................................................................................................ 206 
7.3.2.3. PKMYT1 ..................................................................................................... 207 
7.3.2.4. Cdk1 ............................................................................................................ 208 
7.3.2.5. Cdc25 .......................................................................................................... 209 
7.3.2.6. Cdc14A ....................................................................................................... 210 
7.3.2.7. Drug pumps ................................................................................................. 211 
7.3.3. A reduced growth rate is an important component of AZD1775 resistance ...... 211 
7.3.4. Involvement in resistance of changes in other pathways ................................... 213 
7.3.4.1. Src family member Lyn .............................................................................. 213 
7.3.4.2. Expression of many genes is altered in resistant clones .............................. 213 
7.3.5 AZD1775 resistance summary ............................................................................ 214 
7.4. Overcoming resistance to AZD1775 ......................................................................... 216 
7.5. Limitations of the project .......................................................................................... 216 
7.6. Future prospects ........................................................................................................ 217 
References ........................................................................................................................... 219 
Appendix ............................................................................................................................. 250 
List of Figures                                                                                                                        x 
 
List of Figures 
Figure 1.1: Molecular changes in HGSOC…………………………………………………...13 
Figure 1.2: Summary of DNA damage repair pathways……………………………………..15 
Figure 1.3: Homologous recombination repair………………………………………………17 
Figure 1.4: Mechanism of action of Taxane…………………………………………………22 
Figure 1.5: BRCA1/BRCA2 deficiency and inhibition of PARP leads to synthetic lethality...25 
Figure 1.6: Role of Wee1 kinase in the cell cycle……………………………………………35 
Figure 1.7: Wee1 kinase inhibition at different phases of the cell cycle……………………..38 
Figure 1.8: Chemical structure of AZD1775…………………………………………………39 
Figure 1.9. Possible mechanisms of resistance to AZD1775 in HGSOC…………………….48 
Figure 3.1: Drug sensitivity profiles for the cell line panel treated with (A) AZD1775, (B) 
cisplatin and (C) olaparib…………………………………………………………………….85 
Figure 3.2: Growth curves showing the ability of AZD1775 to enhance sensitivity to 
cisplatin……………………………………………………………………………………...91 
Figure 3.3: Viability curves showing the ability of AZD1775 to enhance sensitivity to 
cisplatin……………………………………………………………………………………...94 
Figure 3.4: Growth curves showing the ability of AZD1775 to enhance sensitivity to 
olaparib………………………………………………………………………………………98 
Figure 3.5: Viability curves showing the ability of AZD1775 to enhance sensitivity to 
olaparib……………………………………………………………………………………..101 
Figure 4.1: Hierarchy of AZD1775 resistant ES-2 clones………………………………….109 
Figure 4.2: Isolation of cisplatin-AZD1775 resistant ES-2 clones………………………….109 
Figure 4.3: Isolation of AZD1775 resistant OVCAR8 clones……………………………....111 
Figure 4.4: Isolation of olaparib resistant ES-2 clones……………………………………...112 
Figure 4.5: Isolation of olaparib resistant OVCAR8 clones………………………………..112 
Figure 4.6: Growth curves showing decreased sensitivity of AZD1775 resistant ES-2 clones 
to AZD1775 treatment……………………………………………………………………...115 
Figure 4.7: Growth curves showing decreased sensitivity of cisplatin – AZD1775 resistant ES-
2 clones to cisplatin…………………………………………………………………………116 
Figure 4.8: Growth curves showing decreased sensitivity of AZD1775 resistant OVCAR8 
clones to AZD1775…………………………………………………………………………116 
Figure 4.9: Decreased sensitivity of olaparib resistant ES-2 clones to olaparib……………118 
List of Figures                                                                                                                        xi 
 
Figure 4.10: Growth curves showing decreased sensitivity of olaparib resistant OVCAR8 
clones to olaparib…………………………………………………………………………...119 
Figure 4.11: Growth curves showing that olaparib resistant ES-2 clones remain sensitive to 
AZD1775..………………………………………………………………………………….120 
Figure 4.12: Growth curves showing that olaparib resistant OVCAR8 clones remain sensitive 
to AZD1775………………………………………………………………………………...120 
Figure 4.13: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 1000nM 
AZD1775…………………………………………………………………………………...122 
Figure 4.14: Cell cycle analysis by flow cytometry after 24 hour treatment of ES-2 clones 
resistant to 800nM CDDP and 100nM AZD1775………………………………………….124 
Figure 4.15: Cell cycle analysis by flow cytometry after 72 hour treatment of ES-2 clones 
resistant to 800nM CDDP and 100nM AZD1775…………………………………………..125 
Figure 4.16: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 250nM 
AZD1775…………………………………………………………………………………...127 
Figure 4.17: Cell cycle analysis by flow cytometry of OVCAR8 clones resistant to 300nM 
AZD1775…………………………………………………………………………………...128 
Figure 4.18: Diagrammatic representation of Wee1 kinase gene, PCR amplicons used for 
sequencing and a mutation found in some AZD1775 resistant ES-2 clones……………….132 
Figure 5.1: Resistance to AZD1775 in HGSOC is not caused by upregulation of AXL 
signalling as seen in SCLC………………………………………………………………….142 
Figure 5.2: Reduced levels of total Cdk1 protein in many AZD1775-resistant ES-2 clones..144 
Figure 5.3: Alterations in levels of Wee1 and PKMYT1 kinases and their Cdk1 
phosphorylation targets in AZD1775 resistant clones………………………………………146 
Figure 5.4: Target engagement of AZD1775 in ES-2, OVCAR8 and derivative AZD1775-
resistant clones……………………………………………………………………………..147 
Figure 5.5: Cdc25C expression in ES-2, OVCAR8 and derivative AZD1775 resistant 
clones……………………………………………………………………………………….149 
Figure 5.6: DNA damage response on AZD1775 treatment of ES-2, OVCAR8 and derivative 
AZD1775-resistant clones………………………………………………………………….152 
Figure 5.7: Cell cycle alterations on AZD1775 treatment of ES-2, OVCAR8 and derivative 
AZD1775-resistant clones………………………………………………………………….153 
Figure 5.8: MDR1 overexpression is not responsible for AZD1775 resistance in HGSOC...154 
Figure 5.9: Kinome phylogenetic tree of tyrosine kinases………………………………….156 
Figure 5.10: Altered activities of tyrosine kinases in ES-2 clones resistant to AZD1775….158 
Figure 5.11: Altered activities of tyrosine kinases in OVCAR8 clones resistant to 
AZD1775…………………………………………………………………………………...160 
List of Figures                                                                                                                        xii 
 
Figure 5.12: Changes in expression in ES-2 derived olaparib resistant clones……………..163 
Figure 5.13: Changes in expression in OVCAR8 and derivative olaparib resistant clones…165 
Figure 5.14: Summary of changes in protein expression observed that could contribute to 
mechanisms of resistance to AZD1775 in ES-2 and OVCAR8…………………………….170 
Figure 6.1: Reduced expression of Lyn in AZD1775 resistant ES-2 clones………………..175 
Figure 6.2: Comparison of expression patterns for cell cycle and related pathway genes 
between ES-2 and AZD1775 resistant ES-2 clones…………………………………………178 
Figure 6.3: Comparison of cell cycle gene expression pattern between OVCAR8 and 
AZD1775 resistant OVCAR8 clones……………………………………………………….179 
Figure 6.4: Cell cycle gene expression changes in untreated ES-2 compared to AZD1775 
treated ES-2………………………………………………………………………………...182 
Figure 6.5: Cell cycle gene expression changes in AZD1775 resistant ES-2 clones compared 
to AZD1775 treated ES-2…………………………………………………………………..183 
Figure 6.6: Cell cycle gene expression changes in AZD1775 resistant OVCAR8 clones 
compared to AZD1775 treated OVCAR8…………………………………………………..184 
Figure 6.7: Comparison of the superimposed RNASeq results on cell cycle control KEGG 
pathway…………………………………………………………………………………….188 
Figure 6.8: Gene expression changes in AZD1775 resistant clones………………………..192 
Figure 6.9: Comparison of Src family kinase activity and gene expression between resistant 
clones and treated parental controls………………………………………………………...195 
Figure 6.10: Sensitivity to inhibitors for upregulated pathways in ES-2 derived AZD1775 
resistant clones……………………………………………………………………………...197 
Figure 6.11: Sensitivity to inhibitors for upregulated pathways in OVCAR8 derived AZD1775 
resistant clones……………………………………………………………………………...198 
Figure 7.1: Role of Wee1 kinase at G2……………………………………………………..208 
Figure 7.2: Role of Cdc25 and Cdc14A at G2………………………………………………210 
Figure 7.3: AZD1775 resistance mechanisms operating in ES-2 and OVCAR8 derived 
clones……………………………………………………………………………………….215
List of Tables                                                                                                                        xiii 
 
List of Tables 
Table 2.1: Panel of cell lines…………………………………………………………………51 
Table 2.2: List of used antibodies and suppliers……………………………………………..53 
Table 2.3: List and sequences of Wee1 kinase exon primers used……………………………57 
Table 2.4: RNA integrity (RIN) values for samples used for RNASeq……………………...73 
Table 3.1. Validation of cell line panel………………………………………………………79 
Table 3.2: p53 mutational status in HGSOC cell line panel………………………………….80 
Table 3.3: Mutations in HGSOC and MMR related genes in the cell line panel…………….82 
Table 3.4: Drug profiles for the cell line panel treated with AZD1775, cisplatin and 
olaparib………………………………………………………………………………………84 
Table 3.5: Summary of SRB growth assay results for the cell line panel treated with CDDP 
alone and in combination with AZD1775……………………………………………………89 
Table 3.6: Summary of Alamar Blue viability assay results for the cell line panel treated with 
CDDP alone and in combination with AZD1775…………………………………………….92 
Table 3.7: Summary of SRB growth assay results for the cell line panel treated with olaparib 
alone and in combination with AZD1775……………………………………………………96 
Table 3.8: Summary of Alamar Blue viability assay results for the cell line panel treated with 
olaparib alone and in combination with AZD1775…………………………………………..99 
Table 4.1: Cell doubling times of AZD1775 resistant clones and parental cell lines………129 
Table 4.2: Samples sequenced for Wee1 kinase gene……………………………………….131 
Table 6.1: Gene lists supporting Figure 6.8…………………………………………………193 
 
List of Appendices                                                                                                               xiv 
 
List of Appendices 
Appendix Table 1: Mutations in genes commonly mutated in cancers that are found in the 
HGSOC cell line panel……………………………………………………………………...250 
Appendix Figure 1: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 1000nM 
AZD1775…………………………………………………………………………………...253 
Appendix Figure 2: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 800nM 
CDDP and 100nM AZD1775………………………………………………………………254 
Appendix Figure 3: Quality control steps for RNA SEQ experiment 1 (ES-2)…………….255 
Appendix Figure 4: Quality control steps for RNA SEQ experiment 2 (OVCAR8)………..256 
Appendix table 2: Gene lists supporting Figures 6.2 and 6.3……………………………….257 
Appendix table 3: Gene lists supporting Figure 6.8 (A and B)……………………………..260 











List of   Abbreviations                                                                                                         xv 
 
List of Abbreviations 
53bp1    p53 binding protein 1 
5-FU    5-fluorouracil  
ABC Transporters  ATP-binding cassette transporters  
AEs   Adverse events 
AKT    Protein kinase B 
ATM    Ataxia-telangiectasia mutated  
ATR    Ataxia telangiectasia and Rad3-related  
BCA    Bicinchoninic Acid (BCA)  
BER    Base excision repair 
BRCA1   Breast cancer susceptibility gene 1 
BRCA2   Breast cancer susceptibility gene 2 
BRCT    BRCA C-terminal 
CCLE    Cancer Cell Line Encyclopaedia  
CCNE1   Cell cycle check point regulator cyclin E1 
Cdc14A   Cell division cycle 14A 
Cdc25    Cell division cycle 25 
CDDP    Cisplatin  
CDKNs   Cyclin dependent kinase inhibitors  
Cdks    Cyclin dependent kinases  
cDNA    Complementary DNA 
CHK1 (CHEK1)  Checkpoint kinase 1 
CHK2 (CHEK2)  Checkpoint kinase 2 
CI    Confidence interval  
CSCs    Cancer stem cells 
DDR    DNA damage response  
DMEM   Dulbecco’s modified Eagle medium  
DMSO    Dimethyl sulfoxide  
dNTP    Deoxynucleoside triphosphate 
ds    double stranded 
List of   Abbreviations                                                                                                         xvi 
 
DSB    Double strand breaks  
dUTP    Deoxyuridine triphosphate 
EDTA    Ethylene diamine tetraacetic acid 
EGFR    Epidermal growth factor receptor  
EGTA  Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid 
EOC    Epithelial ovarian cancer  
EMT   Epithelial to mesenchymal transition 
ERCC1   Excision repair cross complementation group 1 
FA    Fanconi anaemia 
FBS    Foetal Bovine Serum   
FGFR    Fibroblast growth factor receptor  
HGS    High grade serous  
HGSOC  High grade serous ovarian cancer 
HR    Homologous recombination  
HSP90    Heat shock protein 90 
IC    Inhibitory concentration 
ICA    InterCorrelation Analysis 
ICLs   Inter-strand cross-links 
kDa    kilo Dalton 
LFC    Log fold change 
LGS    Low grade serous 
MCM   mini chromosome maintenance protein complex 
MDR1    Multidrug resistance protein 1   
miRNA   micro RNA 
MMR    Mismatch repair pathway  
mol. wt.   Molecular weight 
NER    Nucleotide excision repair 
NF-B    Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NF1    Neurofibromin 1 
NHEJ    Non-homologous end joining  
List of   Abbreviations                                                                                                         xvii 
 
nRTK    Non receptor tyrosine kinase 
NSCLC   Non-small cell lung cancer 
OC    Ovarian cancer 
OD    Optical density 
ORC   Origin recognition complex 
ORF    Open reading frame   
OS   Overall survival 
OSE    Ovarian surface epithelium  
PARG    Poly(ADP-ribose) glycohydrolase 
PARP     Poly(ADP-ribose) polymerase 
PARPi    PARP inhibitior  
PBS    Phosphate-Buffered Saline  
PCA    Principal Components Analysis  
PCR    Polymerase chain reaction 
PDGFR   Platelet-derived growth factor receptor  
PEG    Polyethylene glycol    
PFS   Progression free survival 
PHCD  4-(2-phenyl)-9-hydroxypyrrolo [3,4-c]-carbazole-1,3-(2H,6H)-dione  
PI3K    Phosphatidylinositol 3-kinase 
PKMYT1  Protein kinase MYT1 
PTEN    Phosphatase and tensin homolog deleted on chromosome 10  
PTIP    Pax transactivation domain-interacting protein 
PVDF    Polyvinylidene difluoride  
QC    Quality control 
RB1    Retinoblastoma 1 
RIF1    RAP1-interacting factor 1  
RIN    RNA integrity number  
RIPA buffer   Radioimmunoprecipitation assay buffer 
RNASeq   RNA sequencing  
RNF8    RING finger protein 8  
List of   Abbreviations                                                                                                         xviii 
 
RPA    Replication protein A 
RPMI    Roswell Park Memorial Institute 
RTK    Receptor tyrosine kinase 
RT-PCR   Real time polymerase chain reaction  
SCLC    Small cell lung cancer  
SDS    Sodium dodecyl sulphate 
SEM    Standard error of the mean  
SKP2    S-Phase Kinase-Associated Protein 2  
SNP    Single nucleotide polymorphism 
SRB    Sulphorhodamine B  
ss   single stranded 
STR    Short tandem repeat 
TBE    Tris Borate EDTA   
TBS   Tris Buffered Saline 
TBS-T    Tris Buffered Saline-tween20 
TCA    Tricholoroacetic acid  
TCGA    The Cancer Genome Atlas 
TGF    Transforming growth factor beta 
TGFβR   Transforming growth factor beta receptor 
Thr14 (T14)   Threonine 14 
TLS    Trans-lesion synthesis 
TNF    Tumour necrosis factor 
Tyr15 (Y15)   Tyrosine 15 
VEGF   Vascular endothelial growth factor 
YES    Yamaguchi sarcoma viral oncogene homolog  
β-ME   β-Mercaptoethanol 
Abstract                                                                                                                                     1 
 
Abstract 
High grade serous ovarian cancer (HGSOC) comprises 75-80% of all ovarian 
cancer cases and is characterised by p53 mutation and genetic heterogeneity. There are 
two major molecular categories: homologous recombination repair (HR) pathway 
proficient and deficient. Most cases are treated with a combination of surgery and 
chemotherapy. Patients with HR deficient cancers respond well initially, but the 
majority experience relapse after first line chemotherapy due to drug resistance.  
As p53 is mutated in virtually all HGSOC cases, these cancers rely heavily on 
the G2/M checkpoint for DNA damage repair and survival. The G2/M checkpoint is 
controlled by the phosphorylation status of Cdk1. Wee1 kinase responds to DNA 
damage by phosphorylating Cdk1 and causing G2 arrest, giving time for DNA repair 
before entry into mitosis. We and others have hypothesised that combining a DNA 
damaging agent with Wee1 kinase inhibition would be particularly effective in 
HGSOC.  AZD1775 is a small molecule inhibitor of Wee1 kinase that forces cells into 
mitosis without the repair of damaged DNA.  
The overall aim of the thesis was to characterise mechanisms of resistance to 
AZD1775 in cultured HGSOC cells and identify ways to overcome resistance that 
could be ready to deploy as the inhibitor moved into the clinic. It was hypothesised 
that resistance to AZD1775 could occur in a number of different ways through changes 
in key DNA damage response and cell cycle control pathways. To address the 
additional hypothesis that mechanisms of resistance to AZD1775 could be different in 
HR-deficient and proficient HGSOC, cell lines from each category were used to 
generate resistant clones for mechanistic studies. Given the increased use of the PARP 
inhibitor olaparib as a therapy for HGSOC, olaparib resistant clones were also isolated 
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from the same HR-deficient and proficient HGSOC cell lines with the supplementary 
aim of investigating the effectiveness of AZD1775 therapy in olaparib resistant 
HGSOC. 
I first investigated the effect of AZD1775 as a single agent and in combination 
with the DNA damaging agent cisplatin and olaparib in a panel of twelve HGSOC cell 
lines in cell growth and viability assays. AZD1775 enhanced the sensitivity to cisplatin 
and olaparib in three cell lines from the panel, two of which were HR pathway 
deficient. 
To study mechanisms of resistance to Wee1 inhibition, two cell lines, ES-2 and 
OVCAR8, were chosen representing HR proficient and deficient HGSOC to isolate 
clones resistant to AZD1775, AZD1775 in combination with cisplatin and olaparib 
alone. Compared to the parental lines, AZD1775 resistant clones retained normal cell 
cycle profiles in the presence of AZD1775. No evidence was found for mutation in the 
coding exons of the Wee1 kinase gene in resistant clones. Western blot analysis 
revealed reduced Cdk1 expression in many of the resistant clones, while others showed 
increased Wee1 kinase expression. RNA sequencing based comparison of AZD1775 
resistant clones with the parental ES-2 cell line showed an upregulation of TGFβ 
signalling that fed into the cell cycle control pathway via multiple cell cycle inhibitors. 
An alternative potential mechanism of resistance in some ES-2 and OVCAR8 clones 
involved upregulation of the TNF and NF-κB signalling pathway leading to evasion 
of apoptosis. An attempt to overcome AZD1775 resistance by blocking TGFβ or TNF- 
NF-κB signalling pathways was successful for one resistant ES-2 clone using a 
TGFβR1 inhibitor. 
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Western blotting of olaparib resistant clones isolated from ES-2 and OVCAR8 
showed known changes responsible for olaparib resistance, including reduced 
expression of 53BP1 and down regulation of Poly(ADP-ribose)glycohydrolase. All 
but one of the olaparib resistant clones tested remained sensitive to AZD1775. 
In conclusion, mechanisms of resistance to two important inhibitors for the 
improved treatment of HGSOC have been identified and ways to overcome resistance 
in the clinic have been suggested. 
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Lay Summary 
High grade serous ovarian cancer (HGSOC) is the most common type of ovarian 
cancer. Most cases are treated with a combination of surgery and chemotherapy. By 
studying the different types of genetic change present, HGSOCs can be divided into 
two main categories. Patients in the category with mutations in a DNA repair pathway 
are likely to respond well initially, but the majority experience relapse after first line 
chemotherapy due to drug resistance.  
During the cell division cycle, there are two important checkpoints where DNA 
damage is detected and repaired. p53 is a key protein at the first checkpoint. It detects 
DNA damage and activates the machinery that allows the cell to repair the damage. 
p53 is non functional in virtually all HGSOC cases. Therefore, these cancer cells rely 
heavily on the second checkpoint for DNA damage detection, repair and survival. 
Wee1 kinase plays a central role in controlling the second checkpoint. In presence of 
DNA damage, Wee1 kinase helps the cell to pause the division cycle and repair the 
damage. AZD1775 is a small molecule inhibitor of Wee1 kinase. Inhibition causes the 
cells to proceed with the cell division without the repair of damaged DNA. A cell with 
heavily damaged DNA will die when it tries to divide. Use of AZD1775 alone or in 
combination with other drugs could be an effective new strategy to treat HGSOC. 
HGSOC patients are prone to become resistant to therapy. The main aim of the 
thesis was to study mechanisms of resistance to AZD1775 in cultured HGSOC cells 
and identify ways to overcome resistance that could be ready to deploy as the inhibitor 
moves into the clinic. It was hypothesised that resistance to AZD1775 could occur in 
a number of different ways through changes in key DNA damage response and cell 
cycle control pathways. To address this AZD1775 resistant clones were generated 
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from two HGSOC parent cell lines with different genetic backgrounds. Another 
inhibitor called olaparib is being used extensively in the clinic as a new therapy for 
HGSOC. Olaparib inhibits a different protein involved in repair of damaged DNA. 
Olaparib resistant clones were also isolated from the same cell lines with the aim to 
study the possibility of AZD1775 therapy against olaparib resistant HGSOC. 
To study mechanisms of resistance to Wee1 kinase inhibition, the AZD1775 
resistant clones were compared to the two parental cell lines. Comparison revealed that 
the AZD1775 resistant clones have a slower cell division than the parental cells. 
Protein analysis of resistant clones revealed alteration of expression of proteins that 
help the cell to pause the cell cycle and repair the damaged DNA. RNA based 
comparison of AZD1775 resistant clones with the parental cell lines showed 
upregulation of two different pathways that provide survival advantage to the cells.  
Protein based analysis of olaparib resistant clones showed multiple known 
changes responsible for olaparib resistance and most of the clones tested remained 
sensitive to AZD1775. 
In conclusion, with an improved understanding of the changes in the biology of 
drug resistant cancer cells ways have been suggested to overcome the resistance to 
AZD1775 and olaparib in HGSOC patients in clinic.  




1.1. Ovarian cancer 
Ovarian cancer (OC) can be described as a number of malignant diseases 
involving the tissues of the ovaries (Vaughan et al., 2011). The symptoms include 
constant bloating, swollen abdomen, abdominal discomfort and increased urinary 
frequency.  
1.1.1. Types of ovarian cancer 
The ovaries are made of three types of tissue: epithelial cells covering the ovary, 
germ cells (involved in ovulation) present inside of the ovary and stromal cells 
(involved in hormone production) that hold the ovary together. Depending on the 
origin, there are three types of recognised ovarian cancer: epithelial ovarian cancer 
(EOC), germ cell tumours, and sex cord-stromal tumours (Colombo et al., 2009). 
Although the ovarian surface epithelium (OSE) cells have traditionally been 
considered the only origin of ovarian cancers, based on newer evidence it is now 
accepted that ovarian tumours arise from non-ovarian tissue as well (Dubeau and 
Drapkin, 2013; Crum, 2014). Serous ovarian cancers originate in the fallopian tube 
(Kindelberger et al., 2007) and endometrioid cancers originate from endometrial tissue 
located outside the uterus and peritoneum (Pentheroudakis and Pavlidis, 2010).     
1.1.1. The epidemiology and risk factors of ovarian cancer 
In 2015, around 7,300 women were diagnosed with ovarian cancer in the UK, 
making ovarian cancer the 6th most common cancer in women. 
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(https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/ovarian-cancer). There were nearly 300,000 new cases worldwide in 2018 
(https://www.wcrf.org/dietandcancer/cancer-trends/ovarian-cancer-statistics).  
The recognised risk factors for developing ovarian cancer are as follows: 
1) Increasing age: Most of the EOC cases are diagnosed in postmenopausal women. 
In the UK from 2008 to 2010 53% of cases were diagnosed in women above 65 years 
of age and 75% in women aged 55 and over (Office for National Statistics, Cancer 
Statistics Registrations, England. 2012). 
2) Family history: Individuals with family history of ovarian or breast cancer have an 
increased risk of developing ovarian cancer. Approximately 15% of ovarian cancers 
are familial (Ashworth et al., 2008).  The risk estimate is 2.5% for the sister and 7% 
for the mother of an ovarian cancer patient (Ziogas et al., 2000). These risks are 
increased for BRCA1 (breast cancer susceptibility gene 1) and BRCA2 (breast cancer 
susceptibility gene 2) mutation carriers (Clarke-Pearson, 2009).  
3) Ovulation: late menopause, nulliparity and infertility appear to increase the risk of 
a woman for ovarian cancer (Fathalla, 1971; Salehi et al., 2008). Women who have 
given birth have a reduced risk of ovarian cancer (Wentzensen et al., 2016) and each 
addtional birth is associated with a further 10-20% risk reduction (Wentzensen et al., 
2016; Whittemore et al., 1992). 
4) Environmental carcinogens: The female genital tract allows the movement of fine 
particulate matter from the vagina through the uterus and Fallopian tubes to the surface 
of the ovary (Cramer and Xu, 1995). Studies suggest an association between use of 
cosmetic talc and the risk of EOC development (Cramer et al., 2016; Cook et al., 
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1997). Talc particles have been found in ovarian tumours and women with ovarian 
cancer have reported more frequent use of talcum powder in their genital area than 
healthy women (Cramer et al., 2016; Muscat and Huncharek, 2008; Cramer et al., 
1999; Chang and Risch, 1997). Different studies have shown a ~20% increased risk of 
ovarian cancer among women who used talc in the genital region (reviewed by Terry 
et al., 2013). 
1.1.2. Grading and staging of ovarian cancer 
The grade of OC describes the extent of cellular abnormality. It is decided 
through histopathological examination of the tissue and state of differentiation of the 
cancer cells in the tumour. There are three different grades of tumours: well 
differentiated (low grade), moderately differentiated (moderate grade) and poorly 
differentiated lesions (high grade), as well as types where grade cannot be assessed 
(Heintz et al., 2006). The three tier system was used historically for grading, but in 
2004 a two tier system was introduced (Malpica et al., 2004). On the basis of molecular 
and clinical studies, two discrete types of serous ovarian cancer are now recognised, 
low grade and high grade. A study on comparison between high-grade serous ovarian 
cancer and low-grade serous ovarian cancer found lower overall survival among high-
grade patients compared to women with low-grade tumours (Gockley et al., 2017). 
The International Federation of Gynaecology and Obstetrics (FIGO) ovarian 
cancer staging system is used to identify the stage of the tumour and was first published 
in 1973, and revised in 1988 and 2014  (Prat, 2014; Mutch and Prat, 2014). FIGO 
shows four cancer stages. Stage IA cancer is used to define the tumour when it is 
limited to one ovary or fallopian tube, while in IB cancer the tumour is limited to both 
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ovaries and fallopian tubes and stage IC cancer has tumour with malignant cells. In 
stage IIA, tumour extends to uterus or fallopian tubes or both.  Stage IIIA1 cancer 
shows positive retroperitoneal lymph nodes, while IIIA2 cancer is microscopic, 
extrapelvic and peritoneal involvement is seen with or without retroperitoneal lymph 
nodes. Stages IIIB and IIIC cancer is macroscopic, extrapelvic, and peritoneal 
involvement is seen with or without retroperitoneal lymph nodes. Stage IVA cancer 
indicates pleural effusion while IVB cancer shows hepatic or splenic parenchymal 
metastasis as well as metastasis to extra-abdominal organs. EOC is generally 
diagnosed at late stage (FIGO stage III/IV) when the tumour is disseminated 
throughout the peritoneal cavity.  
1.1.3. Subtypes of epithelial ovarian cancer 
According to a recent classification based on histology, molecular biology and 
natural history of the disease, EOC can be further subdivided into following categories 
(Kurman and Shih, 2011); low-grade serous ([LGS] associated with KRAS and BRAF 
mutations, genomically stable) (Romero et al., 2013; Della Pepa et al., 2015), 
endometrioid (associated with endometriosis, ARID1A, PTEN and PIK3CA 
mutations) (Oswald and Gourley, 2015; Wiegand et al., 2010), clear cell (presents 
with parenchymal metastases, mostly associated with ARID1A and PIK3ca mutations) 
(Tan et al., 2011), and mucinous carcinomas (presents in young patients, mostly 
associated with KRAS mutations) (Brown and Frumovitz, 2014) and high-grade 
serous (presents with p53 mutations, huge genomic instability and copy number 
changes) (Ahmed et al., 2010). 
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1.1.4. Molecular pathogenesis of epithelial ovarian cancer 
The process of oncogenesis in solid tumours is considered to involve a single 
cell and its descendants that go through a series of genetic changes. These changes 
affect proliferation, apoptosis, adhesion and invasion, programmed cell death and 
motility (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011).  
Different types of EOC have distinct molecular profiles reflecting different 
diseases. LGS, endometrioid, clear cell and mucinous carcinomas are genetically 
considered to be stable, characterized by different mutation profiles depending on the 
histological subtype. For example, low grade serous EOC show frequent somatic 
mutations of the MAPKinase pathway genes (KRAS and BRAF), whereas 
endometriosis-associated (clear cell and endometrioid) carcinomas have mutations 
of ARID1A, CTNNB1 and PIK3CA. Finally, mucinous OC are characterized by 
mutations of KRAS, BRAF and RNF43 (Kurman and Shih, 2016). High grade serous 
cancers do not display similar gene mutations found in the other four types. An 
extended TCGA (The Cancer Genome Atlas, a consortium started in 2005 to catalogue 
genomic alterations in each cancer subtype through multiplatform analyses [whole 
exome sequencing, gene expression profile]) study on a serous EOC cohort reported 
germline truncation variants and large deletions across Fanconi anaemia (FA) pathway 
genes in up to 20% of the cases (Kanchi et al., 2014). Fanconi anaemia is a rare 
recessive inherited genomic instability disorder, caused by mutations in genes 
regulating replication-dependent removal of DNA interstrand crosslinks (ICLs) 
(Moldovan and D’Andrea, 2009). This requires coordinated action of endonucleases, 
translesion synthesis DNA polymerases and homologous recombination (Deans and 
West, 2011) and so explains the link between the HR and FA pathway in EOC. 
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1.2. High grade serous ovarian cancer  
High grade serous ovarian cancer (HGSOC) accounts for approximately 70% of 
all ovarian cancer cases (Chan et al., 2008).  
1.2.1. Molecular biology of high grade serous ovarian cancer 
The TCGA project has shed light into the underlying biology of high grade 
serous ovarian cancer (HGSOC). Virtually all HGSOC cases carry a mutation in the 
tumour suppressor gene TP53 (p53) (Cancer Genome Atlas Research Network, 2011; 
Vang et al., 2016). They display high levels of genomic instability, marked by the high 
number of copy number alterations (Cancer Genome Atlas Research Network, 2011). 
The second most frequently mutated genes in HGSOC are BRCA1 and BRCA2 
occuring in 20% of the cases (Cancer Genome Atlas Research Network, 2011). Nearly 
half of HGSOC harbour somatic or genetic defects in the homologous recombination 
(HR) DNA repair pathway.  The hallmark of HR defects in tumours is severe genomic 
instability with massive chromosomal aberrations (including large deletions and copy 
number gains) (Abkevich et al., 2012). Approximately 8% of HGSOC patients also 
show EMSY amplification (Mittempergher, 2016).  EMSY binds to BRCA2 and 
prevents it from functioning (Hughes-Davies et al., 2003), thus giving the tumour cells 
a BRCA2 negative phenotype (Cousineau and Belmaaza, 2011). Genomic alterations 
in other HR genes revealed by the TCGA study included focal deletion or mutation 
of PTEN (7%), hypermethylation of RAD51C (3%), mutation of ATM/ATR (2%), and 
mutations of different FA genes (5%) (Cancer Genome Atlas Research Network, 
2011). PTEN (Phosphatase and tensin homolog deleted on chromosome 10) 
contributes to DSB repair through HR. PTEN depletion after irradiation results in 
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sustained activation of AKT sequestered CHK1 in the cytoplasm, thus impairing the 
G2/M-checkpoint (Mansour et al., 2018). So overall, HR defects might be present in 
as much as 50% of the total HGSOC, as represented in Figure 1.1.  
The other half of the HGSOC cases have an intact HR pathway, and instead show 
an amplification in CCNE1 (cell cycle check point regulator cyclin E1) (Marone et al., 
1998) or defects in Neurofibromin 1 (NF1) (Sangha et al., 2008) or Retinoblastoma 1 
(RB1).  CCNE1 amplification occurs in ∼20% of HGSOC (Noske et al., 2015). 
NF1 encodes a tumour suppressor protein that prevents uncontrolled cell growth by 
regulating cellular levels of Ras proteins (Weinberg, 1995). RB1 is a tumour 
suppressor that restricts cell cycle progression into S-phase by inhibiting E2F 
transcription factor (Weinberg, 1995; Dannenberg et al., 2000). Whole genome 
analysis of HGSOC has reported RB1 and NF1 as frequent targets of gene breakage 
events that account for 20% and 17.5% of HGSOC cases, respectively (Patch et al., 
2015).  
Although BRCA1/BRCA2 germline mutations have mainly been reported in 
HGSOC patients, one third of mutations in the other genes involved in homologous 
recombination (HR) in HGSOC were also reported in 28% of non-serous ovarian 
carcinomas and were identified in nearly every histologic subtype tested, including 
clear cell, endometrioid, and carcinosarcoma (Pennington et al., 2014). This 
observation may be as a result of erroneous historical histological subtype assignment 
in some cases.  
 
 











Figure 1.1: Molecular changes in HGSOC. (Adapted from Cancer Genome Atlas Research 
Network, 2011). The figure illustrates the mutations that occur in different subtypes of 
HGSOC, further divided into homologous recombination deficient and proficient categories.  
1.3. DNA damage repair pathways 
DNA damage response (DDR) is a cellular network of signalling events that 
maintain the genomic integrity of the cell. DDR is triggered in response to genotoxic 
stress. DNA damage repair can be divided into two major pathways that repair damage 
to one of the DNA strands (mismatches, bulky adducts, single-strand break) or 
pathways that repair damage to both DNA strands (crosslinks, double-strand breaks 
(DSBs) (Vollebergh et al., 2012).  
Base excision repair (BER) repairs small single base damage, while bulkier 
single-strand lesions that distort the helical structure of DNA are repaired by 
nucleotide excision repair (NER) (Lord and Ashworth, 2012), as shown in Figure 1.2. 
Mismatch repair pathway (MMR) is a highly conserved, strand-specific DNA repair 
pathway that functions through proteins called Mut proteins. These proteins recognize 
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mismatched or unmatched DNA base pairs or insertion-deletion loops and initiate 
excision and resynthesis of the damaged region. MMR deficiency results in 
microsatellite instability (Peltomaki, 2003). Trans-lesion synthesis (TLS) and template 
switching allow DNA to continue to replicate in the presence of DNA lesions that 
would otherwise halt the process (Lord and Ashworth, 2012). DNA DSBs are the most 
difficult lesions to repair because DNA damage repair systems can no longer depend 
on the complementary strand for acting as a template for correct repair (Roy et al., 
2011). Depending on the phase of cell cycle, DSBs are repaired either by non-
homologous end joining (NHEJ) in G0 or G1 phase or by homologous recombination 
(HR) in the S or G2 phase (Vollebergh et al., 2012). 
The main repair systems work in coordination to maintain the integrity of the 
genome (Lord and Ashworth, 2012). The FA pathway coordinates three classical DNA 
repair pathways, namely NER, TLS and HR, to repair DNA interstrand crosslinks 
(ICLs) (Moldovan and D’Andrea, 2009). FA pathway employs fourteen proteins, 
seven of which form a protein complex, named FA core complex. ATR mediated 
phosphorylation of FA pathway proteins, in the presence of DNA damage, leads to 






















Figure 1.2: Summary of DNA damage repair pathways. (taken from 
http://jonlieffmd.com/blog/the-many-ways-neurons-repair-their-own-dna). The figure shows 
different forms of DNA damage and proteins involved in repair mechanisms initiated by the 
cell. The major DNA repair mechanisms are nucleotide excision repair (NER), base excision 
repair (BER), non homologous end joining (NHEJ), homologous recombination repair (HR), 
and mismatch repair (MMR).  
1.4. Homologous recombination repair 
HR acts mainly during the S and G2 phases of cell cycle to restore the original 
DNA sequence to the damaged site. It removes part of the DNA sequence around the 
DSB, and uses the DNA sequence on a homologous chromatid as a template for the 
synthesis of new DNA at the site of damage (Lord and Ashworth, 2012). On DNA 
damage, the MRN complex (MRE11-RAD50-NBS1) binds to the ends of DSB sites 
and recruits the DNA damage kinase ataxia-telangiectasia mutated (ATM), followed 
by ataxia telangiectasia and Rad3-related (ATR) activation, as shown in Figure 1.3. 
Then the mediators, CHEK2 (Chk2) and BRCA1, initiate the repair by the effectors 
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BRCA2 and RAD51. PALB2 and BRIP1 are two of the several facilitators of HR 
pathway (Roy et al., 2011).  
BRCA1 works with BRCA2 in a common pathway to protect the genome, but at 
different stages of the DNA damage repair (Roy et al., 2011). BRCA1 is a pleiotropic 
DDR protein that functions in both checkpoint activation and DNA repair. It plays an 
essential role in repair of DSBs, mainly through HR (Roy et al., 2011). BRCA2 
primary function is to facilitate HR. It is also involved in repair of replication-mediated 
DSBs generated when replication forks encounter ICLs (Fradet-Turcotte et al., 2016). 
HR pathway is the key mechanism for protecting the integrity of the genome in 
proliferating cells (Roy et al., 2011). In contrast to HR, NHEJ mediates repair by 
simply ligating the ends of DSBs together. This can lead to deletion or mutation of 
DNA sequences at or around the breakage (Lord and Ashworth, 2012). Therefore, 
NHEJ is considered error-prone when compared to HR.  
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Figure 1.3: Homologous recombination repair. (adapted from Figure 12.32 The Biology of 
Cancer, Garland Science 2007). HR takes place in the S and G2 phases. At the ds break site, 
MRN complex attaches to recruit ATM followed by ATR. The mediators (CHK2 and BRCA1) 
help initiate repair by the effectors (BRCA2 and RAD51). The DNA damage repair machinery 
first performs exonuclease activity to produce ss ends at the ds break site that invade the 
undamaged sister chromatid to use as a template to repair the damage.  
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1.4.1. Risks associated with mutations of HR pathway genes  
The BRCA1 gene was mapped in 1990 (Hall et al., 1990) and cloned in 1994 
(Miki et al., 1994) and BRCA2 was characterized shortly after (Wooster et al., 1994). 
Patients with serous OC are more likely to carry mutations specifically 
in BRCA1 and BRCA2 than patients with tumours of other histological subtypes 
(Walsh et al., 2011). Malignant tumours carrying a BRCA mutation have defective 
HR-mediated repair resulting in high genomic instability (Stefansson et al., 2009). The 
probable mechanism of genomic instability is that HR deficiency results instead in 
error-prone repair of DSBs by NHEJ, leading to chromosomal rearrangements such as 
large deletions and copy number gains. 
Germline mutations in BRCA1/BRCA2 lead to increased risks of breast and 
ovarian cancer. Risk of developing breast cancer in BRCA1 mutation carriers is 65% 
by the age of 70 years and 39% for ovarian cancer while for BRCA2 the risks are 45% 
and 11%, respectively (Antoniou et al., 2003). Mean age of OC diagnosis is 52 years 
for BRCA1 mutation carriers, 60 years for BRCA2 mutation carriers and 58 years for 
non-carriers (Kanchi et al., 2014).  
Germline BRCA1 and BRCA2 mutations are often accompanied with loss of the 
second intact allele during mitotic recombination leading to loss of heterozygosity in 
100% and 76% of the cases, respectively (Kanchi et al., 2014). Inactivation of the 
second allele can also take place by somatic mutations (Hennessy et al., 2010) and 
promoter hypermethylation (Hilton et al., 2002). BRCA1/BRCA2 genes were found to 
be defective in about a third of the tumours analysed in the TCGA project (Cancer 
Genome Atlas Research Network, 2011). Germline mutations in BRCA1/BRCA2 were 
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in 14% of the patients, somatic mutations in 7%, and epigenetic silencing 
of BRCA1 through promoter hypermethylation in about 11% of the cases (figure 1.1).  
Pennington et al. (2014), reported that 31% of EOC had a deleterious mutation 
in 1 or more of BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, 
MRE11A, NBN, PALB2, RAD51C and RAD51D, out of which 27% were somatic and 
73% were germline. BRCA1/BRCA2 germline and somatic mutations are most 
frequently mutated events in EOC, while other members of the HR/FA pathway can 
be mutated (8.2%), but at present are not routinely sequenced because of their rarity 
when considering the frequency of mutation of each gene alone. 
Somatic BRCA1/BRCA2 mutations have similar impact to germline mutations on 
overall survival and platinum responsiveness (Pennington et al., 2014).  
A possible explanation for the organ specific cancer predisposition in BRCA1 
and 2 carriers could be hormone driven growth during each menstrual cycle leading to 
production of reactive oxygen species and oxidative DNA damage (Sipe et al., 1994; 
Hamada et al., 2001). Such oxidative DNA damage can produce replication stress that 
requires a functional BRCA1-BRCA2-HR pathway to rectify (Roy et al., 2011).  
1.5. Ovarian cancer treatment  
The standard treatment for advanced ovarian cancer is surgery and 
chemotherapy (Martinek et al., 2010). The majority of patients present with advanced 
disease that cannot be removed completely at surgery and in that case chemotherapy 
is given in an attempt to kill residual tumour.  
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1.5.1. Surgical management of ovarian cancer 
The surgical management in ovarian cancer is always performed with the 
intention to remove all macroscopic disease, regardless of the timing of surgery in 
relation to chemotherapy. This approach is based on clinical data, which suggest that 
in the case of ovarian cancer the reduction of the tumour burden down to zero 
macroscopic residual disease offers a survival advantage (Mutch, 2002). 
1.5.2. Chemotherapy in ovarian cancer 
The first line of chemotherapy for advanced EOC is a platinum-based drug or a 
combination of this with taxanes such as paclitaxel (Winter-Roach et al., 2009). LGS, 
endometrioid, clear cell and mucinous carcinomas are generally considered as 
genomically stable and chemoresistant. On the other hand, high grade serous carries a 
large burden of copy number gains and losses and is chemosensitive in the majority of 
the cases. Patients whose tumours harbour BRCA1 and BRCA2 mutations respond well 
to DNA damaging chemotherapies and show better clinical outcome (Alsop et al., 
2012; Tan et al., 2008). Among HGSOC patients, those with a BRCA (both germline 
and somatic mutations)-associated mutated phenotype also showed improved 
treatment response to platinum based therapies (Candido-dos-Reis et al., 2015; 
Birkbak et al., 2013; Cass et al., 2003; Ben et al., 2002). 14.9% BRCA mutation 
carriers progressed to resistant disease in <6 months after primary chemotherapy 
(Alsop et al., 2012). There was longer progression-free survival (PFS), 2.1 and 5.6 
years for BRCA1 and BRCA2 mutation carriers (Vencken et al., 2011) and longer 
overall survival (OS), 8.4 vs 2.9 years in BRCA mutant patients compared with 
controls from time of diagnosis and  5 vs 1.6 years from the time of first relapse (Tan 
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et al., 2008).  Response rates to first-line platinum-based chemotherapy are around 
80% but the majority of patients go on to develop recurrent disease which is platinum 
resistant. (Robinson et al., 2007). 
1.5.2.1. Use of platinum agents  
Platinum chemotherapy was accidentally discovered in 1965 based on 
observation of cell division inhibition in E. coli by a platinum based compound 
(Rosenberg et al. 1965). The compound was later named ‘cisplatin’ and the effect on 
cancer cell division was confirmed in animal studies in 1970 (Rosenberg and 
VanCamp, 1970).  
Platinum based agents induce DNA damage, by forming intra- and interstrand 
cross-links between the DNA molecules thus interfering with replication and 
transcription of DNA (Todd and Lippard, 2009). The DNA damage response thus 
generated stimulates cycle checkpoints that can trigger cell death (Cruet-Hennequart 
et al., 2009). Some subpopulations of cancer cells can survive after platinum 
chemotherapy by a number of different protective mechanisms that cause drug 
resistance (Borst et al., 2008).  
There are now 5 platinum analogues approved for use in the treatment of cancer: 
cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin. Cisplatin or carboplatin 
monotherapy is used to treat most solid tumours, for example with testicular cancer 
obtaining cure rates of over 90% (Verhoeven et al. 2013). Only cisplatin and 
carboplatin are used to treat ovarian cancer.  
Platinum based therapy continues to be the principal regimen in use to treat 
tumours that recur at least 6 months after prior therapy (Luvero et al., 2014; 
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Markman et al. 1991), although in this setting a platinum containing combination of 
drugs is preferred. A greater interval between primary treatment and recurrent disease 
is associated with an increased likelihood that the patient will respond to retreatment 
for a longer period of time.  
1.5.2.2. Use of Taxanes  
Taxanes such as paclitaxel induce their chemotherapeutic effect by blocking the 
functional reorganization of the cellular microtubules (Schiff and Horwitz, 1980). The 
arrested assembly of the mitotic spindle results in failure of chromosomal segregation 
and a prolonged M-phase arrest ultimately leading to cell death (Long and Fairchild, 
1994) as shown in Figure 1.4.  Resistance to the taxanes has been associated with 
mutations in tubulin and transcriptional changes within the cancer cell (Duan et al., 
2005). 
 
Figure 1.4: Mechanism of action of Taxane. (taken from Gradishar, 2013) The anticancer 
activity of taxanes is due to their ability to inhibit microtubule depolymerisation by binding 
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directly to β-tubulin subunits and enhance microtubule stability. Taxanes can induce cell death 
by disrupting mitotic spindle formation during the late G2 and M phases of the cell cycle. 
1.5.2.3. Combination therapy  
The use of combination of platinum based drugs and taxanes show a survival 
advantage compared to platinum monotherapy without any increased toxicity risks 
(Harter et al., 2010). Alternative combination regimes which favour less toxicity 
include carboplatin combined with gemcitabine and carboplatin combined with 
PEGylated liposomal doxorubicin (Pujade-Lauraine et al., 2010). Gemcitabine is 
a nucleoside analogue that inhibits DNA synthesis (Huang et al., 1991). Incorporation 
of a gemcitabine triphosphate into DNA only allows addition of a single normal 
nucleotide (Gandhi et al., 1996). This position of gemcitabine makes DNA 
polymerases unable to elongate and also inhibits its removal by DNA repair 
enzymes (Huang et al., 1991).  PEGylated liposomal doxorubicin is conventional 
doxorubicin delivered in vesicles called liposomes, surrounded by a dense layer of 
polyethylene glycol (PEG).  PEGylation protects the liposomes from 
reticuloendothelial system (Gabizon and Martin, 1997) and abrogates some of its more 
significant toxicities including cardiotoxicity. Doxorubicin then intercalates into 
DNA, blocking topoisomerase II activity, disrupting DNA replication and 
transcription and generating free radicals (Gewirtz, 1999). 
1.5.2.4. PARP inhibition  
Poly ADP-ribose polymerase (PARP) is an enzyme which is essential for the 
repair of single strand DNA breaks (Amé et al., 2004). Loss of PARP results in 
unrepaired single strand DNA breaks persisting into replication which are converted 
into double strand breaks. Studies in animal models with BRCA1 negative mammary 
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tumours showed that the combination of a PARP inhibitor with chemotherapy resulted 
in improved survival (Rottenberg et al., 2008). Main efficacy of PARP inhibition is 
probably related to PARP trapping which results in collapse of the replication fork.  
PARPi binds to the catalytic site on PARP1 preventing its release from damaged DNA, 
thus trapping PARP1 on the DNA while stopping the catalytic activity (Lord and 
Ashworth, 2017). 
On PARP inhibition, the resulting ds DNA break can be repaired by HR or 
NHEJ. In BRCA-deficient tumours, since the HR pathway is not functional, the cell is 
directed towards error-prone DNA repair resulting in cell death. The absence of either 
an intact HR pathway or single strand break repair pathway alone has no major impact 
on cell viability, but the deficiency of both together leads to synthetic lethality as a 
result of the accumulation of DNA lesions that cannot be correctly repaired, as shown 
in Figure 1.5. BRCA-deficient cells are 1000-times more sensitive to PARP inhibitors 
than wild type cells (Farmer et al., 2005; Bryant et al., 2005). Response to PARP 
inhibitor, olaparib, was first demonstrated in germline BRCA1/2 mutation carriers in 
phase 1 clinical trials (Fong et al., 2009; Fong et al., 2010). Another study showed 
improved progression free survival of patients when treated with a combination of 
olaparib and cediranib (antiangiogenic agent against VEGF receptor) (Liu et al., 2014). 
A phase II trial reported that PARP inhibitors might be a reasonable alternative to 
conventional chemotherapy with a better toxicity profile in patient population with 
relapsed disease and BRCA mutations (Kaye et al., 2012). Kaye et al., 2012 showed 
olaparib is generally well tolerated as compared to PEGylated liposomal doxorubicin. 
The adverse events (AEs) observed were slightly higher at the 400mg than the 200mg 
dose level for olaparib. Nausea, fatigue, and vomiting were the most common AEs 
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related to olaparib treatment. Anaemia was more commonly seen particularly at 400 
mg twice per day. In another phase II study on relapsed HGSOC, the inhibition of 
PARP had an improved clinical outcome with longer time until disease progression 
(PFS of 8.4 months in olaparib vs 4.8 months in placebo arm) (Ledermann et al., 2012). 
A Phase III trial showed that the use of olaparib as maintenance therapy provided a 
significant benefit in progression free survival (risk of disease progression and death 
was 70% lower with olaparib than with placebo) among women with newly diagnosed 













Figure 1.5: BRCA1/BRCA2 deficiency and inhibition of PARP leads to synthetic lethality 
(Hoeijmakers, 2009). Panel A shows cells that have lost functional BRCA1/2 and thus have 
lost the ability to perform homologous recombination to repair the DNA damage (on the right), 
while cells with intact HR pathway (on the left) can repair the damage either through repair 
initiated by PARP or HR.  Panel B compares normal cells and BRCA mutant cells on treatment 
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with PARP inhibitor, where the normal cells can still repair DNA damage, however, PARP 
inhibition results in synthetic lethality in BRCA mutant cells.  
1.6. Chemoresistance in ovarian cancer 
Following first line conventional chemotherapy treatment, 80% of HGSOC 
patients show a positive response. Unfortunately almost 70-80% of these initial 
responders subsequently relapse (Kajiyama et al., 2007; Ledermann and Kristeleit, 
2010). The chemotherapeutic regimes used in recurrent disease vary depending on 
whether the disease remains sensitive to the initial treatment or resistance has been 
acquired.  
1.6.1. Mechanisms of ovarian cancer chemoresistance 
Knowledge about molecular mechanisms underlying the development of 
resistance in ovarian cancer is incomplete, but it is clear that resistance is 
multifactorial. Some of the cellular and molecular events causing intrinsic or acquired 
resistance are: limited intracellular availability of the drug due to increased efflux or 
inactivation, increased DNA repair activity and deregulation of apoptosis in cancer 
cells.  
1.6.2. Resistance to current chemotherapies  
In BRCA1/2 mutated tumours, the most common mechanism of acquired 
resistance described to date is secondary intragenic mutations that restore functional 
BRCA1 or BRCA2 protein (Edwards et al., 2008; Sakai et al., 2008). BRCA1/2 
function can be restored by occurrence of genetic events that cancel the frameshift 
caused by the original mutation leading to restoration of the open reading frame (ORF) 
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and expression of a functional nearly full-length protein, or genetic reversion of the 
inherited mutation which also restores full-length wild-type protein expression. These 
genetic events were originally observed in BRCA1- and BRCA2-mutated cancer cells 
under in vitro selective pressure for resistance to cisplatin or PARPi (Swisher et al., 
2008).   
1.6.2.1. Platinum resistance  
For patients who relapse within six month of previous platinum therapy, the 
second-line therapy should include a non-platinum-based agent. Existing data support 
the use of single agent second line therapy with conventional Topotecan 
(topoisomerase inhibitor), PEGylated liposomal doxorubicin or gemcitabine (Harter et 
al., 2010).  
5% of the HGSOC patients progress during their first cycle of platinum-based 
chemotherapy and another 17% progress within 6 months of completion of treatment. 
They are considered to have tumours that are platinum-resistant and may be considered 
for second line chemotherapy with a different agent. (Markman and Bookman, 2000).  
46% of platinum resistant BRCA mutated HGSOCs exhibit tumour-specific 
secondary mutations restoring the ORF of either BRCA1 or BRCA2 (Norquist et al., 
2011). Multiple reversion events in BRCA1/2 genes have been reported as a 
mechanism of platinum resistance in a whole-genome characterization of 
chemoresistant ovarian cancer (Swisher et al., 2008).  
The uptake and efflux of cisplatin in ovarian cancer cells is also associated with 
the emergence of chemoresistance to cisplatin. ATP7A and B are highly expressed 
copper transporters in chemoresistant cancer cells. They reduce the intracellular 
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accumulation of platinum by increased efflux (Komatsu et al., 2000; Nakayama et al., 
2002; Nakayama et al., 2004). Real time polymerase-chain reaction (RT-PCR) studies 
have reported a higher expression of ATP7B in resistant compared to sensitive ovarian 
cancer cells (Mangala et al., 2009). Another transporter, ABCC2, has been linked to 
clinical chemoresistance and is also considered to increase efflux of the drug (Cui et 
al., 1999).  
Presence of sulphur-containing molecules (such as glutathione) in the 
intracellular environment leads to reduced platinum drug availability. The sulphur 
containing molecules have higher affinity for platinum based compounds as compared 
to DNA. Cisplatin exposure has been shown to cause an increase in the levels of 
glutathione and a subsequent inactivation of the drug, leading to the development of 
drug resistance in cancer cells (Hamilton et al., 1985; Lai et al., 1989; Sadowitz et al., 
2002; Godwin et al., 1992). 
The repair of DNA lesions caused by platinum based compounds is primarily by 
nucleotide excision repair (NER). An increase in NER pathway to remove cisplatin 
adducts is considered to contribute to the cisplatin resistance in ovarian cancer (Lai et 
al.,  1988; Dabholkar et al., 1994; Parker et al., 1991). The excision repair cross-
complementation group 1 (ERCC1) protein, which acts in NER as a heterodimer with 
XPF to make an endonucleolytic incision to the 5' side of a cisplatin lesion, is involved 
in in vitro resistance to cisplatin (Ferry et al., 2000). 75% of platinum resistant EOC 
tumours show increased ERCC1 expression (Steffensen et al., 2009) and siRNA 
silencing of ERCC1 expression increased the sensitivity of platinum-resistant cell lines 
(Selvakumaran et al., 2003). 
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Tumours can also develop chemoresistance by evading apoptosis that is 
normally triggered by DNA damage. Constitutive activation of PI3K-AKT signalling 
(Wang and Lippard 2005) protects cancer cells from cisplatin through several 
mechanisms that inhibit proapoptotic proteins (Fas/FasL and Bcl-2 family proteins) 
(Kim et al., 2001; Barthwal et al., 2003) and stabilise the inhibitors of apoptosis 
(IAPs). Since HGSOC have mutated p53 (Vang et al., 2016; Cancer Genome Atlas 
Research Network, 2011), p53 mediated apoptosis is also effected.   
Other mechanisms underlying HGSOC platinum resistance consist of changes 
in p53 function (Reles et al., 2001; Yang-Hartwich et al., 2015), genome-wide 
mutations (Patch et al. 2015) and epigenetic changes (Wei et al. 2006; Vang et al. 
2013; Chang et al. 2017). These genetic mechanisms together could lead to genomic 
instability induced appearance of resistant cancer cells that are able to adapt and 
survive DNA damage caused by platinum chemotherapy.  
Presence of cancer stem cells (CSCs) (Steg et al. 2012) and epithelial-to-
mesenchymal transition (EMT) (Marchini et al. 2013; Chebouti et al. 2017) are also 
associated with platinum resistance in HGSOC. Platinum chemotherapy is most 
effective on proliferating cells making up the majority of a rapidly growing cancer, 
therefore, populations of latent CSCs within the tumour are less likely to respond to 
platinum chemotherapy.  
1.6.2.2. PARP inhibitor resistance 
Resistance to PARP inhibition (PARPi) can occur by restoration of HR repair or 
through an alternative mechanism to protect DNA replication forks. 
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Analysis of BRCA1 missense mutations suggests that conservation of N- and C-
terminal domains is most important for the response to HR deficiency targeted 
therapies. Tumours carrying the BRCA1-C61G mutation, that disrupts the N-terminal 
RING domain, do not respond well to PARPi, and develop resistance (Drost et al., 
2011). Mutations in the BRCA C-terminal (BRCT) domain of BRCA1 commonly lead 
to improperly folded protein products that are subject to protease-mediated 
degradation. HSP90 may stabilize the BRCT domain of these mutant BRCA1 proteins 
under PARP inhibitor selection pressure (Johnson et al., 2013); the HSP90-stabilized 
mutant BRCA1 proteins have the ability to form RAD51 foci, and confer PARPi and 
cisplatin resistance.  
BRCA1/2 deficient tumour cells can also acquire resistance to PARPi by finding 
independent mechanisms for protecting their replication forks. Upregulation of the 
ATR/CHK1 pathway and activation of the phosphorylation of multiple proteins that 
stabilise the replication fork might render a tumour with HR defect resistant to PARPi 
(Kim et al., 2016). BRCA1 deficient cells were shown to become resistant to PARPi 
by reducing the recruitment of the nuclease, MRE11, to the stalled fork, thereby 
resulting in fork protection (Chaudhuri et al., 2016). BRCA2 deficient tumour cells 
can become resistant to PARPi by reducing the recruitment of another nuclease, 
MUS81, to the stalled fork (Rondinelli et al., 2017).  
Since PARPi functions by blocking the enzymatic action of PARP enzymes, 
another possible mechanism of PARPi resistance may be decreased expression of 
PARP enzymes. This mechanism of resistance may particularly be relevant to the 
PARP-trapping mechanism of action of PARPi. This is where the PARPi binds to the 
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catalytic site on PARP1 preventing its release from damaged DNA, thus trapping 
PARP1 on the DNA while stopping the catalytic activity (Lord and Ashworth, 2017).  
Interestingly, a recent study identified a PARP1 mutation (1771C > T) in an 
ovarian cancer patient who demonstrated de novo resistance to PARP inhibition 
(Pettitt et al., 2018). Loss of PARP1 can only confer PARPi resistance in HR-
proficient cells (Murai et al., 2012) or BRCA-mutated cell lines that exhibit residual 
BRCA activity (Pettitt et al., 2018).  
PARG (poly[ADP-ribose] glycohydrolase) downregulation counteracts the 
deleterious effects of PARPis on replication fork progression, and restored PARylation 
(Gogola et al., 2018). Thus inhibition of PARG can cause resistance to PARP 
inhibitors.  
Changes in drug efflux due to ABC transporter proteins such as P‐glycoprotein 
have been demonstrated in vitro (Gottesman et al., 2002; Ambudkar et al., 1999). 
These proteins can pump drugs out of cells (Krishna and Mayer, 2000). Increased 
expression of these proteins has been reported to correlate with resistance to 
chemotherapy in vitro (Wind and Holen, 2011). The best-characterized transporter 
protein is MDR1/P-glycoprotein, and a number of clinical investigations have 
suggested that its intrinsic or acquired overexpression resulted in a poor clinical 
outcome of chemotherapy. Several studies have shown that response to PARPi may 
be modified by ATP-binding cassette (ABC) transporters (Choi and Yu, 2014). 
Increased expression of ABC transporters in tumour cells reduces the efficacy of many 
compounds by enhancing their extracellular translocation. An increase in expression 
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of ABCB1 (also known as multidrug resistance protein 1 [MDR1]) in ovarian cancer 
cells rendered them resistant to PARPi olaparib (Vaidyanathan, et al., 2016).   
Reduced activity of the 53bp1 (p53 binding protein 1) might cause PARPi 
resistance in BRCA1-mutant cells (Jaspers et al., 2013). Presence of 53bp1 at a DSB 
suppresses HR by protecting the site from BRCA1-mediated end processing and 
instead positively regulates repair of the break by NHEJ (Bouwman et al., 
2010; Bunting et al., 2010; Bakr et al., 2015). Other factors that work with 53bp1 are, 
RAP1-interacting factor 1 (RIF1) and Pax transactivation domain-interacting protein 
(PTIP) which are recruited to DSB sites by ATM-phosphorylated 53bp1 (Callen et al., 
2013; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz and Durocher, 
2013; Feng et al., 2013;  Zimmermann et al., 2013). Loss of 53bp1 restores HR activity 
in HR-deficient BRCA1-mutant cells (Bunting et al., 2012). 53bp1 seems to be 
important for BRCA1 deletion-induced growth arrest but not BRCA2 deletion. 
(Bouwman et al., 2010). Studies on mice with olaparib-sensitive BRCA-deficient 
mammary tumours developed resistance and exhibited partial loss of 53bp1 expression 
(Jaspers et al., 2013). Deletion or reduced expression of RIF1 (RAP1-interacting 
factor) is also reported as a mechanism of PARPi resistance. The RNF8 (RING finger 
protein 8) ubiquitin ligase regulates BRCA1-independent HR in 53BP1-depleted cells 
(Nakada et al., 2012). A 53BP1 effector complex called shieldin functions as a 
downstream effector in the 53BP1 pathway (Ghezraoui et al., 2018). Loss of shieldin 
subunits cause PARPi resistance in BRCA1-deficient cells but not in BRCA2-deficient 
cells (Noordermeer et al., 2018; Dev et al., 2018). 
Stabilization of stalled DNA replication forks can account for PARPi 
resistance (Chaudhuri et al., 2016; Bhat and Cortez, 2018). Inhibition of MRE11 
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nuclease in BRCA deficient cells, protects the replication fork from degradation on 
olaparib treatment, thus helping cells survive (Chaudhuri et al., 2016; Mijic et al., 
2017). Loss of the EZH2/MUS81 axis also promoted resistance to rucaparib and 
cisplatin in BRCA2-deficient ovarian cancer cells through increased fork protection 
(Rondinelli et al., 2017).  
In summary, an individual tumour cell may undergo several different genetic 
and epigenetic changes to become resistant. New drugs are needed to target these 
resistance mechanisms.   
1.7. Targeting Wee1 kinase 
1.7.1. Cell cycle and DNA damage and repair checkpoints 
Cell cycle checkpoints prevent the cell from progressing to the next phase before 
the previous phase is complete. To ensure the genomic integrity of the cells, there are 
DNA damage and repair checkpoints that detect the damage and repair it before 
progressing to the next phase of the cell cycle. If a cell enters S phase with damaged 
DNA this can prevent the completion of DNA synthesis and lead to mutations and 
DNA strand breaks. If a cell proceeds to the mitotic phase with damaged DNA, this 
can prevent proper chromosome segregation and lead to mitotic catastrophe. Two 
major DNA damage checkpoints occur at G1 to S and G2 to M transition (Figure 1.6). 
Cells undergo arrest at G1 or G2, thus prolonging the phase they are in, to repair the 
DNA damage (Curtin, 2012). If the damage is too severe this can trigger apoptosis or 
lead to irreversible withdrawal from cell cycle, called premature senescence (Di 
Leonardo et al., 1994).  
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1.7.2. Cell cycle control by Wee1 kinase 
Cyclin dependent kinases (Cdks) complexed with different cyclins control the 
progression of a cell through the cell cycle. Different combinations are formed in 
different phases of the cell cycle. During most of G1 Cdks 4 and 6 complex with D-
type cyclins (D1, D2, D3), after reaching the Restriction point Cdk2 binds with E-type 
cyclins (E1, E2) to help the cell progress to S phase (Figure 1.6). As the cell enters S-
phase Cdk2 binds with A-type cyclins (A1, A2) while in late S phase the A type cyclins 
form complexes with Cdk1 (also known as Cdc2). With the progression into G2 phase, 
Cdk1 binds B-type cyclins (B1, B2) forming the maturation factor which triggers the 
onset of mitosis.  
Maturation factor is required for the cell to enter mitosis (Santamaría et al., 2007; 
Malumbres and Barbacid, 2009). The activity of the Cdk1/cyclin B complex is mainly 
controlled by two proteins, Wee1 kinase and Cdc25 (cell division cycle 25) causing 
inactivation and activation of the complex, respectively. Wee1 kinase phosphorylates 
Y15 of Cdk1 in the Cdk1/cyclin B complex, as shown in Figure 1.6, while another 
kinase, PKMYT1 (Myt1), works in conjunction with Wee1 to phosphorylate Cdk1 at 
T14. These are both inactivating phosphorylations that promote G2 arrest.  Cdc25 
dephosphorylates the Cdk1/cyclin B complex and pushes the cell into mitosis (Parker 
and Piwnica-Worms, 1992; Heald et al., 1993; Squire et al., 2005; Boutros et al., 
2007). Thus, Wee1 OFF and Cdc25 ON establish the main switch for cell cycle 
progression into mitosis.  Activated Cdk1 activates its activators (Cdc25and MastL) 
and inactivates its inactivators (Wee1 and PKMYT1) by phosphorylations to reinforce 
the signal to proceed.   
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Figure 1.6: Role of Wee1 kinase in the cell cycle. (adapted from Figure 8.8 from The Biology 
of Cancer, Garland Science 2014). Shown in the adapted figure is the cell cycle, with labelled 
R point (restriction point) and two important DNA damage and repair checkpoints, G1-S 
checkpoint and G2-M checkpoint. Wee1 kinase has the ability to inhibit Cdk1 and cyclin B 
complex and help the cell maintain G2 arrest. It can also prolong S phase by inhibiting Cdk1 
and Cyclin A complex.  
                                          -------------------------------------------------------- 
Wee1 was initially identified through genetic studies of cell size control and cell-
cycle progression in Saccharomyces pombe (Nurse, 1975). It is a tyrosine kinase that 
is considered a part of the serine-threonine-specific family of protein kinases based on 
its structure (Russell and Nurse, 1987; Squire et al., 2005). The human Wee1 gene is 
located on chromosome 11: 9,573,681-9,593,457 forward strand (GRCh38 
coordinates) and has 12 exons that can be transcribed into 8 different transcripts. Wee1 
kinase is made of 646 amino acids forming 3 domains: an N-terminal regulatory 
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domain, a central kinase domain, and a short C-terminal regulatory domain (Igarashi 
et al., 1991). The kinase domain seems to be strictly specific for phosphorylation of 
Y15 of Cdk1 complexed with cyclin B in vivo (Parker and Piwnica-Worms, 1992; 
McGowan and Russell, 1995; Squire et al., 2005). In vitro kinase activity assays have 
shown that Wee1 can also phosphorylate Cdk1 and Cdk2 complexed with cyclin A, 
B1, or E, but not with cyclin D1 (Watanabe et al., 1995). Wee1 kinase has a critical 
role in mammalian development, as Wee1 knockout mouse embryos die before 
embryonic day 4, and conditional Wee1 deletion in cultured mouse embryonic 
fibroblast cells results in cell death because of DNA damage (Tominaga et al., 2006). 
1.7.3. Wee1 kinase inhibition  
Kinases are frequent targets in cancer therapy because of changed function by 
mutation, protein fusion, or overexpression (Krause and Van Etten, 2005). Kinases 
regulate cellular functions by their ability to transfer the γ-phosphate from the ATP-
cofactor to diverse substrates. Among various protein kinase structural domains, 
kinase domains, which have both ATP-binding site and catalytic centre, are most 
frequently encoded by genes involved in cancer (Greenman, et al., 2007; Johnson, 
2009). Kinases are often specifically expressed in targeted tissues, and often have 
specific and well characterised ATP, substrate, regulatory subunit or ligand binding 
sites that can be targeted by small molecules (Cuny, 2009; Zhang et al., 2009).  
Wee1 kinase is highly expressed in several types of cancer, like hepatocellular 
carcinoma (Masaki et al., 2003), breast and cervical cancers (Iorns et al., 2009), lung 
cancers (Iorns et al., 2009), squamous cell carcinoma (Magnussen et al., 
2013), glioblastoma (Mir et al. 2010; Music et al., 2016), medulloblastoma (Harris et 
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al., 2014), leukaemia (Tibes et al., 2012), melanoma (Magnussen et al., 2012), 
and ovarian cancers (Slipicevic et al., 2014). Some reports also show a lack of Wee1 
kinase expression in some human cancers and normal tissues for example, low 
expression in colon cancer cell lines and tumour samples (Backert et al.,  1999) and 
undetectable Wee1 protein expression in 66% of tumour samples of non-small cell 
lung cancer (NSCLC) (Yoshida et al., 2004).  
Cancer cells often have a defective G1-checkpoint, for instance in HGSOC due 
to defects in p53 signalling causing accumulation of mutations and genetic 
heterogeneity. This can lead to increased dependence on the G2 DNA damage 
checkpoint as compared to normal cells (Dixon and Norbury, 2002; Bucher 
and Britten, 2008; Chen, et al. 2012). Loss of G2 arrest releases cells into premature 
mitosis, see Figure 1.7,  with unrepaired DNA damage resulting in mitotic catastrophe 
and subsequent cell death (Vogelstein et al., 2000; Zhou and Bartek, 2004; Castedo et 
al., 2004; Kawabe, 2004; Bucher and Britten, 2008). This seems like an effective 
anticancer strategy in combination with DNA damaging therapy, as this selectively 
affects these cancer cells. Hence, inhibition of Wee1 kinase and removal of the G2-M 
checkpoint is an attractive strategy to drive cancer cells to enter into premature mitosis 
and ultimately go through cell death by mitotic catastrophe (De Witt Hamer et al., 
2011). 
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Figure 1.7: Wee1 kinase inhibition at different phases of the cell cycle. (adapted from 
Figure 8.8 from The Biology of Cancer, Garland Science 2014). The adapted figure illustrates 
the points of action of Wee1 kinase inhibitor in the cell cycle. Wee1 kinase inhibition would 
make the cells rush through the S-phase and push the cells from G2 into mitosis.  
1.7.4. Selectivity of Wee1 kinase inhibition 
A number of small molecule compounds based on pyrimidine and pyrrolo-
carbazole derivatives can inhibit Wee1 kinase function (Squire et al., 2005; Palmer et 
al., 2005; Palmer et al., 2006; Smaill et al., 2008a and b). PD0166285 is a pyrido-
pyrimidine derivative and is a potent but nonselective inhibitor of Wee1 kinase. Other 
kinase targets of PD0166285 are c-Src, PKMYT1, epidermal growth factor receptor 
(EGFR), fibroblast growth factor receptor 1 (FGFR1), CHK1, and platelet-derived 
growth factor receptor b (PDGFR-b) (Panek et al., 1997; Dimitroff et al., 1999; Wang 
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et al., 2001). PD0407824 is a pyrrolo-carbazole derivative which is a less potent but 
more selective inhibitor of Wee1, but also of CHK1 (Squire et al., 2005; Palmer et al., 
2006). Other kinase targets of PD0407824, such as AKT, Cdk4, FGFR, PDGFR, and 
c-Src, are inhibited only at higher inhibitor concentrations. Other potent pyrrolo-
carbazole derivatives that inhibit Wee1 kinase include Wee1 inhibitor II and 4-(2-
phenyl)-9-hydroxypyrrolo [3,4-c]-carbazole-1,3-(2H,6H)-dione (PHCD) (Palmer et 
al., 2006; Iorns et al., 2009; Murrow et al., 2010). The Wee1 kinase inhibitor used in 
this thesis, MK1775, now known as AZD1775, is a pyrazolo-pyrimidine derivative 
and is a potent and more selective inhibitor of Wee1 kinase, see Figure 1.8. Other 
kinase targets of AZD1775 consist of Yamaguchi sarcoma viral oncogene homolog 1 
(YES1), and 7 unspecified others out of 223 kinases tested (Mizuarai et al., 2009; Hirai 






Figure 1.8: Chemical structure of AZD1775. (figure from 
https://www.selleckchem.com/products/MK-1775.html) 
1.7.5. Preclinical studies with Wee1 kinase inhibitor 
In vitro, several cancer cell lines have shown loss of G2 arrest on Wee1 kinase 
inhibition. PD0166285 at nanomolar concentrations showed efficient removal of G2 
arrest when combined with irradiation in various cancer cell lines (ovarian, colon, 
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cervical, lung, and hepatocellular carcinoma) (Wang et al., 2001; Li et al., 2002; 
Hashimoto et al., 2003). The effectiveness of G2 arrest abrogation seemed to correlate 
with the functional status of p53. Wee1 kinase inhibitor, PHCD, reduced viability and 
induced apoptosis in breast and cervical cancer cells with high Wee1 gene expression, 
but not in prostate carcinoma cells and normal mammary epithelium with low levels 
of Wee1 gene expression (Iorns et al., 2009). AZD1775-treated ovarian carcinoma 
cells expressing short hairpin RNA (shRNA) against p53 showed greater sensitivity to 
gemcitabine, carboplatin, or cisplatin than the cells harbouring wild-type p53 (Hirai et 
al., 2009). AZD1775 also enhanced the cytotoxic effects of 5-fluorouracil (5-FU) in 
p53-deficient colon cancer cells and pancreatic cancer cells, but not in wild-type p53 
colon cancer cells (Hirai et al., 2010).  
Wee1 kinase inhibition in vivo has resulted in reduction of tumour growth in 
xenografted animal models. AZD1775 administered to nude rats bearing colon 
carcinoma xenografts in combination with gemcitabine resulted in reduced tumour 
growth without animal toxicity (Hirai et al., 2009). Similar results for cervical cancer 
and ovarian cancer xenografts were seen with AZD1775 treatment with carboplatin 
and cisplatin respectively. Marked tumour regression was observed in p53-deficient 
primary pancreatic cancer xenografts in mice after combination therapy with 
AZD1775 and gemcitabine, compared with monotherapy and control groups, but was 
not seen in treated wild-type p53 xenografts (Rajeshkumar et al., 2011).  
These in vitro and in vivo results provide evidence that Wee1 inhibition 
combined with DNA-damaging therapy results in efficient cell death by mitotic 
catastrophe in various human cancer types with a defective G1/S checkpoint as a result 
of p53 mutation. 
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1.7.6. Clinical studies with Wee1 inhibitor  
The inhibitors, PD0166285 and PD0407824, have not been tested in patients. 
Preliminary results of a phase I study (NCT00648648) of oral AZD1775 as 
monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients 
with advanced solid cancer, excluding central nervous system malignancies, were 
reported with good tolerance and strong target engagement (Leijen et al., 2010). Phase 
II study following this phase I trial showed that AZD1775 enhanced carboplatin 
efficacy in p53 mutated tumours (NCT01164995, phase II) (Leijen et al., 2016). 
AZD1775 plus carboplatin demonstrated manageable toxicity and the overall response 
rate was 43% with 5.3 and 12.6 months PFS and OS respectively. Another Phase II 
clinical trial comparing gemcitabine monotherapy to combination of gemcitabine and 
AZD1775 is ongoing (NCT02101775, phase II) for ovarian cancer.   In a phase II study 
of AZD1775 in patients with BRCA mutant tumours, 6 month PFS rate of 19% has 
been reported (Kumaar et al., 2019). Partial responses were reported in 25% of patients 
with BRCA1 serous ovarian cancer (Coyne et al., 2018). Another phase I study showed 
partial response by 20% of BRCA deficient patients to AZD1775 treatment (Mittra et 
al., 2019). 
1.7.7. Other targets for G2-checkpoint abrogation 
Alternative therapeutic targets for removal of G2 arrest are CHK1 and Hsp90 
(Tse et al., 2009). On DNA damage CHK1 kinase activates Wee1 and inactivates 
Cdc25 and therefore, seems to be a suitable alternative therapeutic target. The current 
CHK1 inhibitors are not selective and can also inhibit CHK2 activity to variable levels. 
Clinical trials in patients with advanced solid tumours and lymphoma with the non-
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selective CHK1 inhibitor UCN-01 (also inhibits CHK2, Wee1, and AKT), as 
monotherapy and/or in combination with cisplatin, carboplatin or topotecan showed 
dose-limiting toxicity. At maximal tolerated doses, inhibition of CHK1 activity was 
detected in biopsies but without clinical responses (Sausville et al., 2001; Rini et al., 
2004; Kortmansky et al., 2005; Dees et al., 2005; Perez et al., 2006).  
Hsp90 is a cytoplasmic molecular chaperone involved in activation of several 
proteins including Wee1 kinase and CHK1 (Tse et al., 2009). The Hsp90 inhibitor 
tanespimycin results in nonspecific CHK1 and Wee1 reduction, inducing p53-
dependent G2-checkpoint abrogation (Tse et al., 2009). Clinical trials for use of 
tanespimycin as monotherapy showed a lack of response in metastatic prostate cancer, 
renal cell cancer, and melanoma and minimal response in relapsed multiple myeloma 
(Ronnen et al.,  2006; Heath et al., 2008; Solit et al., 2008; Vaishampayan et al., 2010; 
Richardson et al., 2010). Combination therapy using tanespimycin with sorafenib 
(inhibitor of several tyrosine protein kinases), paclitaxel or trastuzumab (monoclonal 
antibody targeting HER2) showed better antitumour activity and was well tolerated 
(Modi et al., 2007; Ramalingam et al., 2008; Vaishampayan et al., 2010).  
Wee1 kinase inhibition seems to be of particular interest in HGSOC therapy, on 
the basis of several arguments; HGSOC carries mutations in p53, which result in G1/S 
checkpoint deficiencies and high levels of DNA damage, this can lead to dependency 
on Wee1 kinase, which is important for G2/M checkpoint, allowing the cell to repair 
DNA damage prior to entering mitosis.  
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1.8. Kinase inhibitor resistance  
Poor kinase inhibitor efficacy and target selectivity can lead to toxic side effects. 
Due to significant roles of kinases in cell survival, metabolism and function, cells are 
more prone to become resistant to kinase inhibitors. Kinases have many interaction 
interfaces and conformational dynamics, providing multiple points for interference 
with inhibitor action through mutations or other mechanisms that affect drug binding. 
(Valent, 2010; Janne et al., 2009; La Rosee and Hochhaus, 2010; Krishnamurty and 
Maly, 2010; Bixby et al., 2009; Engelman and Settleman, 2008; Buschbeck, 2006; 
Daub et al., 2004).  
Tumour cells can harbour pre-existing primary, or acquire secondary drug-
resistance mechanisms on treatment. The clinically most important mechanism is the 
accumulation of drug-resistant mutations in the targeted kinase genes. Kinase inhibitor 
resistance has become a common clinical complication affecting multiple cancers, 
targeted kinases and drugs. For example, resistance to Imatinib due to mutations in 
BCR-ABL kinase in chronic myeloid leukemia (La Rosee and Deininger, 2010) and 
EGFR mutations leading to resistance to Gefitinib in lung cancer (Kobayashi et al., 
2005). Preclinical studies have unveiled drug-resistance mechanisms for many 
additional kinases (Marmorstein, 2010; Kitzen et al., 2010; Emery et al., 2009; Girdler 
et al., 2008; Zunder et al., 2008; Warmuth et al., 2007).  
1.8.1. Mechanisms of kinase inhibitor resistance  
Many factors can contribute to resistance (pre-existing, acquired and secondary) 
to kinase inhibitors. Drug efficacy is affected by mechanisms extrinsic to the cell, like 
drug distribution, absorption and excretion (Janne et al., 2009; Bixby and Talpaz, 
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2009; van Erp et al., 2009; Daub et al., 2004). Acquired drug-resistance involves cell 
intrinsic mechanisms, like target gene amplification, overexpression, up or 
downregulation of signalling effectors, or secondary missense mutations in the 
targeted kinase which reduce drug effect (La Rosee and Hochhaus, 2010; Bixby and 
Talpaz, 2009; Janne et al., 2009; Buschbeck, 2006; Yano et al., 2008; Burchert, 2007;  
Daub et al., 2004). Tumour cell genetic instability might facilitate the emergence of 
drug resistance.  
Most of the drug-resistance mutations in kinases themselves occur in hotspots 
(Ferguson, 2008; Sharma et al., 2007). For example, mutations in the conserved kinase 
domains of FLT3, KIT and ERBB cause resistance to PKC412, Imatinib and Sorefenib 
in AML, gastrointestinal stromal tumors and gastric cancer respectively (Barouch-
Bentov and Sauer, 2011). It is likely that these mechanisms involve destabilization of 
inactive, or stabilization of active kinase conformations (Ferguson, 2008; Irmer et al., 
2007; Sharma et al., 2007;  Yun et al.,  2007; Zhang et al., 2006). Most mutations 
occur in protein regions involved in drug interactions, or in the transitions between 
active and inactive kinase conformations to impair drug binding to its target kinase. 
ATP-interacting residues of hinge or ATP-phosphate binding regions are infrequently 
involved because mutations of drug binding residues weaken drug binding more 
selectively (Azam et al., 2008; Kornev et al., 2006).  
1.8.2. Overcoming kinase inhibitor resistance 
Overcoming the drug resistance is a major challenge for developing safe and 
effective kinase inhibitors. The optimization of drug pharmaco-kinetic and dynamic 
properties is well established (Mager, 2006). Short-term kinase inhibition by high 
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affinity inhibitors may be preferable to continuous inhibition. Thus, leading to better 
target inhibition while reducing toxicity and, possibly, minimising opportunities for 
drug resistance (Valent, 2010; Shah et al., 2010; Snead et al., 2009).  
Kinase gene amplification or overexpression might be addressed through 
increased inhibitor dose, or by use of a combination of drugs to target mechanisms that 
mediate the overexpression (Bixby and Talpaz, 2009). Combination treatment might 
also overcome drug resistance due to upregulation of effectors that function 
downstream of the targeted kinase (Janne et al., 2009). For example, Gefitinib (EGFR 
inhibitor) in combination with a MET inhibitor is effective in overcoming resistance 
caused by MET signaling in EGFR-mutant cancers both in vitro and in 
vivo (Engelman et al., 2007; Turke et al., 2010). Similarly, PDGFR or IGF-IR inhibitor 
with MEK inhibitors or combination of MEK and BRAF inhibitors is considered to be 
an effective way to overcome acquired resistance to BRAF inhibitors (Nazarian et al., 
2010; Villanueva et al., 2010). A phase I study of Lapatinib (a small molecule tyrosine 
kinase inhibitor for intracellular domain of HER2) plus Trastuzumab (a humanised 
monoclonal antibody for HER2) in patients with advanced HER2-overexpressing 
breast cancer (previously treated with Trastuzumab alone) resulted in an overall 
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1.9. Aims of thesis 
When the project began in September 2015 there had been no published 
characterisation of mechanisms of resistance to Wee1 kinase inhibitor AZD1775 in 
HGSOC, or indeed in any other cancer. The overall aim of the thesis was to 
characterise mechanisms of resistance to AZD1775 in cultured HGSOC cells and 
identify ways to overcome resistance that could be ready to deploy as the inhibitor 
moved into clinic. 
It was hypothesised that resistance to AZD1775 could occur in a number of 
different ways through changes in key DNA damage response and cell cycle control 
pathways (see Figure 1.9): 
1. By mutation of the Wee1 kinase gene itself that affects AZD1775 binding to the 
protein, or by Wee1 kinase overexpression (or increased activity). 
2. By overexpression of PKMYT1, which has the ability to phosphorylate Cdk1 on 
Y15 as well as T14 (Mueller et al., 1995). PKMYT1 could take over the role of 
Wee1 to maintain the ability of the cell to undergo G2 arrest in presence of DNA 
damage. 
3.  By reduced levels of total Cdk1 expression (or decreased activity) resulting in 
lower levels of the active Cdk1 that are needed to drive cells into mitosis with DNA 
damage.  
4. By decreased expression of Cdc25 phosphatase that removes inhibitory Wee1 
kinase catalysed inhibitory phosphorylations from Cdk1, so keeping the Cdk1-
cyclinB complex in an inactive state and maintaining G2 arrest. 
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5.  By increased Cdc14A phosphatase expression. Cdc14A stabilises Wee1 kinase by 
removing Cdk1 mediated phosphorylation that marks it for proteasomal 
degradation (Ovejero et al., 2012) and also inhibits Cdc25 (Vázquez-Novelle et al., 
2010; Sacristán et al., 2011). 
6. By increased expression (or activity) of DNA damage response protein CHK1. A 
recent study on SCLC showed that increased basal expression of the AXL receptor 
and an activated mTOR pathway are associated with intrinsic and acquired 
AZD1775 resistance (Sen et al., 2017). AXL overexpression leads to activated 
ERK/p90RSK and mTOR pathways which, through CHK1 activation of Wee1 
kinase and inhibition of Cdc25, enables SCLC cells to maintain DNA-damaged 
induced G2 arrest and so overcome the effects of Wee1 inhibition.  By targeting 
AXL or mTOR it was possible to overcome both intrinsic and acquired Wee1 




















Figure 1.9. Possible mechanisms of resistance to AZD1775 in HGSOC. Schematic 
representation of the main interactors of Wee1 kinase in the cell cycle where changes might 
lead to resistance to Wee1 kinase inhibitor (AZD1775). For explanation, see text. 
                                                ---------------------------------- 
 To address the additional hypothesis that mechanisms of resistance to AZD1775 
could be different in HR-deficient and proficient HGSOC, cell lines from each 
category were used to generate resistant clones for mechanistic studies.  
Given the increased use of PARP inhibition as a therapy for HGSOC, olaparib 
resistant clones were isolated from the same HR-deficient and proficient HGSOC cell 
lines with the supplementary aims of identifying mechanisms of olaparib resistance 
and investigating the effectiveness of AZD1775 therapy in olaparib-resistant HGSOC. 
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Chapter 2 
Materials and Methods 
2.1. Materials  
2.1.1. General Chemicals  
All chemicals were obtained from Sigma Aldrich unless stated otherwise.  
5M NaCl  
10X Tris Borate EDTA (TBE) 890mM Tris-HCl, 890mM boric acid, 20mM EDTA 
pH 8.3  
1X Phosphate-Buffered Saline (PBS) 137mM NaCl, 27mM KCl, 10mM Na2HPO4, 
and 1.8mM KH2PO4 pH 7.4 
10X Tris Buffered Saline (TBS) 1.37M NaCl, 0.027M KCl, and 0.25M Tris-HCl pH 
7.4 Fisher BioReagents 
0.5M EDTA pH8.0  
14.3 M β-Mercaptoethanol (β-ME)  
Pierce Bicinchoninic Acid (BCA) protein assay kit Pierce 
Contents: BCA Reagent A, (proprietary solution containing Na2CO3, NaHCO3, 
bicinchoninic acid and sodium tartrate in 0.1M NaOH) 
BCA Reagent B (proprietary solution containing 4% CuSO4) 
Albumin Standard Ampoules, 2mg/mL bovine serum albumin (BSA) in 0.9% 
saline and 0.05% sodium azide  
Methanol Fisher chemicals 
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Tris base  
Glycine  
10mM EGTA pH7.0  
Triton X-100  
2.1.2. Drugs used and their concentrations 









DMSO 20mM -80 
Olaparib provided by 
AstraZeneca 
DMSO 200mM -20 





DMSO 10mM -80 
ML120B Sigma Aldrich 
SML1174 
DMSO 10mM -80 
RepSox Selleckchem 
S7223 
DMSO 20mM -80 
SIS3HCl Selleckchem 
S7959 
DMSO 5mM -80 
2.1.3. Mammalian Cell Culture  
Dulbecco’s modified Eagle medium (DMEM) Thermo Fisher Scientific   
RPMI medium 1640 Thermo Fisher Scientific   
Foetal Bovine Serum (FBS) Thermo Fisher Scientific   
100X non-essential amino acids Thermo Fisher Scientific   
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100X sodium pyruvate Thermo Fisher Scientific   
100X L-glutamine Thermo Fisher Scientific   
Penicillin streptomycin (10,000 units penicillin and 10 mg streptomycin/mL)  
Insulin solution Human 10mg/mL  
Trypsin-EDTA (0.05%), phenol red Thermo Fisher Scientific   
Recovery Cell Culture Freezing Medium Thermo Fisher Scientific   
2.1.4. Cell Lines  
 Cell line Obtained from 
1. COV318 European Collection of Authenticated Cell Cultures 
2. ES-2 American Type Culture Collection 
3. EFO21 German Tissue Repository, DSMZ, Germany 
4. FUOV-1 German Tissue Repository, DSMZ, Germany 
5. Kuramochi  Japanese Health Science Research Resources Bank, JCRB, 
Osaka Japan.  
6. OVCAR3 American Type Culture Collection 
7. OVCAR8 American Type Culture Collection 
8. PEO1 Provided by their isolator Dr Simon Langdon, University of 
Edinburgh. (Langdon et al., 1988) 9. PEO4 
10. PEO14 
11. PEO23 
12. SKOV3 European Collection of Authenticated Cell Cultures 
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2.1.5. Western Blotting 
NuPage 4-12% polyacrylamide gradient gels 12 wells Thermo Fisher Scientific   
Novex NuPage MOPS SDS running buffer 20X (proprietary buffer containing 50mM 
MOPS, 50mM Tris Base, 0.1%SDS, 1mM EDTA, pH 7.7)  Thermo Fisher Scientific   
RIPA buffer (10mM Tris pH7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 0.1% SDS, 
1% Triton, 1mM β-ME) 
NuPage 4X sample buffer (proprietary buffer containing lithium dodecyl sulphate, pH 
8.4) Thermo Fisher Scientific   
Page Ruler™ Plus Prestained Protein Ladder Thermo Fisher Scientific   
Tween-20  
1X TBS-T pH 7.4: 10X TBS diluted to 1:10, 0.1% Tween 20 
Transfer buffer pH 8.3: 192mM glycine, 25mM Tris  
Immobilon-p pvdf transfer membrane Merck  
Blocking buffer: 5% w/v non-fat milk powder in TBS-T 
Halt Phosphatase Inhibitor Cocktail Pierce  
Halt Protease Inhibitor Cocktail, EDTA free Pierce  
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2.1.5.1. Antibodies Used  
Antibody  Supplier/Cat. no Dilution used  Secondary  
53BP1 New England Biolabs 100-
305 
1:2000 Anti-Rabbit 
ATM Santa Cruz (SC) 23921 1:500 Anti-Mouse 
ATR SC 1887 1:500 Anti-Goat 
AXL Cell signalling Technology 
(CST) 8661 
1:1000 Anti-Rabbit 
Cdk-1 CST 9116 1:1000 Anti-Mouse 
Cdk1 p-T14 Abcam (AB) 58509 1:1000 Anti-Rabbit 
Cdk1 p-Y15 CST 9111 1:1000 Anti-Rabbit 
Chk1 CST 2360 1:1000 Anti-Mouse 
Chk2 ProSci 2391 1:2000 Anti-Rabbit 
DNA PK CST 12311 1:1000 Anti-Mouse 
ERK1/2  CST 9102 1:1000 Anti-Rabbit 
MDR-1 SC 55510 1:500 Anti-Mouse 
MET SC 10 1:1000 Anti-Rabbit 
MUS81 Sigma M1445 1:2000 Anti-Mouse 
PARP1/2 SC 7150 1:1000 Anti-Rabbit 
pERK1/2_ 
Thr202/Tyr204 
CST 9101 1:1000 Anti-Rabbit 
p-mTOR_S2448 CST 2971 1:1000 Anti-Rabbit 
pS6_S240/244 CST 2215 1:1000 Anti-Rabbit 
RPA Bethyl Laboratories A300-
244A 
1:5000 Anti-Rabbit 
RRM2 Sigma Aldrich 
WH0006241M1 
1:2000 Anti-Mouse 
S6 CST 2217 1:1000 Anti-Rabbit 
Wee1 kinase   CST 4936 1:1000 Anti-Rabbit 
γ H2AX CST 2577 1:1000 Anti-Rabbit 
Table 2.2: List of used antibodies and suppliers 
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2.1.6. Kinase Activity Assay  
PamStation®12 System 
Protein Tyrosine Kinase PamChip® PamGene (with 196 peptides [as kinases 
substrates] with known phosphorylation sites, detecting 100 different protein kinases) 
M-PER Mammalian Extraction Buffer (proprietary detergent in 25 mM bicine buffer 
pH 7.6) Pierce  
PTK reagent kit PamGene  
Contents: Antibody solution (PY20-FITC) 
     10x PTK additive (proprietary reagent) 
     ATP solution (100 mM) 
     2% BSA 
    10x PK buffer (proprietary buffer) 
    1 M DTT solution  
    100x BSA solution  
2.1.7. Drug Sensitivity Assays 
2.1.7.1. Growth Assay 
TCA solution: tricholoroacetic acid (TCA) prepared as 100% w/v stock solution and 
diluted to a 25% v/v TCA working solution.  
SRB solution: 0.4% w/v sulphorhodamine B 1% v/v acetic acid solution.  
1% acetic acid solution: 1% v/v of glacial acetic acid BDH reagents 
10mM Tris pH10.5  
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2.1.7.2. Viability Assay  
Alamar blue cell viability reagent 10X Thermo Fisher Scientific  
2.1.8. Propidium Iodide FACS Assay  
Propidium iodide solution (1 mg/ml in PBS) Cayman Chemicals 
2.1.9. DNA Extraction 
DNeasy blood and tissue kit (50) Qiagen  
Contents: AL lysis buffer 
 AW1 wash buffer 
 AW2 wash buffer 
Illustra ExoStar (Exonuclease I and Alkaline Phosphatase) GE Healthcare  
DyeEx™ column kit Qiagen  
Contents: DyeEx™ Spin Columns 
Collection Tubes (2 ml) 
2.1.10. RNA Extraction  
RNeasy mini kit Qiagen 
Contents: RNeasy Mini Spin Columns  
Collection Tubes (1.5 ml and 2 ml) 
Buffer RLT 
Buffer RW1 
Buffer RPE (concentrate)  
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RNase-Free Water  
QIAshredder homogenizer Qiagen 
RNase-Free DNase Set Qiagen 
Contents: DNase I, RNase-Free (lyophilized) 1500 Kunitz units 
Buffer RDD  
2.1.11. Polymerase Chain Reaction  
AmpliTaqGold 360 masterMix Applied Biosystems 
PCR plate + sticky lid ABgene 
Qiagen Multiplex PCR kit Qiagen 
Contents: QMM 5x containing: HotStarTaq® DNA polymerase, Multiplex 
PCR Buffer (contains 6mM MgCl2), dNTP Mix 
      Q solution (proprietary PCR additive) 
Big Dye Terminator 3.1 (fluorescent dye labelled dNTPs) Thermo Fisher Scientific 
2.1.11.1. Primer Information  
Primers for the Wee1 kinase gene were designed using sequence from GenBank ID 
X62048.1. All primers were dissolved in nuclease free water to make a stock solution 








Sequence  Reverse 
primer  

































































Table 2.3: List and sequences of Wee1 kinase exon primers used.  
2.1.12. RNA Sequencing 
Agilent Bioanalyser Agilent Technologies  
RNA 6000 Nano Kit Agilent  
AMPure XP beads Beckman Coulter  
NextSeq 550 platform Illumina  
NextSeq 500/550 High-Output v2 (150 cycle) Kit Illumina 
Qubit 2.0 Fluorimeter Thermo Fisher Scientific  
Qubit RNA HS Kit Thermo Fisher Scientific 
Qubit DNA HS Kit Thermo Fisher Scientific 
Ribo-Zero Gold Kit Illumina 
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2.2. Methods 
2.2.1. Mammalian Cell Culture 
2.2.1.1. Culturing 
All the cell lines were grown as monolayers. Attached cells were fully 
disaggregated by trypsinization between passages. The cell lines were maintained at 
37°C in an incubator with humidified air and 5% CO2. 
Cell lines were cultured in DMEM or RPMI-1640 media supplemented with 
10% or 15%FBS, 1X non-essential amino acids, 1X sodium pyruvate, 1X L-glutamine 
and 0.01mg/mL insulin, 100 U/mL penicillin and 0.1mg/mL streptomycin. ES-2 was 
grown in DMEM supplemented with 10% FBS, COV318, EFO21, FUOV1 and 
SKOV3 were grown in RPMI with 15% FBS and Kuramochi, OVCAR3, OVCAR8, 
PEO1, PEO4, PEO14, PEO23 were grown in RPMI supplemented with 10% FBS. 
The cells were handled in a sterile class II biological safety cabinet. On reaching 
confluency cells were drained of media, washed once with 1mL of PBS to remove the 
left over media, then treated with 1mL of 0.05% trypsin and incubated at 37°C for a 
few minutes until detached. The cells were then suspended in media to stop the action 
of trypsin and centrifuged at 1300 rpm for 4 minutes in Fisher Scientific accuSpin1 
benchtop centrifuge. The cell pellet was then re-suspended in fresh media and an 
appropriate volume was then transferred to a new flask with fresh medium.   
2.2.1.2. Cryopreservation of Cell Lines 
For permanent storage cells were trypsinised and pelleted as described above 
and then resuspended in Recovery Cell Culture Freezing Medium. The cell stock was 
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frozen slowly in a -70°C freezer and then transferred to a liquid nitrogen tank. To thaw 
cells, vials were rapidly warmed at 37°C then mixed with cold media to dilute the 
DMSO in the freezing medium. Cells were centrifuged at 1300 rpm for 5 minutes in a 
Fisher Scientific accuSpin1 benchtop centrifuge to pellet cells and remove the 
remaining DMSO, the cells were then resuspended in media before plating into a cell 
culture flask. Medium was changed 24 hours later or cultures were split if confluent.  
2.2.1.3. Counting Cells  
To count cells for experiments, the cells were trypsinised, pelleted and re-
suspended in fresh culture medium and a sample was mixed 1:1 with trypan blue. The 
mixture was used to count cells on the Countess II Automated Cell counter.  
2.2.2. Drug Sensitivity Assays 
Most drugs were made up in 100% DMSO, then diluted in media for growth and 
viability assays. The final DMSO concentration in these assays was below 0.01%. 
Since previous work in the laboratory had determined that DMSO concentrations 
below 0.01% had no effect on cell growth or viability, solvent controls were not used 
for the growth and viability assays.  
2.2.2.1. Growth Assay  
The Sulphorhodamine B (SRB) assay, that measures total cell proteins, was used 
to generate growth curves and determine the chemosensitivity of the cell lines. First, 
growth curves were generated to determine the optimal number of cells to use for the 
drug sensitivity assays. This was done to avoid growth inhibition due to low seeding 
or depletion of the medium. For each cell line the highest number of cells plated 
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showing continuing exponential growth after five days was selected for drug response 
assays. 
Response curves were generated for both single agent and combination 
treatments. Cell growth was assessed using the SRB assay after a five day exposure to 
different concentrations of the compounds.  
Cells (2000 cells/well [OVCAR8] to 24000 cells/well [FUOV1]) were seeded in 
96-well plates and allowed to adhere and grow for five days with continuous exposure 
to drugs across a dilution series. Cells were fixed in 5% trichloroacetic acid after which 
plates were rinsed with tap water. Cells were stained with 0.4% SRB in 1% acetic acid. 
Plates were rinsed with 1% acetic acid followed by solubilisation of cell bound dye in 
10mM Tris (pH10.5) with continuous shaking for an hour at 600 rpm using Heidolph 
titramax 1000. The absorbance was read at 540 nm in a Thermo Multiskan Spectrum 
platereader. OD values from all wells seeded with cells were blanked against empty 
wells (without seeded cells) which were treated with SRB stain and then extracted.  
2.2.2.2. Viability Assay  
The cell lines were exposed to a combination of drugs sequentially. Cells were 
seeded in 96-well plates (2000 cells/well [OVCAR8] to 24000 cells/well [FUOV1]) 
and were first exposed to a DNA damage inducing drug causing them to accumulate 
damage and then to Wee1 kinase inhibitor, AZD1775, that drives all the cells with the 
DNA damage into the mitotic phase of the cell cycle. The cells were allowed to grow 
for 24 hours (cisplatin) or 48 hours (olaparib) before 24 hour treatment with AZD1775. 
At the end of AZD1775 treatment, alamar blue was aseptically added to the cells so 
that it formed 10% of the total well volume. The cells were then incubated at 37°C for 
Chapter 2                                                                                                                                 61 
 
4 hours and the reduction of  alamar blue, which is a measure of cell viability, was 
checked using an excitation wavelength at 530-560 nm and emission wavelength at 
590 nm. OD values from all wells seeded with cells were blanked against empty wells 
(without seeded cells) which were treated with alamar blue.  
2.2.2.3. Calculation of IC50 values 
GraphPad prism software was used to fit a dose response curve. A non-linear 
regression curve fit model, using the equation for log inhibitor response variable slope 
(four parameters: IC50, hill slope, top and bottom of the curve), was used to plot graphs. 
The bottom of the curve was constrained to zero. To obtain the IC50 value, the 
concentration of the drug that reduced the growth to 50% of the level in untreated 
samples was manually calculated using the curve. This was done because GraphPad 
prism automatically calculates IC50 values that fall between the highest (always 100%) 
and the lowest value (not always 0, despite the constraining) in the curve. GraphPad 
Prism was also used to plot 95% confidence intervals (CI) that span the IC50 values 
automatically calculated by the software itself. These CIs were used to assess the 
significance of any differences in IC50 values observed between treatments. Non-
overlapping CIs were interpreted as indicating a significant difference between IC50 
values, while overlapping CIs indicated no significant difference. 
2.2.3. Protein Assays 
2.2.3.1. Western Blotting  
2.2.3.1.1. Preparation of Whole Cell Lysate from Cultured Cells  
Cells were grown until they were 70-80% confluent. Before proceeding with the 
lysate preparation, protease and phosphatase inhibitor cocktails were added 1:100 to 
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the RIPA buffer. The cells were then washed with cold PBS thrice. After draining the 
PBS, cells were lysed using ice-cold RIPA buffer (40 µL in 1 well of a 6-well plate) 
and cells were then scraped off the dish using a plastic cell scraper. The cell suspension 
was vortexed and put on ice for 15 minutes, followed by centrifugation in a refrigerated 
microcentrifuge at 15,000 rpm, for 15 minutes. The supernatant was then taken and 
stored at -80°C.  
2.2.3.1.2. Determination of Protein Concentration 
Bicinchoninic acid assay (BCA), using the Pierce BCA protein assay kit, was 
performed to determine the protein concentration of the lysates. The lysate was diluted 
in water (2.5 µL lysate in 25 µL water), and added onto a 96 well plate with known 
concentrations of bovine serum albumin. To each sample 200 µL of BCA solution (50 
parts A+1 part B) was added and the plate was incubated at 37°C for 30 minutes and 
the absorbance was measured at 562 nm using a spectrophotometer. Protein 
concentrations were determined based on the BSA standard curve. New standard curve 
was plotted approximately after every 2 months.   
2.2.3.1.3. Preparation of Samples for Loading into Gels 
Samples were mixed with 4x sample buffer and heated at 70°C for 10 minutes 
and 25µg of denatured proteins were separated on 4-12% precast polyacrylamide mini 
gels (Invitrogen). The gels were run using the XCell SureLock mini cell 
electrophoresis system, submerged in 1x NuPage MOPS SDS running buffer, at 150-
200V for 1-2 hours. The system was run while submerged in ice. 
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2.2.3.1.4. Transfer and Detection of Proteins 
Proteins were transferred from the gel onto immobilon-P PVDF membrane using 
semi-dry blotting. Transfer was done using the BioRad Mini-Trans-Blot system at 
either 40mA overnight at 4°C or 400mA for 1 hour at 4°C. Membranes were removed 
from the transfer cassette and washed with TBS-T for 5 minutes. After repeating the 
wash thrice, the membranes were blocked using 5% w/v non-fat milk for 1 hour.  
Primary antibodies were diluted in TBS-T to the required concentration (see Table 2.2) 
and incubated with the membrane overnight at 4°C with gentle shaking. Following 
primary antibody incubation, the membranes were washed thrice with TBS-T. 
Secondary antibody against the host of primary antibody was used, conjugated with a 
fluorophore. After washing off excess unbound secondary antibody with at least three 
TBS-T washings the signal was read on the LiCor Odyssey imaging machine. 
2.2.3.2. Kinase Activity Assay  
2.2.3.2.1. Preparation of Whole Cell Lysates 
Cells were grown until they were 70-80% confluent. To prepare lysis buffer, 
phosphatase and protease inhibitor cocktails were freshly diluted to 1:100 in M-PER 
Mammalian Extraction Buffer and stored on ice. The cells were then washed with cold 
PBS thrice. After draining the PBS, cells were lysed using ice-cold M-PER 
mammalian extraction buffer (200 µL/25 cm2 flask). Adherent cells were then scraped 
off the dish using a plastic cell scraper. The cell suspension was vortexed and put on 
ice for 15 minutes, followed by centrifugation in a refrigerated microcentrifuge at 
15,000 rpm, for 15 minutes. The supernatant was collected, aliquoted, snap frozen and 
stored at -80°C. The protein was quantified using the Pierce BCA protein assay kit.  
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2.2.3.2.2. Processing Reactions on Pamstation  
Before processing the samples, 1x PK wash buffer (300 μL of 10x PK buffer in 
a final volume of 3.0 mL), ATP dilution (4 μL ATP stock solution (100 mM) with 
water to a final volume of 100 μL) and 1M DTT solution was prepared fresh before 
each run. The closed pouch with PamChip® array was left at RT for 10 minutes before 
opening. The array chips were blocked with 30 μL of 2% BSA and loaded on the 
Pamstation to be washed before sample loading.  
For the assay master mix the following reagents were mixed gently on ice just 
prior to loading the samples onto the array. 
 For 1 reaction (μL) 
10x PK buffer 4 
1 M DTT solution 0.4 
10x PTK additive 4 
100x BSA solution  0.4 
Antibody solution (PY20-FITC)  0.6 
Sample (lysate)  10 (5-7 μg) 
4 mM ATP solution  4 
Total Volume  40 
 
Following the blocking step the samples in assay mix were added onto the array 
chips and run on Pamstation using the PTK evolve protocol.  
2.2.3.2.3. Differential Kinase Activity Analysis  
Image quantification, quality control, statistical analysis, visualization and 
interpretation of the data generated from kinase activity assay was performed using 
the BioNavigator 6 software. Training and support was provided by Faris Naji 
(PamGene International) 
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Signal quantification was done using median signal minus background (median 
SigmBg) which represents the subtraction between the median signal and the median 
background. The PamApp for PTK Upstream Kinase Analysis was used to analyse the 
multiple parallel changes in peptide phosphorylation observed in experiments in which 
groups were compared. The PamApp uses the phosphoNET database to match the 
PamChip target peptides with kinases. The analysis of the difference between 
experimental groups is performed in terms of the upstream kinases instead of peptides. 
The PamApp groups the peptides in non-exclusive sets that belong to individual 
kinases. Based on the collective change between these peptide sets, the corresponding 
upstream kinases are scored for potential involvement in the difference between 
groups. Files generated from the PTK Upstream Kinase Analysis PamApp were then 
uploaded onto KinMap (http://kinhub.org/kinmap/index.html) and kinome 
phylogenetic trees were generated.  
2.2.4. Cell cycle FACS Assay 
The propidium iodide FACS assay was done to analyse the cell cycle status using 
DNA content as a marker for cell cycle stage.  
To perform the assay cells (50,000- 200,000 cells/well) were plated in 6-well 
plates. 12 hours after initial seeding, the cells were treated with varying concentrations 
of cisplatin, cisplatin + AZD1775 and AZD1775. The cells were harvested after 24 
and 72 hours using trypsin and centrifugation. Cells were then washed with PBS once, 
centrifuged and re-suspended in 300 µL of PBS. To this cell suspension cold 100% 
ethanol was added dropwise, while gently vortexing the samples. The samples were 
then stored at 4°C until all samples were collected.  
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The samples were centrifuged at 7000 rpm for 5 minutes at 4°C, washed with 
PBS once and centrifuged again. The cells were re-suspended in 500 µL + 5 µL of 
RNAse A (10 μg/μL) and incubated in a shaker at 37°C for 20 minutes.  Following the 
incubation, 15 µL of 1 mg/ml propidium iodide was added to the solution and the mix 
was left on ice for 1-2 hours.  
Cells were analysed in collaboration with Elisabeth Freyer (MRC Human 
Genetics Unit Technical Services). The cells were sorted using BD LSRFortessa X-20 
SORP (BD Biosciences, Becton, Dickinson and Company) employing a 488nm 
excitation laser at a sample flow rate of 100-500 events/s. Propidium iodide (PI) 
fluorescence was collected with 694/40nm Bandpass. Data from a minimum of 1,000 
(and maximum of 20,000) single cells per sample were collected for different cell 
lines. Data were analysed with FlowJo version 9.9.4 (FlowJo, LLC, Becton, Dickinson 
and Company). Height (PI-H) and Area (PI-A) of the PI signal was used to 
discriminate between single cells and clumps (doublets/triplets). The percentage of the 
single cells with subG1, G0/G1, S, G2/M and >4n DNA content were determined for 
each histogram. 
2.2.5. DNA Analysis 
2.2.5.1. DNA Extraction 
DNA was extracted from cell pellets using the Qiagen DNeasy blood and tissue 
kit. Pellets with up to 5x106 cells were made from growing cultures by trypsinization 
and spinning at 1400 rpm for 4 minutes in Fisher scientific accuSpin1 benchtop 
centrifuge. Cell pellets were re-suspended in 200 µL sterile PBS. To this suspension 
of cells 200 µL of lysis buffer AL + 20 µL 20mg/mL Proteinase-K was added and the 
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sample was incubated at 56°C for 10 minutes. For RNA-free genomic DNA, 4µL 
RNase A (100 mg/ml) was added and incubated for 2 minutes at room temperature. 
Following incubation, 200 µL of absolute ethanol was added and mixed by vortexing. 
The solution was then transferred to a Qiagen column with a 2mL collection tube and 
spun at 10000 rpm for 1 minute in Labnet Prism Microcentrifuge. The flow through 
was discarded with the collection tube. To wash the column, 500 µL of wash buffer 1 
(AW1) was used and the column was incubated with AW1 for 1 minute before 
spinning at 10,000 rpm for 1 minute in Labnet Prism Microcentrifuge. For the second 
wash 500 µL of wash buffer 2 (AW2) was used. The column was incubated at room 
temperature for 1 minute before centrifugation at 14,000 rpm for 3 minutes. The DNA 
was then eluted using 50 µL of elution buffer (EB) following incubation with EB for 
3 minutes and centrifugation at 10,000 rpm for a minute. The DNA was quantified 
using DeNovix spectrophotometer and only samples with an OD260/280 ratio >1.8 
were used.  
2.2.5.2. Polymerase Chain Reaction   
All PCR reactions, except for exon 1, were performed in a final volume of 20 µL. 
For amplification of exon 2 to exon 11 (final volume of 20 µL):  
 For 1 reaction  Final amount  
10ng/ul DNA 2 µL 20ng 
2x TaqGold 
master mix 
10 µL 1x 
20µM Forward 0.2 µL 200nM 
20µM Reverse 0.2 µL 200nM 
Water  7.6 µL  
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For amplification of exon 1(final volume of 30 µL): 
 1 reaction  Final amount  
10ng/ul DNA 4 µL 40ng 
QMM 5x 6 µL 1x 
Q solution 2x  15 µL 1x 
20µM Forward 0.6 µL 400nM 
20µM Reverse 0.6 µL 400nM 
Water  3.8 µL  
 
All components were thawed on ice before use.  Primers for each Wee1 exon were 
used accordingly. The cycle conditions for each amplicon are given below: 
PCR protocol: exon 1 
95°C 5min  
95°C 30s x 40 
58°C 30s  
72°C 1min 
72°C  5min  
4°C End   
 
PCR protocol: exon 2-4 
95°C 5min  
95°C 30s x 40 
56°C 30s  
72°C 1min 
72°C  5min  
4°C End  
 
PCR protocol: exon 5 and exon 6 
95°C 5min  
95°C 30s x 40 
50°C 30s  
72°C 30s 
72°C  5min  
4°C End  
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PCR protocol: exon 7-8, exon 9-10, exon 11 
95°C 5min  
95°C 30s x 40 
55°C 30s 
72°C 30s 
72°C  5min  
4°C End  
 
2.2.5.3. Sanger DNA sequencing  
PCR products were cleaned of extra primer and dNTPs using Illustra ExoStar. 
To 5 µL of PCR product 2 µL of enzyme mix was added. The mix was then spun at 
1000 rpm for 1 minute. The mixture was then put in the thermocycler using the 
following conditions.  
Step 1.  37°C  15 minutes 
Step 2.  80°C  15 minutes 
Step 3.  4°C  
 
After completion of incubation, 7µL of molecular biology grade water was 
added to 1 µL of cleaned reaction volume for dilution. After dilution, a sequencing 
reaction using Big Dye Terminator 3.1 was set up.  
Reagent  Volume  
Diluted cleaned reaction  2 µL 
Big Dye Terminator 3.1  8 µL 
Forward (or reverse primer)  0.5 µL 
Water  6.5 µL 
Total volume  17 µL 
 
After the sequencing reaction run, the reactions were cleaned to remove dyed 
dNTPs using the Dye ex column kit. Before use the spin column was gently vortexed 
to re-suspend the resin. The bottom closure was snapped off and the spin column was 
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placed in a 2mL collection tube and centrifuged at 1000rpm for 3 minutes. The spin 
column was then transferred to a clean microfuge tube. To the bed of the gel, 20µL of 
the sequencing reaction was added slowly.  The samples were then centrifuged at 
5000rpm for 3 minutes. The eluate containing the purified sequencing reaction was 
dried by placing in a heat block and run on the ABI 3730 DNA sequencer in 
collaboration with Jeffery Joseph (MRC Human Genetics Unit Technical Services).   
2.2.5.4. Sequence analysis  
Sequence analysis was done using mutation surveyor 
(https://softgenetics.com/mutationSurveyor.php). Sequences from amplicons were 
aligned against reference sequence GRCh38.p12. 
(https://softgenetics.com/mutationSurveyor.php). 
2.2.6. RNA Analysis 
2.2.6.1. RNA Extraction  
RNA was extracted using the Qiagen RNeasy mini kit. β-ME was added to 
Buffer RLT before use (10µL β-ME per 1mL Buffer RLT).  Buffer RPE was mixed 
with 4 volumes of absolute ethanol to obtain a working solution. 
Cells were grown in T25 flasks until they reached 70% confluency. The cells 
were then scraped in presence of cold PBS. The cells were centrifuged at 1300rpm for 
4 minutes. The pellets were then resuspended in 600µL of buffer RLT + BME to lyse 
the cells. The lysate was passed through a QIAshredder to homogenise the resuspended 
pellets, with a 2mL collection tube, and centrifuged in Labnet Prism Microcentrifuge 
for 2 minutes at full speed.  
Chapter 2                                                                                                                                 71 
 
The pass through eluate was then mixed well with 70% ethanol (in a 1:1 ratio) 
by gentle pipetting. Up to 700µL of sample was transferred to an RNeasy spin column 
placed in a 2mL collection tube and centrifuged for 15 s at ≥10,000 rpm in Labnet 
Prism Microcentrifuge. The flow through was discarded and on column DNase 
digestion was done to remove DNA contamination. The column was first washed by 
addition of 350µL RW1 Buffer and centrifugation for 15 s at ≥10,000 rpm and the 
flow through was discarded. Directly to the RNeasy spin column 10µL of DNase I 
incubation mix (10 µL DNase I stock solution (lyophilised DNase dissolved in 550 μL 
of the RNase free water) + 70 µL Buffer RDD) was added. The column was incubated 
at RT for 15 minutes. Following incubation, the column was washed using 350 µL 
RW1 Buffer and centrifuged for 15 s at ≥10,000 rpm. The flow through was discarded. 
The column was then washed using 500 µL Buffer RPE, and centrifuged for 15 s at 
≥10,000, discarding the flow-through. After a second washing the column was 
centrifuged for 2 minutes at the same speed.  The long centrifugation dries the spin 
column membrane, ensuring that no ethanol is carried over during RNA elution. 
Residual ethanol may interfere with downstream reactions. To make sure there was no 
ethanol carry over, the collection tube was changed and the spin column was 
centrifuged at full speed for 1 minute. The RNA was eluted in 30 µL of RNase-free 
water added directly onto the spin column membrane after centrifugation for 1 minute 
at ≥10,000 rpm.  
The RNA was quantified using the Nanodrop immediately after extraction and 
then sent to be run on the Agilent Bioanalyser for the analysis of integrity.  
Chapter 2                                                                                                                                 72 
 
2.2.6.2. Quality control for RNA isolation 
Before processing, the samples were checked for integrity of isolated RNA using 
Agilent 2100 Bioanalyser. The RNA integrity numbers (RIN) for all samples used for 
RNASeq experiments are given in Table 2.4. To run RNASeq on Illumina platform, 
minimum RIN values that are considered suitable are values equal to or greater than 
8. The lowest RIN value for the samples used in both experiments was 9.6, well in 
excess of the quality threshold. The RNA samples were also tested for DNA 
contamination using Qubit, the amounts were low for all samples and were well within 
the acceptable range for RNASeq. 
2.2.6.3. RNA Sequencing  
RNASeq was performed in collaboration with the Wellcome Trust Clinical 
Research Facility, Western General Hospital using the following protocol.  
Total RNA samples were assessed on the Agilent Bioanalyser with the RNA 
6000 Nano Kit for quality and integrity of total RNA. RNA was quantified and DNA 
contamination was assessed using the Qubit 2.0 Fluorimeter and the Qubit RNA HS 
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Sample number Cell line/Clone name  RIN value 
MKG1 ES-2 (treated 100nM AZD1775) 9.90 
MKG2 ES-2 (untreated) 9.90 
MKG3 ES-2 AZ_250:3 9.80 
MKG4 ES-2 AZ_250:3 9.90 
MKG5 ES-2 AZ_250:7 9.90 
MKG6 ES-2 AZ_1000:2_250:3 9.80 
MKG7 ES-2 AZ_1000:2_250:3 9.80 
MKG8 ES-2 AZ_1000:2_250:7 9.90 
MKG9 ES-2 (treated 100nM AZD1775) 9.90 
MKG10 ES-2 (untreated) 9.90 
MKG11 ES-2 AZ_250:3 9.90 
MKG12 ES-2 AZ_250:7 9.80 
MKG13 ES-2 AZ_250:7 9.80 
MKG14 ES-2 AZ_1000:2_250:3 9.60 
MKG15 ES-2 AZ_1000:2_250:7 9.80 
MKG16 ES-2 AZ_1000:2_250:7 9.80 
MKG101 OVCAR8 (treated 100nM AZD1775) 9.90 
MKG102 OVCAR8 (treated 100nM AZD1775) 9.80 
MKG103 OVCAR8 (treated 100nM AZD1775)  9.90 
MKG104 OVCAR8 AZ_300:2 9.80 
MKG105 OVCAR8 AZ_300:2 9.80 
MKG106 OVCAR8 AZ_300:2 9.70 
MKG107 OVCAR8 AZ_300:3 9.70 
MKG108 OVCAR8 AZ_300:3 9.60 
MKG109 OVCAR8 AZ_300:3 9.60 
MKG110 OVCAR8 AZ_300:4 9.80 
MKG111 OVCAR8 AZ_300:4 9.70 
MKG112 OVCAR8 AZ_300:4 9.60 
Table 2.4: RNA integrity (RIN) values for samples used for RNASeq. 
2.2.6.3.1. Library Preparation  
QC-ed RNA was processed for total-RNA library preparation using the TruSeq 
Stranded Total RNA with Ribo-Zero Gold kit according to the provided protocol.  
500ng of total-RNA was processed to deplete rRNA before being purified and 
fragmented using Ribo-Zero gold kit. Primed RNA fragments were reverse transcribed 
into first strand cDNA using reverse transcriptase and random primers. RNA templates 
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were removed and a replacement strand synthesised incorporating dUTP in place of 
dTTP to generate ds cDNA. AMPure XP beads (Beckman Coulter, #A63881) were 
then used to separate the ds cDNA from the second strand reaction mix, providing 
blunt-ended cDNA. A single 'A' nucleotide was added to the 3' ends of the blunt 
fragments to prevent them from ligating to another during the subsequent adapter 
ligation reaction, and a corresponding single 'T' nucleotide on the 3' end of the adapter 
provided a complementary overhang for ligating the adapter to the fragment. Multiple 
indexing adapters were then ligated to the ends of the ds cDNA to prepare them for 
hybridisation onto a flow cell, before 12 cycles of PCR were used to selectively enrich 
for those DNA fragments that had adapter molecules on both ends and amplify the 
amount of DNA in the library so as to be suitable for sequencing.  
2.2.6.3.2. Library QC  
Libraries were quantified by Qubit using the dsDNA HS assay and assessed for 
quality using the Agilent Bioanalyser with the DNA HS Kit (#5067-4626).  
2.2.6.3.3. Sequencing  
Sequencing was performed using the NextSeq 500/550 High-Output v2 (150 
cycle) Kit on the NextSeq 550 platform. Libraries were combined in two equimolar 
pools and run across two High-Output Flow Cells for experiment 1 and in one 
equimolar pool to run across one High-Output Flow Cell for experiment 2. 
Sequence coverage of each sample (MKG1-16) in Experiment 1 was even across 
both flow cells (see Appendix Figure 3), and all samples generated well in excess of 
50M reads (Minimum: 55M, Maximum: 74M, Mean: 60M). Experiment 2 including 
samples MKG101-112 were run on the same flow cell. Coverage of each sample was 
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relatively equivalent across the flow cell, and all samples generated well in excess of 
30M reads (Minimum: 39.4M, Maximum: 72.8M, Mean: 50.3M). 
2.2.6.3.4. Data Analysis  
RNASeq read mapping and bioinformatics analysis was performed in 
collaboration with Drs Graeme Grimes and John P. Thompson (IGMM). The raw data 
were run through bcbio RNASeq. bcbio RNASeq includes steps for quality control, 
adapter trimming, alignment, variant calling, transcriptome reconstruction and post-
alignment quantitation at the level of the gene and isoform.  
All sequenced reads were aligned to the human reference genome hg38 using 
hisat2 aligner (https://ccb.jhu.edu/software/hisat2/index.shtml). The abundance 
estimates were generated by Salmon, which uses the read counts for genes in each 
sample in the dataset and transforms the data into a matrix, where columns correspond 
to samples and rows represent genes. 
bcbioRNA-Seq pipeline performs QC with Inter-Correlation Analyses (ICA) 
and Principal Components Analyses (PCA) between samples. PCA was used to 
remove one replicate from the OVCAR8 set. After quality control, the samples were 
assessed for differentially expressed genes using DESeq2 guidelines 
(https://github.com/hbc/bcbioRNASeq).  
2.2.6.3.5. QC for RNASeq data 
The sequence data generated from the two runs on the Illumina platform were 
checked using the bcbio pipeline by bioinformatician Dr Graeme Grimes (IGMM). 
bcbio assesses the complexity and quality of the RNASeq data using a combination of 
tools and requires little user intervention. At the end of the assessment a report is 
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generated showing total reads, exonic mapping rate and count density (Appendix 
Figures 3A-C and 4A-C). 
Total reads per sample and mapping rate help to identify imbalances in 
sequencing depth or failures among the samples in a dataset. A similar sequencing 
depth across all samples in a dataset is expected and suggests a good run. Appendix 
Figure 3A and 4A show a similar depth for all samples, well exceeding the quality 
threshold of the standard cut off (~10 reads per million). Exonic mapping plots the 
percentage of reads mapped to the exons. For RNASeq, at least 60% of total reads 
should map to exons and not introns. All ES-2 and OVCAR8 samples exceeded this 
threshold except for sample MKG106, a replicate of clone OVCAR8 AZ_300:2, which 
was excluded from subsequent analysis.  
Comparing the distribution of normalized gene counts across samples assesses 
sample similarity within a dataset. Similar count distributions for all genes across the 
samples are expected unless the library sizes or total RNA expression are different. 
The count density plot (Appendix Figure 3C and 4C) shows log2 TMM (trimmed mean 
of M values-that is, normalised counts per gene). The y-axis plots the density which is 
number of counts per gene per sample. Based on the assumption that expression levels 
of genes between samples are not differentially expressed, it is expected that 
normalised count plots for all samples should be similar to each other. It can be seen  
in Appendix Figure 3C and 4C that all count plots overlap each other, indicating a 
good sequencing run.  
To find out how similar replicates are to each other within the different groups 
in the experiment, bcbio RNASeq performs a QC Principal Components Analysis 
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(PCA) between samples (Appendix Figure 3D and 4D). PCA is a multivariate 
technique that summarizes the patterns of variations in the experiment. It separates 
samples by expression variation, and identifies potential sample outliers. From the 
PCA, again the same replicate, OVCAR8 AZ_300:2 (MKG106), was an outlier, 
confirming the decision to exclude it from further analysis. All other replicates of each 
cell line plotted very close together, increasing confidence in the quality of the 
experiment.  
In summary, after processing raw data for both experiments through QC, only 
one sample was removed from further analysis, while the rest passed all QC steps.  
Before proceeding to further analysis of RNASeq data, only genes that showed 
expression differences of more than 2 fold (LFC>1) and with a p-value of <0.01 were 
included for further analysis.
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Chapter 3 
Analysis of High Grade Serous Cell lines for Sensitivity to Different Agents 
3.1. Introduction 
Wee1 kinase inhibition has been shown to sensitize p53 deficient cells to DNA 
damaging agents (Hirai et al., 2009). Since >96% of HGSOCs carry a mutation in the 
p53 gene (Cancer Genome Atlas Research Network, 2011; Vang et al., 2016), 
AZD1775 is likely to be an effective treatment option. A phase II clinical trial reported 
antitumour activity in p53 mutant refractory or resistant ovarian cancer patients (Leijen 
et al., 2016). However, one study on ovarian cancer cell lines has reported a decrease 
in viability using AZD1775 as a monotherapy irrespective of p53 mutation status 
(Zhang et al., 2017).  
The aim of this chapter was to assemble and characterise a suitable panel of 
HGSOC cell lines for study and to confirm their mutant p53 status.  Then to establish 
their sensitivity to Wee1 kinase inhibitor, AZD1775, and identify sensitivity changes 
in the panel to cisplatin and olaparib in combination with AZD1775.  
3.2. Selection of HGSOC cell line panel 
To represent the different molecular categories in HGSOC, a panel of 12 cell 
lines (see Table 3.1), 7 of which have been investigated by Domcke et al., (2013) for 
their suitability as models of HGSOC. Domcke et al., (2013) compared gene copy 
number alteration, mutation and expression data from HGSOC tumours and available 
HGSOC cell lines and concluded that many of the commonly used HGSOC cell lines, 
Chapter 3                                                                                                                                79 
 
such as IGROV1, SKOV3 and A2780, had little similarity to HGSOC tumours. Based 
on the data, the cell lines were divided into three categories: likely to be high grade 
serous (HGS), possibly HGS and unlikely HGS (Domcke et al., 2013).  The seven cell 
lines in the panel were classified as likely or possibly HGS. Four of the other cell lines 
in the panel were derived as pairs from patients before and after developing resistance 
to platinum (Langdon et al., 1988). They were not investigated by Domcke et al., 
(2013), but were validated independently as HGS by Beaufort et al., (2014) on the 
basis of growth characteristics, mRNA and miRNA expression, exon sequencing, drug 
response, clinical features and site of origin. The panel also includes SKOV3, which 
although considered unlikely HGS (Domcke et al., 2013), was retained because of the 
MMR defect that it carries.  
Cell line Validation Chemotherapy status 
COV318 likely HGS (Domcke et al., 2013)  
EFO21 possibly HGS (Domcke et al., 2013)  
ES-2 possibly HGS (Domcke et al., 2013)  
FUOV1 possibly HGS (Domcke et al., 2013)  
Kuramochi likely HGS (Domcke et al., 2013)  
OVCAR3 possibly HGS (Domcke et al., 2013) Platinum treated + other 
chemo (Hamilton et al., 1983) 
OVCAR8 possibly HGS (Domcke et al., 2013) Platinum treated (Schilder et 
al., 1990) 
PEO1  HGS (Beaufort et al., 2014) Platinum treated*  
PEO4 HGS (Beaufort et al., 2014) Platinum treated* 
PEO14 HGS (Beaufort et al., 2014) Untreated* 
PEO23 HGS (Beaufort et al., 2014) Platinum treated* 
SKOV3 unlikely HGS (Domcke et al., 2013) Other chemo treatment* 
Table 3.1. Validation of cell line panel. Table shows 12 cell lines and their validation 
status by Domcke et al., (2013) or Beaufort et al., (2014). Where known, the 
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chemotherapy status of the patient, prior to cell line isolation, is also indicated. *, 
Beaufort et al., 2014. 
3.3. Molecular characterisation of HGSOC cell lines 
In order to confirm the p53 mutant status of the 12 cell lines, Sanger sequencing 
of eleven exons of the p53 gene was performed in collaboration with Dr. Robert Hollis 
(IGMM) (see Table 3.2). All cell lines, except OVCAR8, showed a mutant p53 allele 
and no wild-type gene sequence. The Cancer Cell Line Encyclopaedia (CCLE) project 
shows a pathogenic p53 splice site SNP present in OVCAR8 cell line. Literature search 
also showed that OVCAR8 expresses a splice variant of p53 protein (Mitra et al., 2015; 
Anglesio et al., 2013; Domcke et al., 2013; Ikediobi et al., 2006). The results showed 
wild type sequence for OVCAR8 as the primers were not designed to detect splice site 
changes. The cell line was also validated using STR analysis and was confirmed as 
OVCAR8. Most of the p53 mutations in other cell lines were previously reported 
missense mutations. It is important to note that although most p53 mutations identified 
here are missense mutations, other mutations can lead to gain of p53 function. 
Cell line p53 Mutation dbSNP ID 
COV318 mutant exon6 I195F rs942158624 
EFO21 mutant exon4 C124R  
ES-2 mutant exon7 S241F rs28934573 
FUOV1 mutant exon5 H179D  rs587780070 
Kuramochi mutant exon8 D281Y rs764146326 
OVCAR3 mutant exon7 R248Q rs11540652 
OVCAR8 wt type, but see above  
PEO1 mutant exon7 G244D rs985033810 
PEO4 mutant exon7 G244D rs985033810 
PEO14 mutant exon8 C277F rs763098116 
PEO23 mutant exon8 C277F rs763098116 
SKOV3 mutant exon4 del.C  
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Table 3.2: p53 mutational status in HGSOC cell line panel.  The table shows the mutations 
detected in the cell lines upon sequencing for p53. The nature of the mutations and the dbSNP 
identifier for previously reported mutations are given.  
                                                --------------------------------------------- 
Data on the cell line panel from CCLE project for key genes frequently altered 
in HGSOC are shown in Table 3.3.  The CCLE project stores genetic and 
pharmacologic characterization of a large panel of human cancer models. Data for 
PEO4, PEO14, and PEO23 were not available from the CCLE project and so their 
information was obtained from literature search.  Genes frequently altered in HGSOC 
are arranged in their order of their appearance in Figure 1.1 going clockwise. There 
are examples in the panel of HR defects resulting from BRCA1 loss (Kuramochi), or 
methylation (OVCAR8), BRCA2 mutation (PEO1, Kuramochi) or EMSY amplification 
(OVCAR3), but not as a result of PTEN loss. For genes not involved in HR that are 
frequently altered in HGSOC, there is CCNE1 amplification/gain (COV318, EFO21, 
FUOV1, OVCAR3), NF1 loss (EFO21, FUOV1, Kuramochi, PEO1, PEO4 [Sangha 
et al., 2008]) and loss of RB1 (EFO21). However, as has been reported from more 
recent studies on HGSOC cancers themselves (Garsed et al., 2018), some HGSOC cell 
lines have alterations in both HR and non HR genes. For instance, Kuramochi (deleted 
BRCA1, mutated BRCA2, mutated ATM and ATR, deleted NF1) and PEO1 (mutant 
BRCA2 and NF1). The nature of the mismatch repair gene deficiency in SKOV3 
(deleted MLH1 and mutated MSH6) is also shown in Table 3.3. 
Mutations in genes commonly mutated in other cancers that are found in eight 
cell lines from the HGSOC cell line panel are shown in Appendix Table 1. Of 
particular note is the V600E mutation in BRAF for ES-2 resulting in constitutive 
activation of the MAPK pathway.  
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 Genes involved in HGSOC Genes involved in MMR 
Cell line BRCA1 BRCA2 EMSY PTEN ATM ATR RAD51C FANCJ CCNE1 NF1 RB1 MLH1 MLH3 MSH6 
COV318         Gain    Het 
loss 
Gain  Splice 
site ins 
EFO21     Gain  Gain  Gain   Gain  Hom del Hom 
del 
   
ES-2  Het loss   Het loss  Gain  Gain    Het 
loss 
   





Kuramochi  Hom del R2318* 
wt 
present 








   Hom del     
OVCAR3 Het loss Het loss Amp  Het loss Gain Gain  Gain  Gain  Gain  Het 
loss 
 Gain   
OVCAR8 Methyla
-ted 
   1.Gain 
2.V613L 
 Gain  Gain         
PEO1   Y1655* 
 







    
PEO4  revertant        A478T     
PEO14               
PEO23               
SKOV3    Het 
loss 






Table 3.3: Mutations in HGSOC and MMR related genes in the cell line panel. The table displays mutation information from The CCLE project and 
literature sources for each cell line. The genes are grouped into those commonly mutated in HGSOC and genes involved in mismatch repair. 
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3.4. Single agent treatment 
In order to evaluate the combined effect in vitro of cisplatin or olaparib combined 
with AZD1775 on the selected panel of high grade serous ovarian cancer cell lines, 
growth assays were first performed to assess the activity of the drugs as single agents. 
Cisplatin was selected as the preferred platinum containing drug due to its higher 
potency than carboplatin (Go and Adjei, 1999). The cells were allowed to grow in 
presence of drugs for five days followed by fixing and staining using the SRB growth 
assay protocol. Table 3.4 shows the IC50 values for AZD1775, cisplatin and olaparib 
for the 12 cell lines in the panel. The growth curves themselves, from which the IC50 
values were obtained, are shown in Figure 3.1. The difference in the IC50 value 
between the most and least sensitive cell line in the panel was 6-, 20- and 37-fold for 
AZD1775, cisplatin and olaparib, respectively. OVCAR3 was the most sensitive cell 
line to AZD1775 and cisplatin, while OVCAR8 was most sensitive to olaparib. Three 
of the four HR defective cell lines, OVCAR8 (BRCA1 methylation), OVCAR3 (EMSY 
amplification) and PEO1 (BRCA2 mutation), were ranked 1-3 for sensitivity to 
olaparib and 4, 1 and 2 for sensitivity to cisplatin. Their sensitivity to AZD1775 did 
not show the same strong association, with rankings 6, 1 and 4. The fourth HR 
defective cell line, Kuramochi, did not show increased sensitivity to any of the single 
agents. The least sensitive cell line to all the single agent treatments was FUOV1 
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Cell line IC50 
AZD1775 (nM) CDDP (nM) Olaparib (µM) 
 135 ± 7 200 ± 40 5.79 ± 2 
 150 ± 20 550 ± 40 13.0 ± 2.5 
 170 ± 25 1890 ± 130 27.3 ± 2 
 175 ± 15 210 ± 45 6.09 ± 2 
 210 ± 10 1200 ± 50 30.3 ± 3 
 215 ± 10 400 ± 35 2.64 ± 0.2 
 240 ± 20 250 ± 70 30.4 ± 8 
 250 ± 15 1550 ± 300 15.2 ± 4 
 370 ± 25 1800 ± 150 20.8 ± 7 
 430 ± 15 1600 ± 150 60.6 ± 20 
 
445 ± 50 600 ± 70 70.6 ± 30 
 860 ± 80 4050 ± 200 98.3 ± 10 
  
Table 3.4: Drug profiles for the cell line panel treated with AZD1775, cisplatin and 
olaparib. Table shows the IC50 values for AZD1775, cisplatin (CDDP) and olaparib for the 




Figure 3.1: Drug sensitivity profiles for the cell line panel treated with (A) AZD1775, (B) 
cisplatin and (C) olaparib. Shown are the growth curves for the panel of cell lines treated 
with AZD1775, cisplatin (CDDP) and olaparib for five days. Curves support the IC50 values 
shown in Table 3.4. The difference between the lowest and the highest IC50 values for 
AZD1775, cisplatin (CDDP) and olaparib was 6-, 20- and 37-fold respectively. The slowest 
growing cell line, FUOV1, has the highest IC50 values for all three drugs. The values are 
normalised against untreated controls.  Each value plotted was based on O.D. values from at 
least four individual wells.  (Figure on the next page)
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3.5. Changes in sensitivity to DNA damaging agents in combination with 
AZD1775  
The ability of Wee1 kinase inhibition combined with DNA damaging agents to 
force cells to undergo premature mitosis with damaged DNA leading to mitotic 
catastrophe has been proposed as an anticancer strategy (Mir et al., 2010). AZD1775 
has been reported to synergize with various genotoxic drugs in the treatment of 
different cancers (Matheson et al., 2016a; Kreahling et al., 2013; Hirai et al., 2010). 
However, when this project started, the efficacy of Wee1 kinase inhibitors combined 
with DNA damaging agents for HGSOC was not known. The data from single agent 
growth curves, described in the previous section, were used to select suitable 
AZD1775 concentrations in combination with cisplatin and olaparib for growth and 
viability assays on the HGSOC cell line panel.  
For growth assays the cells were directly seeded onto a 96 well plate in DNA 
damaging drug and AZD1775 and allowed to grow for a period of five days. On the 
fifth day the cells were fixed and then stained using SRB growth assay protocol. In 
case of viability assays, the cells were allowed to grow overnight in 96 well plates, and 
then treated sequentially with DNA damaging agent (cisplatin for 24 hours, or olaparib 
for 48 hours), followed by 24 hour treatment with AZD1775 before staining with 
Alamar Blue to determine viability. 
3.5.1. Cisplatin-AZD1775 combination treatment  
To determine the effect of Wee1 kinase inhibition and cisplatin activity when 
used in combination against HGSOC in vitro, the panel of HGSOC cell lines was 
treated in separate growth and viability assays with a range of cisplatin concentrations 
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(from 2 to 51200 nM) in the presence of two or three fixed concentrations of 
AZD1775. The AZD1775 concentrations used were expected to reduce cell growth by 
30 – 70%. The fold enhancements for each cell line are the ratios of the IC50 and IC20 
values for cisplatin alone compared to the equivalent values in the presence of 
AZD1775. For both assays the enhancement responses were categorised as major 
where cell lines showed >5-fold enhancement based on either IC50 or IC20 
comparisons, moderate where the changes were above 2-fold, borderline for cell lines 
where enhancement was <2-fold and no response for cell lines with no positive fold 
changes (see Tables 3.5 and 3.6). Curves for one representative cell line (ES-2, 
OVCAR8, OVCAR3 and PEO23) from each enhancement category are shown in 
Figures 3.2 and 3.3 for growth and viability assays, respectively.   
A previous study on medulloblastoma suggested synergistic activity of 
AZD1775 with cisplatin (Matheson et al., 2016b). A phase I clinical trial using a 
combination of three drugs; AZD1775, cisplatin, and docetaxel, in head and neck 
squamous cell carcinoma patients also reported promising antitumour activity 
(Méndez et al., 2018).  The data also show increases in sensitivity to cisplatin on 
treatment with AZD1775 in some of the cell lines, but not all. The most prominent 
change in sensitivity in the growth assay was observed in the HR proficient cell line 
ES-2, which showed 3-7 fold reduction in cisplatin IC50 and 8-14 fold reduction in 
cisplatin IC20 on AZD1775 exposure. OVCAR8 (HR deficient cell line) also showed 
a moderate enhancement in response and was ranked second in the growth assays 
(Table 3.5). Four cell lines, SKOV3, OVCAR3, PEO14 and PEO4, showed only a 
borderline enhancement with AZD1775. The six remaining cell lines (Kuramochi, 
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COV318, PEO23, FUOV1, PEO1 and EFO21) showed no enhancement effect of 
AZD1775 in the growth assay.   
On sequential treatment of the cell lines with the two drugs, the viability assay 
results demonstrated that OVCAR3, a HR proficient cell line, showed the biggest 
enhancement effect. There was 8-20 fold increased sensitivity to cisplatin as 
determined by IC20 values and >2 fold enhancement for IC50 values. OVCAR8 
showed a moderate enhancement response in the viability assay, while three cell lines, 
FUOV1, PEO14 and EFO21, showed borderline enhancement. ES-2, which showed 
the largest increase in sensitivity in the growth assays showed no AZD1775 
enhancement in the viability assay.  
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Table 3.5: Summary of SRB growth assay results for the cell line panel treated with CDDP alone and in combination with AZD1775 
























ES-2 1100 ± 
50 
100 71 160 ± 30s 7 700 ± 
55 
100 50 ± 10 14 Major 
150 55 220 ± 50s 5 150 60 ± 25 12 
175 43 180 ± 50s 6 175 50 ± 10 14 
200 40 400 ± 45s 3 200 85 ± 15 8 
OVCAR8 620 ± 
60 
200 77 240 ± 20s 3 225 ± 
20  
200 100 ± 10 2 Moderate 
250 73 300 ± 35s 2 250 125 ± 15 2 





90 93 1055 ± 90s 2 700 ± 
100 
90 300 ± 35 2 Borderline 
 120 86 1140 ± 90s 2 120 380 ± 40 2 
OVCAR3 400 ± 
65 
80 72 220 ± 45s 2 70 ± 20 80 45 ± 10 2 Borderline 
120 68 235 ± 75s 2 120 60 ± 20 No effect 
PEO14 650 ± 
80 
150 62 520 ± 100 No effect 235 ± 
35 
150 100 ± 25 2 Borderline 
225 44 500 ± 115s 2 225 390 ± 30 -2 
PEO4 1100 ± 
125 
300 44 1000 ± 450 No effect 330 ± 
40 
300 120 ± 55 3 Borderline 
425 30 2100 ± 300 -2 425 490 ± 150 -2 
Kuramochi 2000 ± 
450 
250 86 1840 ± 320 No effect 800 ± 
180 
250 335 ± 100 2 None 
375 67 2300 ± 360 No effect 375 660 ± 140 No effect 
COV318 1100 ± 
300 
90 96 1000 ± 200 No effect 600 ± 
150 
90 575 ± 85 No effect None 
350 45 1400 ± 500 No effect 350 690 ± 220 No effect 
PEO23 1930 ± 
325 
175 44 2183 ± 650 No effect 410 ± 
95 
175 418 ± 150 No effect None 
225 28 2495 ± 600 No effect 225 389 ± 250 No effect 
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CDDP (nM) Fold 
change 
FUOV1 1055 ± 
240 
400 71 1626 ± 400 -2 120 ± 
45 
400 161 ± 75 No effect  None 
550 46 1780 ± 415 -2 550 197 ± 85 -2 
PEO1 1060 ± 
350 
100 63 1770 ± 350 -2 185 ± 
80 
100 220 ± 45 No effect None 
175 48 2490 ± 800 -2 175 185 ± 85 No effect 
EFO21 595 ± 40 90 50 1297 ± 150 -2 130 ± 
15 
90 247 ± 45 -2 None 
125 40 1520 ± 220 -3 125 195 ± 50 -2 
 
Table 3.5: Summary of SRB growth assay results for the cell line panel treated with CDDP alone and in combination with AZD1775. Table 
shows the IC50 and IC20 values for cisplatin and the fold enhancement of sensitivity to cisplatin for cell lines treated with cisplatin alone and with 
multiple concentrations of AZD1775. The percent control growth is (cell growth in presence of AZD1775/ cell growth of untreated cells) x 100. The 
fold change for each cell line are the ratios of the IC50 and IC20 values for cisplatin alone compared to the equivalent values in the presence of 
AZD1775. Where applicable, the IC values are the means of 2 or more experiments. The last column summarises the cisplatin enhancement response 
in the presence of AZD1775. The largest increase in sensitivity was observed for the ES-2 cell line with >5 fold decreases in both IC50 and IC20 values.   
S indicates IC50 values for AZD1775 combination treatments with cisplatin that are significantly different (i.e. lower) from the corresponding IC50 
value for cisplatin alone based on the 95% confidence interval estimates for IC50 values. These 95% confidence intervals are shown for selected cell 
lines in Figure 3.2, where non-overlapping IC50 confidence intervals indicate a significant difference. 



















Figure 3.2: Growth curves showing the ability of AZD1775 to enhance sensitivity to 
cisplatin. Plots support the data in Table 3.5, where the enhancement response is divided into 
four categories: major, moderate, borderline and no effect. Growth curves for four 
representative cell lines treated with cisplatin alone and with increasing concentrations of 
AZD1775 are shown. ES-2 shows a major enhancement response, with a >5-fold reduction in 
the IC50 for cisplatin in the presence of AZD1775. The OD vlues are normalised against 
untreated controls for CDDP only, and AZD1775 treated control for CDDP + AZD1775 
treatment curves. Note that 95% confidence intervals for all IC50 values are plotted, but will 
only be separated if there is no overlap between intervals. For each value plotted, the 
experiment had at least four O.D. values from four individual wells.
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Table 3.6: Summary of Alamar Blue viability assay results for the cell line panel treated with CDDP alone and in combination with AZD1775 










+ [X] nM AZD1775 





CDDP (µM) Fold 
change 







OVCAR3 4.85 ± 
1.0 
200 96 2.00 ± 0.4s 2 2.50 ± 
0.43 
200 0.30 ± 0.09 8 Major 
400 88 1.20 ± 0.3s 4 400 0.12 ± 0.03 20 
800 63 1.90 ± 0.5s 3 800 0.12 ± 0.03 20 
OVCAR8 6.74 ± 
0.72 
250 95 3.43 ± 0.4s 2 2.37 ± 
0.33 
250 0.91 ± 0.12 3 Moderate 
500 84 2.94 ± 0.3s 2 500 0.64 ± 0.10 4 
1000 71 4.05 ± 0.4s 2 1000 1.12 ± 0.14 2 
FUOV1 31.9 ± 
4.0 
1000 75 30.1 ± 3.4 No effect 14.6 ± 
2.12 
1000 8.45 ± 1.39 2 Borderline 
1500 72 33.6 ± 4.0 No effect 1500 10.3 ± 1.55 No effect 
2000 60 13.1 ± 4.8s 2 2000 13.7 ± 2.07 No effect 
PEO14 14.1 ± 
2.2 
300 100 10.6 ± 1.4 No effect 4.35 ± 
0.93 
300 1.77 ± 0.33 2 Borderline 
600 94 12.1 ± 2.0 No effect 600 2.72 ± 0.66 2 





250 86 12.7 ± 1.6 No effect 1.84 ± 
0.46 
 
250 1.88 ± 0.34 No effect Borderline 
1000 82 14.1 ± 1.9 No effect 1000 1.63 ± 0.29 No effect 
2000 84 11.4 ± 3.3 No effect 2000 0.52 ± 0.18 4 
ES-2 2.00 ± 
0.2 
150 88 1.71 ± 0.2 No effect 0.70 ± 
0.08 
150 0.58 ± 0.10 No effect None 
250 81 1.89 ± 0.4 No effect 250 0.55 ± 0.14 No effect 
500 67 2.76 ± 0.3 No effect 500 0.60 ± 0.08 No effect 
1000 59 2.96 ± 0.8 -2 1000 0.59 ± 0.23 No effect 
Kuramochi 28.9 ± 
5.4 
500 97 28.1 ± 7.0 No effect 12.4 ± 
2.79 
500 9.04 ± 2.77 No effect None 
1000 92 32.3 ± 4.7 No effect 1000 9.91 ± 1.73 No effect 
2000 78 34.6 ± 6.2 No effect 2000 8.69 ± 1.40 No effect 
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PEO1 34.2 ± 
3.4 
250 98 35.6 ± 4.5 No effect 12.7 ± 
1.68 
250 12.8 ± 2.13 No effect None 
500 97 34.7 ± 3.2  No effect 500 12.3 ± 1.50 No effect 
1000 92 34.0 ± 2.7  No effect 1000 14.2 ± 6.48 No effect 
COV318 7.94 ± 
1.1 
700 83 8.55 ± 1.0 No effect 4.45 ± 
0.82 
700 4.24 ± 0.67 No effect None 
1400 77 9.08 ± 1.0  No effect 1400 4.26 ± 0.59 No effect 
2100 71 9.90  ±1.0  No effect 2100 4.83 ± 0.72 No effect 
PEO4 20.0 ± 
5.0 
500 96 21.1  ± 3.5  No effect 4.63 ± 
1.66 
500 3.35 ± 0.81 No effect None 
1000 90 24.5 ± 4.5  No effect 1000 3.48 ± 0.82 No effect 
2000 79 33.3 ± 5.0 -2 2000 6.53 ± 1.23 No effect 
PEO23 33.5 ± 
3.8 
300 100 54.6  ± 5.2 -2 15.5 ± 
2.17 
300 13.6 ± 6.35 No effect None 
600 96 37.2 ± 4.5  No effect 600 14.4 ± 2.16 No effect 
1200 94 30.3 ± 3.5  No effect 1200 11.1 ± 1.73 No effect 
SKOV3 8.13 ± 
1.0 
250 88 7.96 ± 1.4  No effect 1.90 ± 
0.32 
250 1.82 ± 0.45 No effect None 
1200 83 8.80 ± 1.7  No effect 1200 1.28 ± 0.34 No effect 
2000 60 13.4 ± 3.7 -2 2000 1.57 ± 0.57 No effect 
Table 3.6: Summary of Alamar Blue viability assay results for the cell line panel treated with CDDP alone and in combination with AZD1775. Table shows 
the IC50 and IC20 values for cisplatin and the fold enhancement of sensitivity to cisplatin for cell lines treated with cisplatin alone and with multiple concentrations of 
AZD1775. The percent control viability is (cell viability in presence of AZD1775/ cell viability of untreated cells) x 100. The fold change for each cell line are the 
ratios the IC50 and IC20 values for cisplatin alone compared to the equivalent values in the presence of AZD1775. Where applicable, the IC values are the means of 2 
or more experiments. The last column summarises the cisplatin enhancement response in the presence of AZD1775. The largest increase in sensitivity was observed 
for the OVCAR3 cell line with >2-fold decreases in IC50 and >8 decreases in IC20 values. S indicates IC50 values for AZD1775 combination treatments with cisplatin 
that are significantly different (i.e. lower) from the corresponding IC50 value for cisplatin alone based on the 95% confidence interval estimates for IC50 values. These 
95% confidence intervals are shown for selected cell lines in Figure 3.3, where non-overlapping IC50 confidence intervals indicate a significant difference. 




















Figure 3.3: Viability curves showing the ability of AZD1775 to enhance sensitivity to 
cisplatin. Plots support the data in Table 3.6, where the enhancement response is divided into 
four categories: major, moderate, borderline and no effect. Viability curves for four 
representative cell lines treated with cisplatin alone and with increasing concentrations of 
AZD1775 are shown. OVCAR3 shows a major enhancement response based on IC20 values, 
with a ~10-fold increase in sensitivity for cisplatin in the presence of AZD1775. Note: The 
CDDP only curves are normalised against untreated controls and AZD1775 treated control for 
CDDP + AZD1775 treatment curves. For each value plotted, the experiment had at least four 
O.D. values from four individual wells.  
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3.5.2. Olaparib-AZD1775 combination treatment  
To study the effect of AZD1775 on olaparib sensitivity in HGSOC in vitro 
combination treatment experiments were performed with a range of olaparib 
concentrations, from 0.05 to 1024 µM, using two or three fixed concentrations of 
AZD1775, as shown in Table 3.7, for each cell line in growth and viability assays. The 
AZD1775 concentrations used were mostly the same as for the cisplatin - AZD1775 
combination and the same enhancement response categories were used. Results for the 
cell line panel are shown in Tables 3.7 and 3.8 for growth and viability assays 
respectively. Curves for representative cell lines (ES-2, OVCAR8, OVCAR3 and 
PEO1 or PEO14) from the different enhancement categories are shown in Figures 3.4 
and 3.5 for growth and viability assays, respectively.   
Studies on AML and ALL (Garcia et al., 2017) and gastric cancer (Lin et al., 
2018) have reported an increased antitumour response, when olaparib is used with 
AZD1775 instead of olaparib monotherapy.  An in vitro study on one ovarian cancer 
cell line (OVCAR3) and two endometrial cell lines (KLE and Hec50) has also shown 
that Wee1 kinase inhibition by AZD1775 increases sensitivity to olaparib and 
gemcitabine (Meng et al., 2018).  Data from growth assays (Table 3.7) showed an 
increase in sensitivity to olaparib in combination with AZD1775 for ES-2 and 
OVCAR8 with major enhancement in both IC50 and IC20 values, and for OVCAR3, 
PEO4 and SKOV3 with moderate enhancement. For sequential exposure to the two 
drugs using viability assays, OVCAR3 showed the largest enhancements observed for 
any cell line in any of the combination treatment assays, with >10-fold enhancement 
at IC50 and >90-fold at IC20. Contrary to its response in the growth assay, ES-2 showed 
no enhancement response in the viability assay.  
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Table 3.7: Summary of SRB growth assay results for the cell line panel treated with olaparib alone and in combination with AZD1775  


























ES-2 25.3 ± 
3.4 
150 68 4.78 ± 1.1s 5 6.89 ± 
1.2 
150 1.02 ± 0.19 7 Major 
200 44 4.23 ± 1.9s 6 200 0.73  ± 0.14 9 
OVCAR8 4.29 ± 
0.3 
200 84 1.12 ± 0.1s 4 0.99 ± 
0.2 
200 0.48 ± 0.05 2 Major 





80 86 1.43 ± 0.4s 4 1.03 ± 
0.4 
80 0.30 ± 0.06 3 Moderate 
120 66 0.94 ± 0.3s 6 120 0.24 ± 0.08 4 
PEO4 65.6 ±  
25 
300 74 14.4 ± 5.4s 5 5.02 ± 
3.4 
300 1.37 ± 0.89 4 Moderate 
425 56 13.1 ± 6.2s 5 425 1.01 ± 0.81 5 
SKOV3 36.1 ± 
7.1 
90 80 24.3 ± 5.5  2 5.60 ± 
1.3 
90 4.08 ± 1.19 No effect Moderate  
120 65 20.6 ± 4.8s 2 120 2.89 ± 0.99 2 
EFO21 18.2 ± 
3.7 
90 42 20.3 ± 4.3  No effect 1.91 ± 
0.4 
90 1.18 ± 0.22 2 Borderline 
350 33 28.2 ± 9.4  -2 350 1.23 ± 0.36 2 
COV318 155 ±  
50 
90 80 175 ± 55 No effect 17.6 ± 
7.1 
90 16.8 ± 6.56 No effect None 
350 45 240 ± 90 -2 350 23.5 ± 10.7 No effect 
FUOV1 30.4 ± 
9.6 
400 58 29.4 ± 7.2  No effect 3.03 ± 
1.1 
400 3.18 ± 0.85 No effect None 
550 50 26.1 ± 7.0  No effect 550 2.20 ± 0.58 No effect 
PEO1 6.13 ± 
0.8 
100 72 6.31 ± 1.2  No effect 0.72 ± 
0.1 
100 0.52 ± 0.10 No effect None 
175 57 10.9 ± 3.7 -2 175 1.14 ± 0.42 -2 
PEO14 38.0 ±  
10 
150 79 48.7 ± 25  No effect 2.79 ± 
0.9 
150 2.26 ± 1.48 No effect None 
225 59 45.6 ± 20  No effect 225 1.87 ± 1.12 2 
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+ [X] nM AZD1775 
















PEO23 21.4 ± 
6.2 
175 50 50.0 ± 15 -2 8.43 175 6.12 ± 3.66 No effect None 
225  32 98.5 ± 30  -5 225  12.4 ± 6.82 -2 
Kuramochi 25.2 ± 
7.1 
250 85 64.3 ± 10 -2 2.79 250 5.43 ± 0.95 -2 None 
375 52 174 ± 60 -7 375 18.0 ± 6.95 -6 
 
Table 3.7: Summary of SRB growth assay results for the cell line panel treated with olaparib alone and in combination with AZD1775. Table shows 
the IC50 and IC20 values for olaparib and the fold enhancement of sensitivity to olaparib for cell lines treated with olaparib alone and with multiple concentrations 
of AZD1775. The percent control growth is (cell growth in presence of AZD1775/ cell growth of untreated cells) x 100. The fold change for each cell line are 
the ratios the IC50 and IC20 values for olaparib alone compared to the equivalent values in the presence of AZD1775. Where applicable, the IC values are the 
means of 2 or more experiments. The last column summarises the olaparib enhancement response in the presence of AZD1775. The largest increase in sensitivity 
was observed for the OVCAR8 and ES-2 cell lines with >5-fold decreases in both IC50 and IC20 values. S indicates IC50 values for AZD1775 combination 
treatments with cisplatin that are significantly different (i.e. lower) from the corresponding IC50 value for cisplatin alone based on the 95% confidence interval estimates 
for IC50 values. These 95% confidence intervals are shown for selected cell lines in Figure 3.4, where non-overlapping IC50 confidence intervals indicate a significant 
difference. 
 




















Figure 3.4: Growth curves showing the ability of AZD1775 to enhance sensitivity to 
olaparib. Plots support the data in Table 3.7, where the enhancement response is divided into 
four categories: major, moderate, borderline and no effect. Growth curves for four 
representative cell lines treated with olaparib alone and with increasing concentrations of 
AZD1775 are shown. ES-2 and OVCAR8 show a major enhancement response, with a >5-
fold reduction in the IC50 for olaparib in the presence of AZD1775. The OD values are 
normalised against untreated controls for olaparib only, and AZD1775 treated control for 
olaparib + AZD1775 treatment curves. For each value plotted, the experiment had at least four 
O.D. values from four individual wells. 
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Table 3.8: Summary of Alamar Blue viability assay results for the cell line panel treated with olaparib alone and in combination with AZD1775 



























OVCAR3 187 ± 17 200 97 8.10 ± 3.9s 23 82.9 ± 
10.8 
200 0.72 ± 0.30 115 Major 
400 85 8.80 ± 2.7s 21 400 0.80 ± 0.31 104 
800 55 15.0 ± 2.4s 12 800 0.91 ± 0.17 91 
OVCAR8 28.2 ± 
7.5 
250 100 11.5 ± 2.4s 3 3.10 ± 
1.02  
250 1.71 ± 0.45 2 Moderate  
500 97 10.8 ± 2.1s 3 500 1.77 ± 0.44 2 
1000 79 11.5 ± 2.2s 3 1000 2.00 ± 0.50 2 
SKOV3 540 ± 75 250 99 345 ± 45s 2 151 ± 
30.1 
250 67.5 ± 13.1 2 Moderate 
1200 94 320 ± 35s 2 1200 66.5 ± 10.6 2 
2000 90 300 ± 30s 2 2000 58.2 ± 8.78 3 
FUOV1 424 ± 65 1000 100 280 ± 45s 2 88.7 ± 
19.8 
1000 36.9 ± 7.99 2 Moderate 
1500 100 270 ± 40s 2 1500 32.2 ± 6.69 3 
2000 97 255 ± 30s 2 2000 31.5 ± 6.81 3 
PEO4 524 ± 
120  
500 96 425 ± 65  No effect 140 ± 
46.9 
500 80 ± 17.3 2 Borderline  
1000 96 455 ± 60  No effect 1000 90 ± 15.0 2 
2000 81 400 ± 50  No effect 2000 65 ± 10.6 2 
Kuramochi 773 ± 
190 
500 95 730 ± 150  No effect 245 ± 
64.6 
500 170 ± 48.1 No effect None 
1000 88 665 ± 145  No effect 1000 145 ± 37.1 2 
2000 83 600 ± 120  No effect 2000 130 ± 31.9 2 
PEO14 790 ± 85 300 100 700 ± 100  No effect 390 ± 
39.8 
300 190 ± 30.9 2 None 
600 95 800 ± 85  No effect 600 275 ± 33.6 No effect 
1200 80 940 ± 150  No effect 1200 350 ± 56.5 No effect 
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Olaparib  (µM) Fold 
change 
ES-2 35.5 ± 9.2 250 90 25.5 ± 5.6  No effect 3.76 ± 
1.21 
250 2.99 ± 0.79 No effect None 
500 84 32.1 ± 7.3  No effect 500 3.53 ± 0.99 No effect 
1000 80 35.8 ± 8.6  No effect 1000 3.94 ± 1.18 No effect 
PEO23 230 ± 50 300 95 220 ± 45  No effect 27.2 ± 
8.72 
300 20.8 ± 6.43 No effect None 
600 94 280 ± 50  No effect 600 24.1 ± 6.32 No effect 
1200 86 300 ± 55  No effect 1200 42.9 ± 11.5 -2 
PEO1 31.9 ± 7.4 200 90 43.1 ± 8.1  No effect 2.11 ± 
0.48 
200 4.45 ± 0.99 -2 None 
500 83 75.3 ± 15 -2 500 10.9 ± 3.07 -5 
1000 80 83.1 ± 20 -3 1000 10.5 ± 2.79 -5 
COV318 1730 ± 
480  
700 77 3450 ± 420 -2 200 ± 80 700 725 ± 180 -4 None 
1400 75 4955 ± 700 -3 1400 900 ± 250 -5 





250 87 1825 ± 1202 -2 82.6 ± 50 250 73.4 ± 26.2 No effect None 
1000 76 3730 ± 2330 -3 1000 65.3 ± 21.1 No effect 
2000 76 20700 -18 2000 93.5 ± 52.3 No effect 
Table 3.8: Summary of Alamar Blue viability assay results for the cell line panel treated with olaparib alone and in combination with AZD1775. Table shows 
the IC50 and IC20 values for olaparib and the fold enhancement of sensitivity to olaparib for cell lines treated with olaparib alone and with multiple concentrations of 
AZD1775. The percent control viability is (cell viability in presence of AZD1775/ cell viability of untreated cells) x 100. The fold change for each cell line are the 
ratios the IC50 and IC20 values for olaparib alone compared to the equivalent values in the presence of AZD1775. Where applicable, the IC values are the means of 2 
or more experiments. The last column summarises the olaparib enhancement response in the presence of AZD1775. The largest increase in sensitivity was observed 
for the OVCAR3 cell line with >10-fold enhancement at IC50 and >90-fold at IC20. *These values are unreliable because of inability to use sufficiently high olaparib 
concentrations to get the curve below the 50 percent viability level. S indicates IC50 values for AZD1775 combination treatments with cisplatin that are significantly 
different (i.e. lower) from the corresponding IC50 value for cisplatin alone based on the 95% confidence interval estimates for IC50 values. These 95% confidence 
intervals are shown for selected cell lines in Figure 3.5, where non-overlapping IC50 confidence intervals indicate a significant difference.  




















Figure 3.5: Viability curves showing the ability of AZD1775 to enhance sensitivity to 
olaparib. Plots support the data in Table 3.8, where the enhancement response is divided into 
four categories: major, moderate, borderline and no effect. Viability curves for four 
representative cell lines treated with olaparib alone and with increasing concentrations of 
AZD1775 are shown. OVCAR3 shows a major enhancement response, with a ~10-fold 
reduction in the IC50 for olaparib in the presence of AZD1775.  The olaparib curves are 
normalised against untreated controls and AZD1775 treated control for olaparib + AZD1775 
treatment curves. For each value plotted, the experiment had at least four O.D. values from 
four individual wells.  
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3.6. Discussion  
Mutations found in p53 in human cancers are mostly missense and normally 
occur in the conserved DNA binding core domain of the protein, leading to loss of 
function (Levine, 1997; Hansen and Oren, 1997). However, some cells with mutant 
p53 have the ability to express elevated levels of full length mutant protein, with a gain 
of function (Michalovitz et al., 1991). p53 mutants can also have dominant negative 
effects on the wild type p53 protein expressed in the same cell (Michalovitz et al., 
1991). All except one of the mutations observed in the cell lines used were missense 
mutations that were already reported (see Table 3.2).  
BRCA1 and BRCA2 proteins are involved in the preservation of genome 
integrity (Scully, 2001). They are required for the repair of double strand DNA breaks 
by HR and their loss can lead to accumulated damage (Venkitaraman, 2002). HGSOC 
subtypes with HR defects are more likely to respond to DNA damaging agents that 
cause double strand DNA breaks, or platinum based therapies that generate interstrand 
crosslinks. The PARP inhibitor olaparib leads to the accumulation of double strand 
breaks on replication. So HR defective HGSOC cell lines (which need to repair the 
double strand breaks by alternative means such as NHEJ) are also sensitive to PARP 
inhibition (Scott et al., 2015). I found that three of the four HR defective cell lines in 
the panel, OVCAR8 (BRCA1 methylation), OVCAR3 (amplification of EMSY that 
binds to BRCA2 preventing its function [Hughes-Davies et al., 2003]) and PEO1 
(BRCA2 mutation), were ranked 1-3 for sensitivity to olaparib and 4, 1 and 2 for 
sensitivity to cisplatin.  
It was also expected that the HR defective cell lines would be more sensitive to 
Wee1 kinase inhibition and show greater enhancements of sensitivity in combination 
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treatments with cisplatin and olaparib. Their sensitivity to AZD1775 did not show the 
same strong association, with rankings 6 (OVCAR8), 1 (OVCAR3) and 4 (PEO1) 
while the fourth HR defective cell line, Kuramochi, did not show increased sensitivity 
to any of the single agents or combination treatments. However, two of the three cell 
lines that showed the strongest enhanced sensitivity responses in the growth and 
viability assays with the cisplatin-AZD1775 and olaparib-AZD1775 combination 
treatments were the HR defective lines OVCAR3 and OVCAR8. The other strong 
responder in growth assays was the HR proficient cell line ES-2. 
In the presence of AZD1775 in combination treatments it was predicted for cells 
to show increased sensitivity to cisplatin or olaparib, reflected in a leftward shift in 
sensitivity curves and a corresponding reduction in IC50 and IC20 levels. For instance, 
see Figure 3.2 and Table 3.5 for ES-2 in the growth assay combination of AZD1775 
and cisplatin and Figure 3.5 and Table 3.8 for OVCAR3 in the viability assay 
combination of AZD1775 and olaparib. While the major and moderate enhanced 
sensitivities observed in combination treatments were maintained over a range of 
AZD1775 concentrations, the curves failed to show further shifts to the left as 
AZD1775 concentration was increased.  This could be because the enhanced 
sensitivity to DNA damage in combination with increased concentrations of AZD1775 
was counterbalanced by its increased toxicity.  
It is noteworthy that ES-2, on sequential treatment with AZD1775 and cisplatin 
or olaparib in the viability assay, did not demonstrate any enhanced sensitivity, but 
showed major enhancement when treated simultaneously in the growth assays with the 
same combinations. While OVCAR3, which was categorised as a borderline and 
moderate responder for cisplatin – AZD1775 and olaparib – AZD1775 in the 
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simultaneous treatment growth assay, showed major enhancement in response to both 
sequential treatments in the viability assay. The AZD1775 treatment might need longer 
exposure time for ES-2 to produce enhanced sensitivity to the DNA damaging drugs, 
than for OVCAR3.  
An additional complicating factor in the interpretation of these experiments is 
the observed differences in growth rates while culturing the cell lines. The least 
sensitive cell line to all the single agent treatments was FUOV1. It was the slowest 
growing cell line in the panel. Most chemotherapeutic agents are known to 
preferentially target growing and dividing cells (Moore et al., 2012). The slow growth 
of FUOV1 likely makes it less susceptible to the treatments used.   
The paired cisplatin sensitive and resistant cell lines, PEO1/4 and PEO14/23, 
showed the expected 8- and 6-fold increase in IC50, respectively, for the resistant 
member of each pair on treatment with cisplatin alone (Table 3.4). However, PEO1 
did not demonstrate the same expected low cisplatin IC50 in the subsequent cisplatin – 
AZD1775 combination treatment assay done some time after the single agent 
treatment assays (Table 3.5). PEO1 carries a point mutation in BRCA2 that is known 
to revert spontaneously in higher passage cultures (Norquist et al., 2011). In an attempt 
to minimise this complication the earliest passage PEO1 cultures available from their 
original isolation (Langdon et al., 1988) were used. When the unexpected result was 
obtained in the combination assay, the early frozen stocks were used to repeat the 
experiment, but the result was the same.  
From the results with combination treatments for the panel of twelve cell lines, 
two were chosen to be used as parental cell lines for generation of clones resistant to 
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AZD1775 alone, AZD1775 in combination with cisplatin and olaparib alone. The 
choice was between OVCAR3 and ES-2 for an HR proficient line and between 
Kuramochi and OVCAR8 for an HR deficient subtype. OVCAR3 was not selected 
because, although it had CCNE gene gain (typical of HR proficient HGSOC), it also 
carries an EMSY amplification (Table 3.3), found in HR deficient subtypes. 
Kuramochi was not taken forward as the HR deficient line because no enhancements 
were seen with the combination treatments. ES-2 and OVCAR8 were selected to 
represent the HR proficient and HR deficient HGSOC, respectively. In addition to their 
good response to the combination treatments in growth assays, their favourable cell 
line characteristics were also taken into consideration. These included good growth 
rate and ease of maintenance in cell culture and the ability for clonal growth when 
seeded at low densities. 
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Chapter 4 
Isolation and Characterisation of Resistant Clones 
4.1. Introduction  
Compared to normal cells, tumour cells have increased ability to adapt to change 
in the tumour environment to help them survive. They can activate or inactivate 
signalling pathways to improve survival and evade death, thus becoming resistant to 
chemotherapy drugs (Debatin and Krammer, 2004; Lowe et al., 2004). HGSOC 
exhibits a complex genomic landscape, showing widespread gene copy number 
alterations and genomic instability. Genomic instability in several cancers has been 
reported to increase the frequency of chemoresistance (Duesberg et al., 2000; Swanton 
et al., 2009).   
The aim of this chapter was to first generate independent clones from the 
HGSOC cell lines ES-2 and OVCAR8 that are resistant to AZD1775, cisplatin – 
AZD1775 and olaparib, then to characterise the level of resistance to the different 
agents in these clones and begin an investigation of the mechanisms of resistance.  
4.2. Selection of resistant clones 
Choosing appropriate cell lines to generate resistant clones in vitro forms the 
basis of the study of resistance mechanisms, as the mutations the parental cell lines 
carry will affect the ways the cells gain resistance. The basis of selection of the ES-2 
and OVCAR8 lines, as described in Section 3.6, was their different HR status, coupled 
with their ease of maintenance in culture and ability to grow clonally.  The 
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nomenclature system for clones was chosen to indicate the cell line used, the selective 
agent, its concentration, and an identifying number. Thus, ES-2 AZ_250:3 is ES-2 
clone number 3 selected for resistance to 250nM AZD1775. While ES-2 
AZ_1000:1_250:3 was isolated after two rounds of selection in AZD1775; ES-2 clone 
number 1 selected for resistance to 1000nM AZD1775 from clone ES-2 AZ_250:3. 
4.2.1. Generation of AZD1775 resistant clones from HR proficient and deficient 
cell lines 
Before starting an experiment to get resistant clones, a pilot experiment was set 
up to check the ability of ES-2 cells to survive at high concentrations of AZD1775. 
The pilot experiment used low seeding densities in a six well plate (100,000, 200,000 
and 250,000 cells per well), where cells were treated with three different 
concentrations of AZD1775, 100nM, 200nM and 300nM.  The plates were monitored 
for growth, and medium was changed as required. The wells that were treated with 
100nM AZD1775 in addition to the wells that received 250,000 cells per well were 
nearly confluent after a week and were discarded. The wells with lower seeding 
densities (100,000 and 200,000) started forming colonies after ten days at the 200 and 
300nM concentrations of AZD1775. Treatment with 250nM of AZD1775 was selected 
as the initial concentration to isolate resistant clones. For comparison the ES-2 IC50 for 
AZD1775 in the 5-day growth assay was 210nM (see Table 3.4). 
To check the ability of ES-2 cells to form colonies at the low seeding densities 
required for clonal isolation, cells were plated in a 96 well plate at four different 
seeding densities, 250, 500, 1000 and 2000 cells per well. From these seeding 
densities, two seeding densities (500 and 1000 cells per well) were chosen to proceed 
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as cells became confluent when seeded at 2000 cells per well and were too sparse at 
250 cells per well to form colonies. For isolation of resistant clones, cells were plated 
directly into drug-containing medium and left for a week before checking for 
developing colonies, with drug-containing medium then being changed as required. 
Colonies started appearing after two weeks and were isolated when they had reached 
a sufficient size (~1000 cells).  Only the wells with single colonies were trypsinized. 
The frequency of colony formation was 7x10-4 (Calculated by counting total colonies 
observed on a 96-well plate/total number of cells plated). The picked colonies were 
taken on to a 12 well plate and allowed to grow in non-selective media till they became 
~40% confluent, after which selection was added and cells were then continuously 
grown in selection. Fifteen independent clones (ES-2 AZ_250:n, where n=1-15) were 
isolated from this 250nM selection step (Figure 4.1).  
Two of these fifteen clones (ES-2 AZ_250:3 and ES-2 AZ_250:7) were 
randomly selected for a second challenge with a higher concentration of AZD1775. 
The 250nM AZD1775 resistant clones were also plated at low densities (500 and 1000 
cells per well) in a 96 well plate and treated with 1000nM AZD1775. Colonies 
appeared at a frequency of 3 x 10-4 and were isolated, grown up and maintained as 
described above. Ten clones (ES-2 AZ_1000:n_250:3, n=1-10) from ES-2 AZ_250:3 
and seven (ES-2 AZ 1000:n_250:7, n=1-7) from ES-2 AZ_250:7 were isolated at this 
















Figure 4.1: Hierarchy of AZD1775 resistant ES-2 clones. Independent clones were 
generated from HR proficient ES-2 cell line in two steps with increasing AZD1775 treatment 
dose. The clones shown in light blue, light green and light orange boxes were isolated after 
the first exposure step and are resistant to 250nM AZD1775. Two independent 250nM 
AZD1775 resistant clones, AZ_250:3 (light green box) and AZ_250:7 (light orange box) were 
then selected for the second selection step to generate clones resistant to 1000nM AZD1775 
(shown in dark green and dark orange boxes). The clones isolated at both steps were 
maintained under continuous selection. Details of the number of clones isolated at each stage 






Figure 4.2: Isolation of cisplatin-AZD1775 resistant ES-2 clones. Independent clones were 
generated from HR proficient ES-2 cell line resistant to cisplatin and AZD1775. The clones 
shown in yellow boxes were isolated after the parental cells were challenged with 0.8µM 
CDDP + 100nM AZD1775. Details of the number of clones isolated are given in the text. Only 
clones used for subsequent analysis are shown here. 
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To get clones resistant to combination of cisplatin - AZD1775, the cells were 
first checked for their ability to grow in presence of both drugs. For the pilot 
experiment, ES-2 was plated at 250,000 cells/well in a six well plate and treated with 
1.6µM CDDP, 250nM AZD1775, 1.6µM CDDP + 50nM  AZD1775, 1.6µM CDDP 
+100nM AZD1775, 1.6µM CDDP +200nM  AZD1775 and 1.6µM CDDP +250nM 
AZD1775. There was no growth after more than two weeks in any cisplatin - 
AZD1775 combination wells. So the CDDP concentration was halved to 0.8µM, the 
experiment was repeated and 0.8µM CDDP + 100nM AZD1775 was identified as the 
best combination to obtain resistant clones. The experiment was set up in a 96 well 
plate with 500 and 1000 cells per well. Colonies appeared at a frequency of 5 x 10-4 
and were isolated, grown up and maintained as described above. From this experiment, 
fifteen resistant clones (ES-2 AZ_100_CP800:n, n=1-15) were isolated (Figure 4.2).   
As OVCAR8 has an IC50 of 215nM in the 5-day growth assay (see Table 3.4) 
and based on the experience with ES-2, 300nM of AZD1775 was used for isolation of 
resistant clones.  A pilot experiment was first set up to check the cloning ability in 
AZD1775 at five seeding densities in 96 well plates, 100, 250, 500, 1000 and 1500 
cells per well. The same seeding densities (500 and 1000 cells per well) were selected 
for OVCAR8 as for ES-2 to isolate resistant clones. Colonies appeared at a frequency 
of 6 x 10-4 and were isolated, grown up and maintained as described above. Seven 
clones (OVCAR8 AZ_300:n, n=1-7) resistant to 300nM AZD1775 were isolated from 
OVCAR8 (Figure 4.3). 
 
 





Figure 4.3: Isolation of AZD1775 resistant OVCAR8 clones. Independent clones resistant 
to AZD1775 were isolated from the HR deficient OVCAR8 cell line. The clones shown in 
light purple boxes were isolated after the parental cell line was treated with 300nM AZD1775. 
The clones isolated were maintained under continuous selection. Details of the number of 
clones isolated are given in the text. Only clones used for subsequent analysis are shown here. 
4.2.2. Generation of olaparib resistant clones from HR proficient and deficient 
cell lines  
A pilot experiment was set up to check the ability of ES-2 and OVCAR8 cells to 
survive at high concentrations of olaparib. This experiment used a seeding density of 
200,000 and 250,000 cells per well for each cell line in a six well plate, where cells 
were treated with two different concentrations of olaparib, 25 and 50µM for ES-2 and 
6 and 12µM for OVCAR8. In the 5-day growth assay, olaparib IC50 was 30µM for ES-
2 and 2.6µM for OVCAR8 (see Table 3.4). The plates were monitored for growth, and 
media was changed as required. The wells started showing growth a month after 
seeding. Both olaparib concentrations were used to isolate independent ES-2 clones 
and 12µM to isolate independent OVCAR8 clones.  
Independent olaparib resistant ES-2 clones were isolated by thinly plating (1000 
and 1500 cells per well) in a 96 well plate and treating with 25 and 50µM olaparib. 
The cells were left for a week in the selection before checking for colonies. The 
colonies starting appearing after 5 weeks. Colonies appeared at a frequency of 8x10-5. 
Single colonies were picked and taken into a 12 well plate and allowed to grow in non-
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selective media till they became ~40% confluent, after which selection was added and 
cells were then continuously grown in selection. Six clones (ES-2 OLA_25:n, n=1-6) 
resistant to 25µM and two clones (ES-2 OLA_50:n, n=1-2) resistant to 50µM were 




Figure 4.4: Isolation of olaparib resistant ES-2 clones. Independent clones resistant to 
olaparib were generated from HR proficient ES-2 cell line. The clones shown in green and 
blue boxes were isolated after the parental cells were challenged with 25 and 50µM olaparib, 
respectively. The clones were maintained under continuous selection. Details of the number 






Figure 4.5: Isolation of olaparib resistant OVCAR8 clones. Independent clones resistant to 
olaparib were isolated from HR deficient OVCAR8 cell line. The clones shown in pink boxes 
were isolated after the parental cell line was treated with 12µM olaparib. Details of the number 
of clones isolated are given in the text. Only clones used for subsequent analysis are shown 
here. 
                                                       ------------------------------ 
OVCAR8 clones resistant to olaparib were isolated by thinly plating (1000 and 
1500 cells per well) in a 96 well plate and challenging with 12µM olaparib. The cells 
were left for a week in the drug containing media before checking for development of 
colonies. The colonies took more than a month to start appearing. Colonies appeared 
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at a frequency of 5 x 10-5 and were isolated, grown up and maintained as described 
above. Nine clones (OVCAR8 OLA_12:n, n=1-9)  from OVCAR8 resistant to 12µM 
olaparib were isolated (Figure 4.5). 
4.3. Confirmation of resistance 
Level of resistance in the clones was checked using the standard five day growth 
assay, where the independently derived resistant clones and the parent cell lines were 
treated with a range of concentrations of AZD1775, CDDP and olaparib. After five 
days the cells were fixed and stained using the SRB protocol and the IC50 values of 
resistant clones were compared to those of parent cell lines. 
4.3.1. AZD1775 resistant clones 
AZD1775 resistant ES-2 clones showed clear increases in IC50 values (Figure 
4.6). Three independent ES-2 clones resistant to 250nM AZD1775, ES-2 AZ_250:1, 
ES-2 AZ_250:3 and ES-2 AZ_250:7 showed 4, 3 and 3-fold increase in IC50 values, 
respectively (Figure 4.6 A). Five independent ES-2 clones, ES-2 AZ_1000:1_250:3, 
ES-2 AZ_1000:3_250:3, ES-2 AZ_1000:6_250:3, ES-2 AZ_1000:7_250:3 and ES-2 
AZ_1000:8_250:3, resistant to 1000nM AZD1775 that were isolated from  ES-2 
AZ_250:3 showed a noticeable decrease in sensitivity to AZD1775 as compared to 
parent cell line ES-2 with 6, 6, 9, 6 and  11-fold  increases in IC50 values (Figure 4.6 
B). When compared to ES-2 AZ_250:3, these clones showed smaller 2, 2, 3, 2 and 3-
fold increases in IC50 values. Growth assay for three independent ES-2 clones, ES-2 
AZ_1000:2_250:7, ES-2 AZ_1000:3_250:7 and ES-2 AZ_1000:4_250:7, resistant to 
1000nM AZD1775 and derived from ES-2 AZ_250:7 also showed a marked increase 
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in IC50 values (7, 6 and 8-fold, respectively) as compared to parent cell line ES-2 
(Figure 4.6 C). In comparison with their progenitor clone, ES-2 AZ_250:7, the clones 
showed smaller 3, 2 and 3-fold increase in IC50 values. As expected, the step wise 
isolation of clones has allowed for derivation of clones resistant to higher 







Figure 4.6: Growth curves showing decreased sensitivity of AZD1775 resistant ES-2 
clones to AZD1775 treatment.  For each value plotted, the experiment had at least four O.D. 
values from four individual wells. The IC50 values for all resistant clones shown here are 
significantly different (based on non-overlapping 95% confidence intervals) from the parent. 
A) Growth curves for three independent ES-2 clones resistant to 250nM AZD1775. ES-2 is 
shown in red and the clones are shown in light blue (ES-2 AZ_250:1), green (ES-2 AZ_250:3) 
and orange (ES-2 AZ_250:7). IC50 values for each curve (in nM ± SEM) are shown in 
brackets. Clones show a 4, 3 and 3-fold increase in IC50 values, respectively, over the ES-2 
parent. B) Growth curves for five independent ES-2 clones resistant to 1000nM AZD1775 and 
their clonal predecessor. ES-2 is shown in red, clonal predecessor ES-2 AZ_250:3, resistant to 
250nM AZD1775, is shown in light green and the five independent derivatives resistant to 
1000nM AZD1775 are shown in dark green. ES-2 AZ_1000:1_250:3, ES-2 
AZ_1000:3_250:3, ES-2 AZ_1000:6_250:3, ES-2 AZ_1000:7_250:3 and ES-2 
AZ_1000:8_250:3 show 2, 2, 3, 2 and 3-fold increases in IC50 as compared to ES-2 AZ_250:3 
and 6, 6, 9, 6 and 11-fold increases as compared to ES-2, respectively. C) Growth curves for 
three additional independent ES-2 clones resistant to 1000nM AZD1775 and their clonal 
predecessor. ES-2 is shown in red, clonal predecessor ES-2 AZ_250:7, resistant to 250nM 
AZD1775, is shown in light orange and the three independent derivatives resistant to 1000nM 
AZD1775 are shown in dark orange. ES-2 AZ_1000:2_250:7, ES-2 AZ_1000:3_250:7 and 
ES-2 AZ_1000:4_250:7 show 3, 2 and 3-fold increases in IC50 values as compared to ES-2 
AZ_250:7 and 7, 6 and 8-fold as compared to ES-2, respectively. (Figure on the next page) 



























ES-2 clones resistant to cisplatin – AZD1775 combination also showed 
increased IC50 values as compared to parental ES-2 cell line when treated with a range 
of cisplatin concentrations in a five day growth assay (Figure 4.7). ES-2 
AZ_100_CP800:2, ES-2 AZ_100_CP800:3, ES-2 AZ_100_CP800:7 and ES-2 
AZ_100_CP800:12 showed 3, 2, 2 and 3-fold increases in cisplatin IC50 values as 
compared to ES-2, respectively.  









Figure 4.7: Growth curves showing decreased sensitivity of cisplatin – AZD1775 resistant 
ES-2 clones to cisplatin. Growth curves for four independent ES-2 clones resistant to 0.8µM 
CDDP and 100nM AZD1775. ES-2 is shown in red and the clones are shown in yellow. 
Cisplatin IC50 values for each curve (in nM ± SEM) are shown in brackets. ES-2 
AZ_100_CP800:2, ES-2 AZ_100_CP800:3, ES-2 AZ_100_CP800:7 and ES-2 
AZ_100_CP800:12 show 3, 2, 2 and 3-fold increases in IC50 values as compared to ES-2, 
respectively. For each value plotted, the experiment had at least four O.D. values from four 
individual wells. The IC50 values for all resistant clones are significantly different (based on 
non-overlapping 95% confidence intervals) from the parent.   
Figure 4.8: Growth curves showing decreased sensitivity of AZD1775 resistant OVCAR8 
clones to AZD1775.  Growth curves for seven independent OVCAR8 clones resistant to 
300nM AZD1775. OVCAR8 is shown in blue and the clones (OVCAR8 AZ_300:1-7) are 
shown in light purple. IC50 values for each curve (in nM ± SEM) are shown in brackets. All 
clones except OVCAR8 AZ_300:1 show a ~2-fold increase in IC50 values as compared to 
OVCAR8. For each value plotted, the experiment had at least four O.D. values from four 
individual wells. The IC50 values for all resistant clones, except clone OVCAR8 AZ_300:1, 
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are significantly different (based on non-overlapping 95% confidence intervals) from the 
parent.   
                                                        ------------------------------- 
Eight independent OVCAR8 derived clones resistant to 300nM AZD1775 were 
also analysed (Figure 4.8). All clones, except OVCAR8 AZ_300:1, showed a ~2-fold 
increase in IC50 values as compared to OVCAR8. The increase in AZD1775 IC50 
values was not as prominent as for ES-2 clones. 
4.3.2. Olaparib resistant clones  
To check the level of resistance of clones resistant to olaparib, four independent 
ES-2 clones, two resistant to 25µM, ES-2 OLA_25:5 and ES-2 OLA_25:6, and two 
resistant to 50µM olaparib, ES-2 OLA_50:1 and ES-2 OLA_50:2, were initially tested 
in a five day growth assay with a range of olaparib concentrations (Figure 4.9A). ES-
2 OLA_50:1 and ES-2 OLA_50:2 showed a nearly 3-fold decrease in sensitivity as 
compared to ES-2. However, when the 95% confidence intervals were taken into 
account,  the smaller increases in IC50 values for ES-2 OLA_25:5 and ES-2 OLA_25:6 
were considered, at best, only marginal.  
Reasoning that the standard five day growth assay was too short to reveal the 
true level of olaparib resistance in the ES-2 clones, the SRB assay was modified into 
an eleven day survival assay in 6-well plates. ES-2 OLA_25:6 and ES-2 were plated 
at 100,000 cells per well in different concentrations of olaparib (0, 1, 5, 20, 50 and 
100µM) for 11 days before processing in the standard way. An image of the plates 
before extraction revealed a much higher level of resistance in ES-2 OLA_25:6 (Figure 
4.9C), which was confirmed by the 6-fold higher IC50 determination from the survival 
curve (Figure 4.9B). 













Figure 4.9: Decreased sensitivity of olaparib resistant ES-2 clones to olaparib. A) Growth 
curves for four independent ES-2 clones resistant to 25µM or 50µM olaparib. ES-2 is shown 
in red, the 25µM clones are shown in green and the 50µM clones are in blue. IC50 values for 
each curve (in µM ± SEM) are shown in brackets. ES-2 OLA_50:1 and ES-2 OLA_50:2 show 
~3-fold increases in IC50 as compared to ES-2, while the IC50 increases for ES-2 OLA_25:5 
and ES-2 OLA_25:6 are marginal. 95% confidence intervals for IC50 values are shown as 
coloured vertical bars. For each value plotted, the experiment had at least four O.D. values 
from four individual wells. The IC50 values for 50 µM olaparib resistant clones, but not 25 
µM olaparib resistant clones, are significantly different (based on non-overlapping 95% 
confidence intervals) from the parent.  B) Survival curves for an ES-2 clone resistant to 25µM 
olaparib (blue) and ES-2 (red). IC50 values for each curve (in µM ± SEM) are shown in 
brackets. ES-2 OLA_25:6 shows a 6-fold increase in IC50 value in the 11 day assay. C) SRB 
stained plates for the 11 day assay. ES-2 (upper plate) and ES-2 OLA_25:6 (lower plate) 
showing the improved survival of the clone, compared parental cell line ES-2, in presence of 
high concentrations of olaparib.  
Chapter 4                                                                                                                               119 
 
OVCAR8 derived clones resistant to olaparib showed much larger increases IC50 
levels when compared to OVCAR8 in the standard five day growth assay than their 
ES-2 equivalents (Figure 4.10). OVCAR8 olaparib resistant clones OLA_12:1, 
OVCAR8 OLA_12:3, OVCAR8 OLA_12:4 and OVCAR8 OLA_12:5 all showed 








Figure 4.10: Growth curves showing decreased sensitivity of olaparib resistant OVCAR8 
clones to olaparib.  Growth curves for four independent OVCAR8 clones resistant to 12µM 
olaparib. OVCAR8 is shown in blue, resistant clones are in pink. IC50 values for each curve 
(in µM ± SEM) are shown in brackets. OVCAR8 OLA_12:1, OVCAR8 OLA_12:3, OVCAR8 
OLA_12:4 and OVCAR8 OLA_12:5 show 25, 27, 25 and 33-fold increases in IC50 as 
compared to OVCAR8, respectively.  For each value plotted, the experiment had at least four 
O.D. values from four individual wells. The IC50 values for all resistant clones are significantly 
different (based on non-overlapping 95% confidence intervals) from the parent. 
4.4 Olaparib resistant clones remain sensitive to AZD1775 
Since one of the aims of the project was to overcome resistance to first line 
therapy for HGSOC, I wanted to investigate the response of olaparib resistant ES-2 
and OVCAR8 clones to AZD1775 in a five day growth assay using a range of 
AZD1775 concentrations. Out of the three independent ES-2 clones tested, only ES-2 
OLA_50:1 showed a small increase (<2 fold) in AZD1775 IC50 value as compared to 
ES-2 (Figure 4.11), while all four OVCAR8 olaparib resistant clones had the same 
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sensitivity to AZD1775 as the parent OVCAR8 cell line (Figure 4.12). I concluded 
that clones from two HGSOC cell lines selected for resistance to olaparib remain 








Figure 4.11: Growth curves showing that olaparib resistant ES-2 clones remain sensitive 
to AZD1775.  AZD1775 growth curves for three independent ES-2 clones resistant to 25µM 
(green) or 50µM olaparib (blue) are shown. ES-2 curve is in red. AZD1775 IC50 values for 
each curve (in nM ± SEM) are shown in brackets. 95% confidence intervals for IC50 values 
are shown as coloured vertical bars. Only ES-2 OLA_50:1 shows a small increase in AZD1775 
IC50 value as compared to ES-2.  For each value plotted, the experiment had at least four O.D. 
values from four individual wells. The IC50 values for resistant clones are significantly 









Figure 4.12: Growth curves showing that olaparib resistant OVCAR8 clones remain 
sensitive to AZD1775. AZD1775 growth curves for four independent OVCAR8 clones 
resistant to 12µM olaparib (pink) are shown. OVCAR8 is in blue. AZD1775 IC50 values for 
each curve (in nM ± SEM) are shown in brackets. All olaparib resistant clones show the same 
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sensitivity to AZD1775 as the OVCAR8 parent (based on overlapping 95% confidence 
intervals). For each value plotted, the experiment had at least four O.D. values from four 
individual wells.                                           
4.5. Cell cycle analysis of AZD1775 resistant clones 
In an attempt to gain an insight into the mechanism of resistance to AZD1775, 
cell cycle profiles of the clones and parental cell lines were studied in presence and 
absence of AZD1775 and cisplatin. DNA content was determined by the intensity of 
staining with propidium iodide using flow cytometry.  
Figure 4.13 shows cell cycle profiles obtained for parent cell line ES-2 and 
resistant clones ES-2 AZ_1000:7_250:3 and ES-2 AZ_1000:2_250:7 (both resistant to 
1000nM AZD1775 but derived from different 250nM progenitor clones) after four 
separate 24h treatments: untreated, 0.4µM cisplatin, 1000nM AZD1775, and a 
combination treatment with 0.4µM cisplatin and 1000nM AZD1775. The ES-2 profile 
was unaffected by cisplatin treatment, but with AZD1775 the normal sharp distinction 
in the population between cells in S and G2 phases was not apparent and there was an 
increased frequency of cells in G2 and reduced frequency in G1. These effects were 
more pronounced in the combination treatment. In marked contrast, the profiles of both 
resistant clones appeared largely unaffected by AZD1775 treatment. For both clones 
the frequency of S phase cells was reduced compared to ES-2, likely reflecting their 
slower growth rate (see Section 4.6). A slight G2 arrest was observed after cisplatin 
and combination treatment in ES-2 AZ_1000:2_250:7, but not in ES-2 
AZ_1000:7_250:3. Cell cycle profiles for six more independent clones resistant to 
1000nM AZD1775 and derived from different 250nM progenitor clones after 
treatment for 24 hours with 1000nM AZD1775 are shown in Appendix Figure 1. All 
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showed normal profiles after AZD1775 treatment, compared to the same dysregulated 













Figure 4.13: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 1000nM 
AZD1775. Untreated parent cell line ES-2, resistant clones ES-2 AZ_1000:7_250:3 and ES-2 
AZ_1000:2_250:7, and cells treated for 24 hours with 400nM cisplatin, 1000nM AZD1775 
and a combination treatment with 400nM cisplatin and 1000nM AZD1775, were fixed and 
stained with propidium iodide to display their DNA content and so their cell cycle status. 
Intensity of propidium iodide staining (DNA content) on the x axis, frequency (count) on the 
y axis. The percentage of cells with sub G1, G1, S, G2/M, and >4n DNA content is indicated 
across the top of each profile. Sample cell number counts: highest, 20,000; lowest, 4,000. Note 
the aberrant profiles for parent ES-2 cells treated for 24 hours with 1000nM AZD1775 alone 
and in combination with 400nM cisplatin. Note also the modest cisplatin-induced G2 arrest in 
AZD1775-resistant clone ES-2 AZ_1000:2_250:7. 
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Three independent clones resistant to 0.8µM cisplatin and 100nM AZD1775 
(ES-2 AZ_100_CP800:2, ES-2 AZ_100_CP800:3 and ES-2 AZ_100_CP800:7) along 
with ES-2 were treated for 24 hours with 0.4µM cisplatin, 250nM AZD1775 and a 
combination treatment with 0.4µM cisplatin and 250nM AZD1775 (Figure 4.14). The 
ES-2 cell cycle profiles were unaffected by the short, low concentration AZD1775 and 
cisplatin treatments, apart from displaying a slight G2 arrest. While the three cisplatin-
AZD1775 resistant clones only showed a slight G2 arrest after the cisplatin treatment.  
To investigate the effects of the same low concentration AZD1775 and cisplatin 
treatments over a longer time course, the treatment duration was increased to 72 hours. 
The cell cycle profiles are shown in Figure 4.15. ES-2 cells treated for 72 hours with 
250nM AZD1775 alone and in combination with 0.4µM cisplatin showed an even 
more dysregulated profile than seen in Figure 4.13. In addition to the same indistinct 
boundary between S and G2, the increased frequency of cells in G2 and reduced 
frequency in G1, the profiles also have distinct populations of sub G1, possibly 
apoptotic, cells and cells with >4n DNA content. In striking contrast, the cell cycle 
profiles of the resistant clones did not show any noticeable changes on treatment. Two 
more clones resistant to 0.8µM cisplatin and 100nM AZD1775 treated for 72 hours 




















Figure 4.14: Cell cycle analysis by flow cytometry after 24 hour treatment of ES-2 clones 
resistant to 800nM CDDP and 100nM AZD1775. Untreated parent cell line ES-2, resistant 
clones ES-2 AZ_100_CP800:2, ES-2 AZ_100_CP800:3, ES-2 AZ_100_CP800:7 treated for 
24 hours with 400nM cisplatin, 250nM AZD1775 and a combination of 400nM cisplatin and 
250nM AZD1775, were fixed and stained with propidium iodide to display their DNA content 
and so their cell cycle status. Intensity of propidium iodide staining (DNA content) on the x 
axis, frequency (count) on the y axis. The percentage of cells with sub G1, G1, S, G2/M, 
and >4n DNA content is indicated across the top of each profile. Sample cell number counts: 
highest, 10,000; lowest, 1,200. The ES-2 profiles appear unaffected by the short duration 
AZD1775 treatment. ES-2 AZ_100_CP800:2 cells show a slight cisplatin-induced G2 arrest. 
The irregular S-phase profiles for ES-2 AZ_100_CP800:3 are likely due to the low cell 
numbers counted for these samples.  
 





















Figure 4.15: Cell cycle analysis by flow cytometry after 72 hour treatment of ES-2 clones 
resistant to 800nM CDDP and 100nM AZD1775. Untreated parent cell line ES-2, resistant 
clones ES-2 AZ_100_CP800:2, ES-2 AZ_100_CP800:3, ES-2 AZ_100_CP800:7, and cell 
lines treated for 72 hours with 400nM cisplatin, 250nM AZD1775 and a combination treatment 
with 400nM cisplatin and 250nM AZD1775, were fixed and stained with propidium iodide to 
display their DNA content and so their cell cycle status. Intensity of propidium iodide staining 
(DNA content) on the x axis, frequency (count) on the y axis. The percentage of cells with sub 
G1, G1, S, G2/M, and >4n DNA content, is indicated across the top of each profile. Sample 
cell number counts: highest, 20,000; lowest, 4,000. Note that ES-2 cells treated for 72 hours 
with 250nM AZD1775 alone and in combination with 400nM cisplatin show a highly 
dysregulated profile with discrete populations of cells with sub G1 and >4n DNA content, 
while profiles for all resistant cultures appear normal. 
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Since the cell cycle profiles for ES-2 did not show any prominent irregularities 
when treated with 250nM AZD1775 for 24 hours (Figure 4.14), subsequent 
experiments were all done with 72 hours treatment.  Clones resistant to 250nM 
AZD1775 (ES-2 AZ_250:1, ES-2 AZ_250:3 and ES-2 AZ_250:7) and ES-2 were 
treated with 0.8µM cisplatin and 250nM AZD1775 separately and 0.4µM cisplatin in 
combination with 250nM AZD1775 for 72 hours (Figure 4.16). ES-2 cells, as 
expected, showed the same highly dysregulated profile, with sub G1 populations and 
>4n DNA content, after both single and combination AZD1775 treatments. Two of the 
three resistant clones, ES-2 AZ_250:1 and ES-2 AZ_250:3 have normal profiles when 
treated with AZD1775 and cisplatin alone and in combination. However, although 
clone ES-2 AZ_250:7 did not show any irregularity when treated with 250nM 
AZD1775, it appeared unusually sensitive to cisplatin alone and in combination with 
AZD1775. ES-2 AZ_250:7 showed similar features to AZD1775 treated ES-2, with 
loss of distinction between S and G2 phases, increased G2 frequency, reduced G1 
frequency with increased levels of sub G1 and >4n DNA populations. This difference 
of response to cisplatin between AZD1775 resistant clones suggests that resistance can 





















Figure 4.16: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 250nM 
AZD1775. Untreated parent cell line ES-2, resistant clones ES-2 AZ_250:1, ES-2 AZ_250:3 
and ES-2 AZ_250:7, and cell lines treated for 72 hours with 800nM cisplatin and 250nM 
AZD1775 separately and 400nM cisplatin in combination with 250nM AZD1775, were fixed 
and stained with propidium iodide to display their DNA content and so their cell cycle status. 
Intensity of propidium iodide staining (DNA content) on the x axis, frequency (count) on the 
y axis. The percentage of cells with sub G1, G1, S, G2/M, and >4n DNA content, is indicated 
across the top of each profile. Sample cell number counts: highest, 11,000; lowest, 4,800. ES-
2 cells treated for 72 hours with 250nM AZD1775 alone and in combination with 400nM of 
cisplatin show a highly dysregulated profile with discrete populations of cells with sub G1 
and >4n DNA content. While profiles for resistant clones ES-2 AZ_250:1 and ES-2 AZ_250:3 
appear normal, clone ES-2 AZ_250:7 shows a cisplatin-induced G2 arrest and a discrete sub 
G1 peak. 
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OVCAR8 and two independent clones resistant to 300nM AZD1775, OVCAR8 
AZ_300:6 and OVCAR8 AZ_300:7, were treated for 72 hours with 300nM AZD1775. 
While, as expected, the resistant clones showed normal cell cycle profiles after 
AZD1775 treatment, the effect on the OVCAR8 parent was not as noticeable as on 
ES-2, with some loss of distinction between S and G2, a modest increase in cells in S 
















Figure 4.17: Cell cycle analysis by flow cytometry of OVCAR8 clones resistant to 300nM 
AZD1775. Untreated parent cell line OVCAR8, resistant clones OVCAR8 AZ_300:6 and 
OVCAR8 AZ_300:7, and cell lines treated for 72 hours with 300nM AZD1775, were fixed 
and stained with propidium iodide to display their DNA content and so their cell cycle status. 
Intensity of propidium iodide staining (DNA content) on the x axis, frequency (count) on the 
y axis. The percentage of cells with sub G1, G1, S, G2/M, and >4n DNA content, is indicated 
across the top of each profile. Sample cell number counts: highest, 10,000; lowest, 1,500. 
OVCAR8 cells treated for 72 hours with 300nM AZD1775 show a slightly abnormal profile, 
while resistant clones appear normal. 
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4.6. AZD1775 resistant clones have slower growth rates than their parents  
Compared to the ES-2 parent, AZD1775 resistant ES-2 clones survive and grow 
in the drug-containing media and retain a normal cell cycle profile. They do have a 
reduced frequency of S phase cells and it was postulated that this may be important for 
their survival. To investigate this possibility further, the doubling times of both ES-2 
and OVCAR8 parents and some of their AZD1775 resistant clones under their normal 
growth conditions (normal medium for the parents and selective AZD1775 
concentrations for the clones) were first determined. 
Both parental lines had a doubling time of around 1 day (Table 4.1). Two clones 
resistant to 250nM AZD1775 (ES-2 AZ_250:3 and ES-2 AZ_250:7) had doubling 
times of around 2 days, while two of their derivatives resistant to 1000nM AZD1775 
(ES-2 AZ_1000:2_250:3 and ES-2 AZ_1000:2_250:7) had doubling times of around 
4 days. Two OVCAR8 clones resistant to 300nM AZD1775 (OVCAR8 AZ_300:6 and 
OVCAR8 AZ_300:7) also had doubling times of around 4 days. 
Cell line Doubling time  
ES-2 1.0 ± 0.2 
ES-2 AZ_250:3 1.9 ± 0.3 
ES-2 AZ_250:7 2.2 ± 0.2 
ES-2 AZ_1000:2_250:3 4.1 ± 0.5 
ES-2 AZ_1000:2_250:7 4.3 ± 0.3 
OVCAR8 1.2 ± 0.1 
OVCAR8 AZ_300:6 4.6 ± 0.3 
OVCAR8 AZ_300:7 4.2 ± 0.2 
 
Table 4.1: Cell doubling times of AZD1775 resistant clones and parental cell lines. Cell 
line doubling times in days (± SEM, n = 3), calculated between successive passages according 







Where, q1= number of cells seeded at time t1, q2= number of cells at time t2, T= cell doubling 
time. 
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4.7. Wee1 kinase gene mutation is not responsible for AZD1775 resistance in 
ES-2 and OVCAR8 
The most obvious possible mechanism of resistance to AZD1775 amongst those 
considered in the Introduction, and the one that was investigated first, was mutation in 
the Wee1 coding region itself preventing inhibition by AZD1775.  
Wee1 kinase gene is located on chromosome number 11, from 9,573,670 to 
9,589,985, with a length of 16,087 nucleotides. The 1,938 nucleotide coding region 
encodes the 646 amino acid protein. The eleven coding exons were sequenced using 
primers (see details in Methods section 2.1.11.1 and 2.2.5.2.) and aligned against 
reference sequence GRCh38.p12 using mutation surveyor software 
(https://softgenetics.com/mutationSurveyor.php). Twenty-four clones (names given in 
Table 4.2) and two parental cell lines were sequenced with the help of Ms. Laura 
Agundez Muriel (Research Assistant at Nicola Murray Centre for Ovarian Cancer 
Research) and Mr. Joseph Jeffery (Technical Services HGU). The sequencing results 
did not show any changes in the coding regions of the gene for any of the 24 clones 
sequenced. The sequencing did reveal intronic changes in some of the ES-2 and 
OVCAR8 clones as compared to reference sequence, all but one of these changes were 
also present in the parental cell lines. The exception is shown in Figure 4.18. The 
Figure 4.18 shows the mutation and its location on the gene at position 9,577,302, 
where a change of T>A was observed in seven ES-2 clones from three different 
selection experiments. This mutation is present at the 5' end of intron 5 at the 37th 
nucleotide after the splice site and so does not involve the known consensus donor 
splice signal. Thus, it was considered unlikely to affect gene function. 
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Table 4.2: Samples sequenced for Wee1 kinase gene. Given in the table are names of clones 
whose DNA was sequenced using primers for Wee1 kinase gene. Two parental cell lines, ES-
2 and OVCAR8, nineteen ES-2 clones (four resistant to 250nM AZD1775, ten resistant to 
1000nM AZD1775 and five resistant to 0.8µM cisplatin and 100nM AZD1775 combination) 
and five OVCAR8 clones resistant to 300nM AZD1775 were sequenced.  
 
Figure 4.18: Diagrammatic representation of Wee1 kinase gene, PCR amplicons used for 
sequencing and a mutation found in some AZD1775 resistant ES-2 clones. The eleven 
exons of the Wee1 kinase gene are drawn to scale and shown in blue, with introns (not to scale) 
in between. Two important sites for Wee1 kinase activity, the binding site for ATP and the 
active site, are indicated with green and blue arrows, respectively.  Below are the names of 
resistant clones that have a mutation in the intronic region between exon 5 and 6 that is not 
found in the ES-2 parental cell line. Shown on the left is the sequence around the junction 
between exon 5 and intron 5 with the single nucleotide change (T>A) that is present in the 
clone ES-2 AZ_100_CP800:6 compared to the reference sequence found in the ES-2 parent. 
All clones listed harbour the same mutation. This change does not affect the donor splice site 
(consensus sequence shown).  (Figure on next page)
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4.8. Discussion 
Response to chemotherapy for ovarian cancer is often compromised by 
development of drug resistance in the tumour. With an aim to understand resistance 
mechanisms to AZD1775 in HR deficient and proficient HGSOC cell lines, ES-2 and 
OVCAR8 derived resistant clones were isolated. The genetic heterogeneity of HGSOC 
tumours (Hoogstraat et al., 2014; Bashashati et al., 2013) adds an additional 
complexity to the identification of resistance mechanisms. HGSOC cell lines, like the 
tumours from which they were derived, are also likely to harbour sub-populations of 
cells with differences in genetic make-up. Each sub-population has the ability to 
branch into a new population in response to treatment. To overcome this problem, the 
experiments were designed to isolate clones representing different resistant sub 
populations instead of generating resistant pools with all the sub populations 
combined. Thin plating of the cells in 96 well plates ensured presence of fewer 
subpopulations with an ability to survive on treatment in each well. Thus, all cells 
originating from a single colony, in a well containing just this colony, will have gained 
resistance through the same genetic or expression change. Each colony is considered 
separate and is treated as a different population. On average, for every 10,000 cells 
plated one colony emerged on continuous exposure to the AZD1775 selection, while 
the frequency of clones from olaparib treatment was much lower (one colony for every 
100,000 cells plated) and resistant clones took much longer to appear.  
ES-2 and OVCAR8, both have IC50 values at the lower end of the range for the 
cell lines tested for response to AZD1775 (see Section 3.4). With an IC50 value of 
210nM, no ES-2 cells would likely have survived if directly challenged with a 
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concentration of 1000nM of AZD1775, which is nearly 5 times the IC50 value. The 
step-wise dose escalation of AZD1775 used while isolating clones aided in generating 
clones that are resistant to a final higher concentration. The isolated ES-2 clones 
resistant to 1000nM AZD1775 showed a high level of resistance (IC50 for AZD1775 
was >6-fold higher than for the ES-2 parent), while OVCAR8 clones resistant to 
300nM were only ~2-fold more resistant than their OVCAR8 parent. Given more time, 
a similar strategy of step wise dose escalation for OVCAR8 could also have led to 
isolation of clones with a greater level of AZD1775 resistance.  
A study on AZD1775 resistance mechanisms in small cell lung cancer (Sen et 
al., 2017) studied primary and acquired resistance using SCLC cell lines (AZD1775 
IC50 values ranging from 30nM to >1µM). The concentration of 100nM was chosen 
by (Sen et al., 2017) to define resistance. Do et al., (2015) previously reported that 
plasma concentration for AZD1775 can reach to an average maximum serum 
concentration of 1,650 nmol/L after the fifth dose in patients with solid refractory 
tumours, given 225mg AZD1775 twice per day. Sen et al., (2017) generated resistant 
pools from SCLC cell lines sensitive to AZD1775 to study the mechanisms of acquired 
resistance. The cell lines with acquired resistance were made resistant to 1000nM 
AZD1775 in seven exposure cycles where each cycle included 3 days of exposure and 
removal of drug for 4 days. In this study, 48 hours exposure of AZD1775-sensitive 
cell lines with 100nM AZD1775 resulted in accumulation of presumed apoptotic cells 
in sub G1 phase and did not affect intrinsically resistant cell lines. It was necessary to 
treat parental ES-2 and OVCAR8 cells with 250nM (near IC50 of ES-2 and OVCAR8) 
for 72 hours to be able to see the effects of AZD1775 on the cell cycle. One possible 
explanation for this different behaviour of ES-2 and OVCAR8 could be their higher 
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level of intrinsic resistance to AZD1775 as compared to the more sensitive SCLC cell 
lines used in the study by Sen et al., (2017).  
The PARP1 enzyme detects SSBs in DNA and helps in their repair (Satoh and 
Lindahl, 1992). On PARP inhibition, PARP trapping can lead to collapse of replication 
forks resulting in DSBs. PARP inhibition is particularly effective in the absence or loss 
of functional BRCA proteins that are important for the HR pathway. Due to resulting 
synthetic lethality from absence of HR pathways and PARP inhibition the cells 
ultimately die. PARP1 also assists HR by recruitment of repair factors such as NBS1, 
MRE11 and BRCA1 to double stranded break sites (Cruz-Garcia, et al., 2014; 
Bunting, et al., 2010; Hochegger, et al., 2006; Scully et al., 1997). This role of PARP1 
suggests that loss or inhibition of PARP1 might also affect cells with intact HR 
pathways. However, there are also PARP independent mechanisms to recruit BRCA1 
to DSBs (Schwertman, et al., 2016), which the cells can use in presence of PARP 
inhibition to repair DSBs. Olaparib resistant clones were isolated from both HR 
proficient and deficient cell lines, to be able to study the differences in the resistance 
mechanisms in two different genetic backgrounds. Both cell lines required longer 
periods of exposure for appearance of resistant colonies to olaparib as compared to 
AZD1775. In the case of ES-2 this could be attributed to the long time it takes for cells 
to become affected by PARP inhibition in presence of an intact HR pathway. In the 
five day growth assay done to confirm the level of olaparib resistance, ES-2 resistant 
clones showed only small increases in the IC50 value (~3-fold more than the parent), 
whereas when the cells were given longer exposure to olaparib in the 11-day survival 
assay, the differences between the parent and the resistant clone became much more 
apparent (IC50 value ~6-fold more than the parent). For OVCAR8 derived olaparib 
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resistant clones, >25-fold increase in IC50 was observed in a five day growth assay 
when compared to parental cells.  
Another olaparib resistance study has been done on an ovarian cancer cell line, 
A2780 (note that this is not considered an HGSOC cell line [Beaufort et al., 2014]), 
where olaparib-resistant cells were generated following continuous increasing drug 
concentrations (Vaidyanathan et al., 2016). IC50 value for A2780 parental cells to 
olaparib was 0.59µM. The cells were treated with increasing dose up to 20µM to 
mimic plasma concentrations in ovarian cancer patients. The resulting resistant cells 
had up to 36-fold higher IC50 for olaparib compared to parental cell lines. Similar 
levels of resistance was observed in OVCAR8 derived clones, OVCAR8 being one of 
the most sensitive HGSOC cell lines used in the study.  The fold increase in olaparib 
IC50 for ES-2 derived olaparib resistant clones compared to parent was much lower,  
ES-2 having one of the highest IC50 values for olaparib (30µM) in the cell line panel 
(Section 3.4, Table 3.4). 
With the increasing use of olaparib maintenance therapy for patients, resistance 
to olaparib can pose a major threat, necessitating the use of an alternative therapy to 
control tumour growth. I found that the olaparib resistant ES-2 and OVCAR8 clones 
remained sensitive to AZD1775, implying use of Wee1 kinase inhibition for patients 
resistant to olaparib is a realistic therapeutic alternative. As far as I am aware, this is 
the first demonstration of this therapeutic possibility.  
Multiple reversion mutations in BRCA genes restoring the reading frame leads 
to acquired resistance in platinum and PARP inhibitor sensitive patients (Cheng et al., 
2018; Carneiro et al., 2018; Quigley et al., 2017; Wang et al., 2016; Edwards et al., 
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2008; Perrin-Vidoz et al., 2002). It was possible that to overcome the effects of 
AZD1775 the resistant clones had undergone a mutation in Wee1 kinase gene to make 
the protein unavailable for inhibitor binding. In the sequencing of the Wee1 kinase 
gene from a number of clones no evidence of mutations in the coding exons was found. 
A small number of mutations were observed in introns. However, only one was present 
in some ES-2 clones and not the sensitive parent cell line and there was no evidence 
that it would affect gene function. I concluded that mutation of the coding region of 
the Wee1 kinase gene is not involved in the development of resistance in the HGSOC 
cell lines. 
In addition to the role of Wee1 kinase at G2 to M transition, mediated through 
Cdk1, and resulting in G2 arrest of cells with damaged DNA, Wee1 kinase also plays 
a role in S-phase of the cell cycle. Cdk2 activation regulates the timing of DNA 
replication during S-phase and undergoes an inhibitory phosphorylation at tyrosine-15 
by Wee1 kinase, which is removed by Cdc25A. Thus, inhibition of Wee1 by 
AZD1775, removes the S-phase checkpoint (Beck et al., 2012) and results in more 
rapid progression of cells through S-phase. Wee1 silencing by siRNA causes 
accumulation of DNA damage in S-phase which is reduced when cells are exposed to 
the Cdk inhibitor roscovotine (Beck et al., 2010). AZD1775 can cause premature entry 
into mitosis in early S-phase arrested cells (Aarts et al., 2012). Compared to the highly 
dysregulated cell cycle profiles of parental ES-2 cells treated with 250nM AZD1775 
for 72 hours, or with 1000nM AZD1775 for 24 hours, which show high levels of S-
phase cells, lack of a clear transition between S and G2 phases and continued 
replication in the absence of cell division (see Figures 4.13, 4.15 and 4.16), AZD1775 
resistant ES-2 clones  have normal profiles with lower levels of S-phase cells, implying 
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that the resistant cells are able to overcome the effects of Wee1 kinase inhibition on S-
phase. The increased cell doubling times for resistant as compared to parental cell lines 
also support this interpretation. The resistant clones show much slower growth than 
the parental cell lines, giving ample time for resistant cells to properly perform DNA 
damage repair in the absence of Wee1-induced G2 arrest. Based on these findings it is 
suggested that the key to the development of resistance to AZD1775 could be 
overcoming the effect that the inhibitor has in accelerating the transition through S-
phase, resulting in the accumulation of replication induced DNA damage, rather than 
overcoming its ability to block G2 arrest.  
The different cell cycle responses (see Figure 4.16) of three ES-2 clones, selected 
for resistance to 250nM AZD1775 (ES-2 AZ_250:1, ES-2 AZ_250:3 and ES-2 
AZ_250:7) also suggest that resistance can arise by different mechanisms. All three 
clones showed similar increased IC50s for AZD1775 in the growth assay (Figure 
4.6A). The cell cycle profiles of all three were unaffected by AZD1775 treatment, but 
clone ES-2 AZ_250:7 appeared unusually sensitive to cisplatin treatment alone and in 
combination with AZD1775.  
Further studies to investigate the mechanism of resistance in both AZD1775 and 
olaparib resistant HR proficient and deficient HGSOC clones are described in the next 
two Chapters. 
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Chapter 5 
Identification of Protein Expression Changes in Resistant Clones 
5.1. Introduction 
Cancer arises from a series of genetic mutations which result in uncontrolled 
growth (Sandal, 2002). A number of changes have to occur over time and be present 
together to transform a normal cell into a tumour cell. Ideally, chemotherapeutic agents 
target these transformed cells with uncontrollable growth and the disease subsides. 
However, these dividing tumour cells can mutate further and evolve to evade the 
effects of chemotherapeutic drugs.  This resistance to chemotherapy can be due to 
genetic changes, for instance leading to loss of the binding site for an inhibitor, or 
changes in regulation of protein expression that help the tumour cell to survive in 
presence of drug. This is called acquired resistance. Some tumour cells are instead 
intrinsically resistant to chemotherapeutic drugs because of their genetic and/or 
expression profiles. For example, increased expression of matrix metalloproteinase 1 
was found to be associated with intrinsic and acquired resistance in breast carcinoma 
cells to doxorubicin (Turton et al., 2001), Nrf2 was found to mediate intrinsic 
resistance to isothiocyanates, epoxides, peroxides, hydroquinones and quinones, 
NaAsO2, and various other mutagens, including cisplatin (Higgins and Hayes, 2011), 
MDR1 overexpression is also associated with chemotherapy failure in many cancers, 
including kidney, colon and liver cancers, and leukaemias and lymphomas (Triller et 
al., 2006; Nooter et al., 1997). Also, a germline deletion in the gene encoding BIM 
found in East Asian populations has been associated with intrinsic resistance to 
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tyrosine kinase inhibitor therapies in chronic-phase CML and EGFR-mutant lung 
cancer (Ng et al., 2012). 
The aim of this chapter was to analyse the changes in protein expression of the 
AZD1775 and olaparib resistant clones relative to their sensitive ES-2 and OVCAR8 
parental cell lines. Initially the possibility that HGSOC cells acquired resistance to 
AZD1775 in a similar way as SCLC was investigated, before going on to understand 
changes in the effects of AZD1775 on the substrates of Wee1 kinase and their cell 
cycle control interactors between sensitive parent and resistant clones. Changes in 
AZD1775 resistant clones at the kinome level were investigated before going on to 
probe the mechanisms of olaparib resistance by western blotting.  
5.2. The resistance mechanism to AZD1775 in HGSOC is different to that found 
in SCLC  
Mechanisms of intrinsic and required resistance to AZD1775 have been reported 
in SCLC cell lines (Sen et al., 2017). Increased expression of the AXL receptor and 
activation of the mTOR pathway were associated with intrinsic resistance to 
AZD1775. AXL and mTOR mediated activation of the ERK/p90RSK pathways led to 
activation of CHK1 which allowed SCLC cells to overcome the effects of Wee1 kinase 
inhibition. In the cell lines with acquired resistance, upregulation of AXL, p-S6, and 
MET was observed. In both intrinsic and acquired resistant cell lines, resistance could 
be reversed using inhibitors of AXL and mTOR (shown in Figure 5.1A).  
Protein cell lysates were sent to AstraZeneca, to be checked for changes in 
expression in the pathways observed in AZD1775 resistant SCLC by Sen et al., (2017). 
In the Figure 5.1 B, parental cell lines, ES-2 and OVCAR8, are compared with ES-2 
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AZ_250:1, ES-2 AZ_250:3 and ES-2 AZ_250:7 (resistant to 250nM AZD1775), ES-
2 AZ_100_CP800:5 and ES-2 AZ_100_CP800:6 (resistant to 0.8µM cisplatin – 
100nM AZD1775 combination) and ES-2 AZ_1000:2_250:3 (resistant to 1000nM 
AZD1775) and OVCAR8 AZ_300:6 and OVCAR8 AZ_300:7 (resistant to 300nM 
AZD1775).  The parental cell lines were grown in non-selective media while the clones 
were grown in selection before extraction of protein lysates. Similar to the situation 
reported in SCLC and, where levels of total CHK1 were clearly visible, western blots 
showed an increase of activated (phosphorylated at S345) CHK1 in resistant ES-2 and 
OVCAR8 clones compared to the sensitive parents. However, although there were 
small increases in AXL and Met receptor expression in the two OVCAR8 clones, there 
was no evidence in any of the ES-2 and OVCAR8 clones for consistent increased 
expression of any of the three markers for activation of the downstream signalling 
pathways (S6 pS240/244, mTOR pS2448 and ERK pT202/Y204) seen in SCLC. It 
was concluded that the resistance mechanism to AZD1775 in the HGSOC clones is 

























Figure 5.1. Resistance to AZD1775 in HGSOC is not caused by upregulation of AXL 
signalling as seen in SCLC. (A) Upregulation of AXL signalling in AZD1775-resistant SCLC 
(Sen et al., 2017).  (B) Western blots of CHK1 pS345 (mol. wt. 56kDa), CHK1, AXL (mol. 
wt. 138kDa), MET (mol. wt. 140kDa), S6 pS240/244 (mol. wt. 32kDa), S6, mTOR pS2448 
(mol. wt. 289kDa), mTOR, ERK pT202/Y204 (mol. wt. 42,44kDa), ERK and vinculin (mol. 
wt. 115kDa) as loading control for ES-2, OVCAR8 and derived resistant clones. Parental cells 
were grown in the absence of AZD1775, while resistant clones were maintained in AZD1775. 
Blot carried out at AstraZeneca by Dr Anderson Wang.  
5.3. Reduced levels of total Cdk1 in ES-2 resistant clones 
As part of the DNA damage response Cdk1 is inactivated by inhibitory 
phosphorylation on tyrosine 15 by Wee1 kinase and on threonine 14 by PKMYT1, 
arresting the cell in G2 phase and so allowing time for repair before entry into mitosis. 
Western blots of total Cdk1 for ES-2, OVCAR8 and many of their clonal derivatives 
resistant to AZD1775 and the cisplatin – AZD1775 combination were carried out 
(Figure 5.2). A reduction in total Cdk1 level was observed in a large majority of the 
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twenty six ES-2 derived resistant clones tested, but in only one of the eight OVCAR8 
clones. Three of the remaining OVCAR8 clones appeared to show a slight increase in 
Cdk1 levels. The reduction in total Cdk1 was most pronounced in clones resistant to 
1000nM AZD1775. These results suggest that reduced levels of Cdk1 may be involved 







Figure 5.2. Reduced levels of total Cdk1 protein in many AZD1775-resistant ES-2 clones. 
(A) and (B) Western blots of total Cdk1 (mol. wt. 34kDa) for ES-2, OVCAR8 and some of 
their AZD1775-resistant clonal derivatives reprobed for actin (mol. wt. 40kDa) as loading 
control. Parental cells were grown in the absence of AZD1775, while resistant clones were 
maintained in AZD1775. The positions of molecular weight markers are shown for the 
leftward blot. (C) Histogram showing levels of total Cdk1 in resistant clones corrected for 
differences in actin signals and expressed relative to their respective ES-2 or OVCAR8 parent 
cell lines. The first seven ES-2 clones shown are resistant to 250nM AZD1775; the following 
12 ES-2 clones, resistant to 1000nM AZD1775, are derivatives of two individual clones 
resistant to 250nM, as indicated by matched light and dark green and orange colours. The 
seven ES-2 clones represented in yellow are resistant to 0.8µM CDDP and 100nM AZD1775. 
The seven OVCAR8 clones are resistant to 300nM AZD1775. Data derived from the above 
and additional blots. Error bars are shown where values plotted are the means of three separate 
determinations. The reduction in total Cdk1 levels is most pronounced in 1000nM ES-2 clones, 
while 3 of 7 OVCAR8 clones appear to show a slight increase. (Figure on the next page) 
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5.4. Changes in Wee1 and PKMYT1 kinase and Cdk1 phosphorylation levels 
The Cdk1-cyclinB complex is inactivated, to arrest the cell in G2, through 
phosphorylation of Tyr15 and Thr14 by Wee1 kinase and PKMYT1 (Booher et al., 
1997; Parker and Piwnica-Worms, 1992). Wee1 kinase specifically phosphorylates 
Tyr15, but although PKMYT1 shows a preference for Thr14, it can also phosphorylate 
Tyr15. Over expression of target can be a possible mechanism to overcome effects of 
an inhibitor (Palmer and Kishony, 2014). So Wee1 and PKMYT1 kinase expression 
were checked through western blot analysis in ES-2, OVCAR8 and some of their 
AZD1775 resistant clones (Figure 5.3). Both OVCAR8 clones had increased 
expression of Wee1 kinase, but no consistent pattern was observed in the ES-2 clones. 
One of the three ES-2 clones resistant to 250nM AZD1775 (ES-2 AZ_250:3) showed 
an increase, but the Wee1 kinase level was very low in its derivative clone resistant to 
1000nM AZD1775 (ES-2 AZ_1000:2_250:3). PKMYT1 expression was much lower 
in ES-2 than in OVCAR8 cells. PKMYT1 expression was marginally increased over 
parental levels in ES-2 AZ_250:3 and OVCAR8 AZ_300:6, but reduced in most of the 
ES-2 clones. As expected, the phosphorylation status of Cdk1 at Thr14 followed a 
similar pattern as for PKMYT1 expression. The situation was different for Cdk1 Tyr15 
and Wee1 kinase.  As expected, the levels of Cdk1 pY15 were very low in all ES-2 
clones, which were maintained under selection, compared to the ES-2 parent grown in 
the absence of AZD1775. Although levels of Cdk1 pY15 were lower in OVCAR8 
clones than the parent, the reduction was not as marked as for ES-2 clones. These 
results suggest that increased levels of Wee1 kinase, but not PKMYT1, might be 
involved in AZD1775 resistance in OVCAR8 clones, but not in their ES-2 equivalents.  








Figure 5.3. Alterations in levels of Wee1 and PKMYT1 kinases and their Cdk1 
phosphorylation targets in AZD1775 resistant clones. Western blots of Wee1 kinase (mol. 
wt. 95 kDa), PKMYT1 (mol. wt. 77kDa), Cdk1 pY15 (mol. wt. 34kDa), Cdk1 pT14, Cdk1 
and vinculin (mol. wt. 115kDa) as loading control for ES-2, OVCAR8 and derived resistant 
clones. Parental cells were grown in the absence of AZD1775, while resistant clones were 
maintained in AZD1775. Blot carried out at AstraZeneca by Dr Anderson Wang. 
5.5. Target engagement by AZD1775 
To confirm target engagement by AZD1775 in parental cell lines and clones, 
ES-2 was treated with AZD1775 for 24 hours, and resistant clones (ES-2 AZ_250:3, 
ES-2 AZ_250:7, ES-2 AZ_1000:2_250:3 and ES-2 AZ_1000:2_250:7) which grow in 
continuous selection were taken out of selection for 24 hours. Lysates from AZD1775 
treated and untreated ES-2 and AZD1775 resistant clones were blotted for Cdk1 pY15. 
Both parent and the two resistant clones where total Cdk1 was readily detected (ES-2 
AZ_250:3 and ES-2 AZ_250:7) showed major reduction in Cdk1 phosphorylation at 
Tyr15 on treatment with AZD1775 and so demonstrate target engagement (Figure 
5.4A). The experiment was repeated for OVCAR8 parent and resistant clones 
(OVCAR8 AZ_300:1, OVCAR8 AZ_300:2, OVCAR8 AZ_300:3 and OVCAR8 
AZ_300:4) with and without AZD1775 treatment for 48 hours (Figure 5.4B).  The 
result again showed clear target engagement.  
 
















Figure 5.4. Target engagement of AZD1775 in ES-2, OVCAR8 and derivative AZD1775-
resistant clones. (A) Western blots of ES-2 and some AZD1775 resistant derivative clones 
for Cdk1 pY15 (mol. wt. 34kDa), total Cdk1 and reprobed for vinculin (mol. wt. 115kDa) as 
loading control. ES-2 which normally grows without AZD1775 (-) was treated with AZD1775 
for 24 hours (+), and the clones which normally grow continuously in selection (+) were grown 
without selection for 24 hours (-). The histogram shows the reduction in Cdk1 phosphorylation 
at tyrosine 15 on treatment with AZD1775. For each cell line the relative Cdk-1 pY15 
expression is the vinculin loading control corrected Cdk-1 pY15 signal in the presence of 
AZD1775 relative to the loading control corrected Cdk-1 pY15 signal in the absence of 
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AZD1775. A cross on the x-axis indicates that a relative expression value could not be 
obtained because band intensity was too low. Blot carried out at AstraZeneca by Dr Anderson 
Wang but analysed in Edinburgh. (B) Western blots of OVCAR8 and some AZD1775 resistant 
derivative clones for Cdk1 pY15 and reprobed for actin as loading control. OVCAR8 was 
treated with AZD1775 for 48 hours, and the clones which normally grow continuously in 
selection were grown without selection for 48 hours. The histogram shows the reduction in 
Cdk1 phosphorylation at tyrosine 15 on treatment with AZD1775. 
5.6. Alterations in Cdc25C expression 
Different Cdc25 family members are responsible for influencing transition 
between cell cycle phases by dephosphorylation of phospho-threonine and -tyrosine 
residues on inactivated Cdks leading to their activation (Pines, 1999; Dunphy and 
Kumagai, 1991). Cdc25A functions in G1/S entry through its activating 
dephosphorylation of Cdk2/cyclin E complexes, while Cdc25B and Cdc25C have an 
equivalent role in the G2 to M transition by activating the Cdk1/cyclin B complex. 
Additional activating phosphorylation of Cdc25C can be mediated by the Cdk1/cyclin 
B complex itself in a positive feedback loop in order to upregulate Cdk1/cyclin B 
activity and so drive cells into mitosis (Izumi and Maller, 1993). It was postulated 
earlier (see Introduction Figure 1.9) that reduced expression of Cdc25 could be 
involved in resistance to AZD1775. 
Antibodies against Cdc25B and C were obtained and cell lysates from ES-2, 
OVCAR8 and their derivative clones were blotted. Although no signal could be 
detected for Cdc25B, a weak band within the expected size range (55-70 kDa) was 
seen for Cdc25C (Figure 5.5). The expression of Cdc25C in OVCAR8 appeared higher 
than in ES-2. Attempts to improve the quality of the blot were unsuccessful and, 
although the Cdc25C signals did appear to be reduced in resistant clones, I was unable 
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to make any firm conclusions about the role of reduced Cdc25 expression in resistance 















Figure 5.5. Cdc25C expression in ES-2, OVCAR8 and derivative AZD1775 resistant 
clones. Western blot of Cdc25C (expected mol. wt. 55-70 kDa), reprobed for actin (mol. wt. 
40 kDa) as loading control for ES-2, OVCAR8 and some AZD1775 resistant derivative clones. 
Parental cells were grown in the absence of AZD1775, while resistant clones were maintained 
in AZD1775. The positions of molecular weight markers are shown. 
5.7. Altered DNA damage response in AZD1775 resistant clones 
The cell cycle has several checkpoints that regulate the activities of Cdks. The 
G2 DNA damage checkpoint exerts its effect mainly through the inhibitory 
phosphorylation of Cdk1. In the presence of damaged DNA, ATM/ATR are activated 
by phosphorylation and in turn phosphorylate and activate CHK1/CHK2. CHK1 
phosphorylates and activates Wee1 kinase to phosphorylate and inhibit Cdk1. 
Activated CHK1 also inhibits Cdc25 (Chen and Poon, 2008) so preventing it from 
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removing the Wee1 catalysed inhibitory phosphorylation and maintaining Cdk1 in its 
inactive state leading to G2 arrest (see Figure 1.7). In the presence of Wee1 kinase 
inhibitor, AZD1775, the damage response is blocked by the failure of Wee1 kinase to 
phosphorylate and inhibit Cdk1 so cells would not spend enough time in G2 to repair 
the DNA damage before continuing into mitosis.  
To compare the DNA damage response between the parental cells and resistant 
clones, western blots for ES-2 and OVCAR8 parents, treated with AZD1775 for 24 
hours, and their clones grown without selection for 24 hours were carried out for DNA 
damage response proteins (Figure 5.6). As expected, the AZD1775 treated lysates for 
all the cell lines assayed showed an increased level of the H2AX chromatin marker 
for DNA damage (Kinner et al., 2008) as compared to untreated lysates.  However, 
compared to the ES-2 parent, all AZD1775 resistant ES-2 clones showed a much 
reduced level of H2AX when treated with AZD1775. While three of the four 
OVCAR8 clones showed a similar increased H2AX response to AZD1775 as 
OVCAR8, one clone (OVCAR8 AZ_300:1) showed a reduced response like the ES-2 
clones.  
Changes in the level of activated DNA-PK, involved in the repair of ds DNA 
breaks by NHEJ, between AZD1775 treated ES-2 clones and the parent were equally 
striking. Although the levels of DNA-PK pS2056 in untreated cells were too low to 
permit quantification, levels were much lower in all ES-2 treated clones than the 
parent. One of the AZD1775 treated OVCAR8 clones (OVCAR8 AZ_300:4) showed 
the same low level of activated DNA-PK as ES-2 clones, the remaining three showed 
the same high level of activated DNA-PK as the OVCAR8 parent. 
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The activated RPA response, a marker for regions of single stranded DNA 
(Vassin et al., 2009), in AZD1775 treated cells essentially paralleled the DNA-PK 
result. Levels of RPA pS4/S8 were much lower in all ES-2 treated clones than the 
parent. While levels of activated RPA were slightly lower in three treated OVCAR8 
clones than the parent and marginally elevated in OVCAR8 AZ_300:3. The activated 
ATM and CHK2 responses mirrored the RPA result, but note that the low level of 
expression of CHK2 pT68 in treated compared to untreated ES-2 AZ_250:3 is due to 
an elevated level of activated CHK2 in the untreated lysate rather than a smaller 
increase in the AZD1775 treated clone compared to the treated parent. This elevated 
response in untreated ES-2 AZ_250:3 is no longer present in its more resistant 
derivative ES-2 AZ_1000:2_250:3. 
These altered DNA damage responses to AZD1775 treatment in AZD1775 
resistant clones compared to their parents suggest that reducing the amounts of 
different types of DNA damage occurring during exposure to AZD1775 are important 
components in developing resistance to AZD1775. The altered DNA damage 
responses are more pronounced in AZD1775 resistant ES-2 than OVCAR8 clones and 





















Figure 5.6. DNA damage response on AZD1775 treatment of ES-2, OVCAR8 and 
derivative AZD1775-resistant clones. Western blots of γH2AX (mol. wt. 15KDa), DNA-PK 
pS2056 (mol. wt. 450kDa), DNA-PK, RPA pS4/S8 (mol. wt. 32kDa), ATM pS1981 (mol. wt. 
370kDa), ATM, CHK2 pT68 (mol. wt. 62kDa), and CHK2 for ES-2, OVCAR8 and some 
AZD1775 resistant derivative clones reprobed for vinculin (mol. wt. 115kDa) as loading 
control. ES-2 and OVCAR8 parents which normally grow without AZD1775 (-) were treated 
with AZD1775 for 24 hours (+), and the clones which grow continuously in selection (+) were 
grown without selection for 24 hours (-). Blot carried out at AstraZeneca by Dr Anderson 
Wang.  
5.8. Other cell cycle alterations on treatment with AZD1775  
Western blot analysis of Cyclins B1 (partner of Cdk1 in G2/M) and A2 (partner 
of Cdk2 in early S and partner of Cdk1 in late S and early G2), H3 pS10 (a marker for 
chromosome condensation and mitosis (Hendzel et al., 1997), Histone H3 and RRM2 
(a surrogate for Cdk2 activity [Buisson et al., 2015]) was done for ES-2, OVCAR8 
and some derivative AZD1775 resistant clones, where ES-2 and OVCAR8 were 
treated with AZD1775 for 24 hours, and the clones were grown without selection for 
Chapter 5                                                                                                                               153 
 
24 hours (Figure 5.7). No consistent changes were seen in the levels of cyclins B1 and 
A2 and RRM2 in AZD1775 treated ES-2 or OVCAR8 clones compared to their 
respective parents. However, the histone H3 mitotic marker was highly elevated (>8-
fold) in both AZD1775 treated parental lines, reflecting the role of AZD1775 in 
preventing G2 arrest and leading to premature mitosis. While in both ES-2 and 
OVCAR8 AZD1775 treated clones, the levels of the mitotic marker were much 
reduced, suggesting that this too could be an important component of the resistance 
mechanism. Although note that in OVCAR8 AZ_300:2, the failure to see increased 
H3 pS10 expression on AZD1775 treatment is due to an unusually high basal level of 











Figure 5.7. Cell cycle alterations on AZD1775 treatment of ES-2, OVCAR8 and 
derivative AZD1775-resistant clones. Western blots of Cyclin B1 (mol. wt. 55kDa), Cyclin 
A2 (mol. wt. 54kDa), H3 pS10 (mol. wt. 17kDa), Histone H3 and RRM2 (mol. wt. 45kDa) for 
ES-2, OVCAR8 and some AZD1775 resistant derivative clones reprobed for vinculin (mol. 
wt. 115kDa) as loading control. ES-2 and OVCAR8 parents which normally grow without 
AZD1775 (-) were treated with AZD1775 for 24 hours (+), and the clones which grow 
continuously in selection (+) were grown without selection for 24 hours (-). Blot carried out 
at AstraZeneca by Dr Anderson Wang.  
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5.9. MDR1 overexpression not found in AZD1775- resistant clones 
MDR1 (encoded by ABCB1) is an efflux pump for various chemotherapeutic 
agents used in the treatment of ovarian cancer including paclitaxel, etoposide and 
doxorubicin. MDR1 overexpression has been associated with olaparib resistance 
(Vaidyanathan et al., 2016). In 8% of the recurrent high grade serous, fusions of 
SLC25A40 with ABCB1 were observed that resulted in a fused transcript. These 
tumours showed high expression of MDR1 and failed to respond to one or more MDR1 
substrates (Patch et al., 2015). Use of Elacridor (MDR1 inhibitor) in one cell line with 
SLC25A40 and ABCB1 fusion showed increased re-sensitivity to paclitaxel but not 
cisplatin (Christie et al., 2019). Although there have been no reports implicating 
MDR1 in resistance to AZD1775, this possibility in the ES-2 and OVCAR8 resistant 
clones was investigated (Figure 5.8). HCT-15, a colorectal cancer cell line that over 
expresses MDR1, was used as a positive control (Nakumura et al., 2003). There was 
some minor variation in MDR1 levels, but no evidence to suggest overexpression of 





Figure 5.8. MDR1 overexpression is not responsible for AZD1775 resistance in HGSOC. 
Western blot of MDR1 (130-180kDa) for HCT-15, ES-2, OVCAR8 and some AZD1775 
resistant derivative clones. Untreated human colon cancer cell line, HCT-15, which 
overexpresses MDR1. ES-2 and OVCAR8 parents which normally grow without AZD1775  
(-) were treated with AZD1775 for 24 hours (+), and the clones which grow continuously in 
selection (+) were grown without selection for 24 hours (-). Blot carried out at AstraZeneca 
by Dr Anderson Wang.  
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5.10. Alterations in the kinome 
In an attempt to relate the changes in protein levels of some of the protein kinases 
seen by western blotting to changes in kinase activity and to investigate kinome wide 
changes between AZD1775 resistant clones and sensitive parents, protein lysates were 
tested using the PamGene platform. Tyrosine kinase assays designed by PamGene 
comprise an array of 196 peptides on a chip that can detect their phosphorylation by 
the different kinases present in the cell lysates over time and thus give a measure of 
their activities.  The data generated from PamGene were then exported to KinMap - a 
freely available online tool that generates a dendrogram of human kinome (Figure 5.9). 
Tyrosine kinases can primarily be divided into two major categories: receptor tyrosine 
kinase (RTK) e.g. EGFR, PDGFR, FGFR and non-receptor tyrosine kinase (nRTK) 
e.g. SRC, ABL, FAK (Schlessinger, 2000). RTKs are activated by ligand binding to 
the extracellular domain, followed by dimerization of receptors, facilitating trans-
phosphorylation in the cytoplasmic domain, whereas the activation mechanism of 
nRTKs is more complex, involving heterologous protein-protein interaction to enable 
phosphorylation (Heldin, 1995). Please note that some of the key nRTKs showing 
changes between parent and resistant clone in the western blots (e.g. Wee1 kinase, 
Cdk1, PKMYT1) are unfortunately not detected by the PamGene chip, either because 
it does not have the necessary peptides to detect these Tyr kinases (Wee1 kinase), or 
because they are actually Ser/Thr kinases (CHK1). 
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Figure 5.9. Kinome phylogenetic tree of tyrosine kinases. A) KinMap phylogenetic tree of 
all human kinases. B) Expanded part of dendrogram focusing on the tyrosine kinases (TK). 
Tyrosine kinases are mainly divided into receptor tyrosine kinases (RTK) and non-receptor 
tyrosine kinases (nRTK).  The position of the Src family of tyrosine kinases is also indicated. 
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Kinase activities in AZD1775 resistant clone lysates were compared to treated 
parental cell lysates in triplicates. To avoid inter chip variability, ES-2 parental cells 
and all clones were tested on one chip and OVCAR8 and OVCAR8 derived clones on 
another.  Figure 5.10 shows differences in activity of tyrosine kinases between some 
AZD1775 resistant ES-2 clones and the sensitive ES-2 parent displayed on the kinome 
phylogenetic tree of tyrosine kinases using KinMap.  The specificity score (size of 
circle) is a measure of how specifically each kinase activity is detected by the 
PamGene analysis. The normalized kinase statistic is a measure of the degree of 
change of the kinase activity on a log2 scale (red is UP in clone, green is DOWN). 
Most of the kinase activities with high specificity score were decreased in the resistant 
clones, except for some receptor tyrosine kinases which were elevated in clone ES-2 
AZ_1000:2_250:7, but not in the progenitor clone ES-2 AZ_250:7. The most 
consistent change seen in all clones was reduced activity of the Src family members, 
although the extent of this reduction for individual family members varied between 
clones and there was no consistent relationship between expression of family members 
between 1000nM AZD1775 resistant clones (ES-2 AZ_1000:2_250:7 and ES-2 
AZ_1000:2_250:3) and their 250nM progenitor clones (ES-2 AZ_250:7 and ES-2 
AZ_250:3). The Met and AXL receptors were detected by the chip but, just as with 
the western blot data described earlier (Section 5.2), there was no evidence to implicate 






























Figure 5.10: Altered activities of tyrosine kinases in ES-2 clones resistant to AZD1775. 
Up or down regulated activity of tyrosine kinases in AZD1775 resistant clones compared to 
the ES-2 parent detected using the PamGene platform are displayed on the kinome 
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phylogenetic tree of tyrosine kinases generated using KinMap.  The normalized kinase statistic 
is a measure of the magnitude of change detected on a log2 scale. Red colour represents 
increased activity and green decreased activity in the resistant clone as compared to parent. 
The specificity score (size of circle) is a measure of how specifically each kinase activity is 
detected by the PamGene analysis. The bigger the circle the higher the specificity score. Note 
that the tyrosine kinase activity alterations detected in the two clones resistant to 1000 nM 
AZD1775 (ES-2 AZ_1000:2_250:7 and ES-2 AZ_1000:2_250:3) are different from one 
another and from their respective progenitors resistant to 250 nM AZD1775 (ES-2 AZ_250:7 
and ES-2 AZ_250:3) respectively.  
                                                 ---------------------------------------- 
Kinome analysis for OVCAR8 derived clones also showed little consistency 
between the four clones analysed (Figure 5.11). One of the clones (OVCAR8 
AZ_300:1), when compared to treated parent cell line, showed comparatively more 
increases in kinase activity than other clones resistant to the same concentration of 
AZD1775. Unusually, compared to the ES-2 clones, Src family members were 
prominent in this increased activity group. While clones OVCAR8 AZ_300:3 and 
OVCAR8 AZ_300:4 both showed predominantly reduced patterns of RTK and nRTK 
activity, closer examination revealed many differences between the clones in the actual 
kinases showing the reduced activity. Again, as with the ES-2 PamGene data, there 
was no support for increased AXL and Met activity being involved in resistance to 































Figure 5.11: Altered activities of tyrosine kinases in OVCAR8 clones resistant to 
AZD1775. Up or down regulated activity of tyrosine kinases in AZD1775 resistant clones 
compared to the OVCAR8 parent detected using the PamGene platform are displayed on the 
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kinome phylogenetic tree of tyrosine kinases generated using KinMap.  The normalized kinase 
statistic is a measure of the magnitude of change detected on a log2 scale. Red colour 
represents increased activity and green decreased activity in the resistant clone as compared 
to parent. The specificity score is a measure of how specifically each kinase activity is detected 
by the PamGene analysis. The bigger the circle the higher the specificity score.  
5.11. Changes in olaparib resistant clones  
Several PARPi resistance mechanisms are known. These include, upregulation 
of PgP/MDR1 (Evers et al., 2008; Rottenberg et al., 2008) and secondary BRCA 
mutations that lead to restoration of HR pathway (Edwards et al., 2008; Swisher et al., 
2008). To identify changes in olaparib resistant clones, protein lysates were made in 
Edinburgh and protein expression was analysed by western blots done at AstraZeneca 
by Dr. Elisabetta Leo. Parental cells were grown under normal non-selective 
conditions and the resistant clones were maintained under continuous selection.  
ES-2 and three derived clones resistant to two different concentrations of 
olaparib were blotted (Figure 5.12). As expected, some elevation in levels of γH2AX 
were seen in all olaparib resistant clones which were maintained in olaparib. Loss of 
PAR glycohydrolase (PARG) is a frequent mechanism of resistance to PARP 
inhibition in BRCA2-mutated tumours (Gogola et al., 2018). When PARP is recruited 
to single stranded breaks it catalyses self poly ADP ribosylation as part of the DNA 
damage response, resulting in the recruitment of repair proteins. PARG causes 
degradation of polyADP ribose (PAR) and thus accentuates the action of PARP 
inhibitors in blocking repair (Pascal and Ellenberger, 2015). A major reduction in 
PARG levels was observed in all the resistant clones as compared to the parent. 
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 Previous studies on resistance mechanisms to PARP inhibition have shown that 
loss of 53BP1, RIF1 or REV7 can lead to increased repair of ds breaks by the HR 
pathway (Francica and Rottenberg, 2018). While REV7 levels were unaffected in 
resistant clones, all clones analysed showed reduced levels of RIF1 (with a major 
reduction in clone ES-2 OLA_50:1) and 53BP1 (with a major reduction in clone ES-2 
OLA_25:6).    
Localization of EZH2 at replication fork methylates Lys27 on histone 3 
(H3K27me3) and recruits MUS81 nuclease to degrade the fork. Low EZH2 levels 
prevent MUS81 recruitment at stalled forks and thus stabilize and protect the fork. 
This stabilisation can provide resistance to PARPi (Rondinelli et al., 2017). Although 
one of the two 25 µM clones (ES-2 OLA_25:5) showed a decreased level of EZH2 
and H3K27Me, MUS81 levels were unaffected. The clones did not have a marked 
increase in MDR1 expression as seen in other studies where sensitive cells acquired 
resistance by MDR1 over expression (Vaidyanathan et al., 2016). Levels of PARP1 
itself were also unaffected. Note that the low levels of PARP1 self poly ADP 



































Figure 5.12: Changes in protein expression in ES-2 derived olaparib resistant clones. (A)  
Western blots of 53BP1 (predicted mol. wt. 220kDa), BRCA1 (mol. wt. 220kDa), RIF1 (mol. 
wt. 265kDa),  PARP1 (mol. wt. 116kDa), PARG (mol. wt. 111kDa), MDR1 (mol. wt. 
170kDa), MUS81 (mol. wt. 62kDa), REV7 (mol. wt. 24kDa), EZH2 (mol. wt. 85kDa), 
H3K27Me3 (mol. wt. 15kDa), γH2AX (mol. wt. 45kDa) for ES-2 and three olaparib resistant 
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ES-2 derived clones reprobed for GAPDH (mol. wt. 37kDa) as loading control. ES-2 was 
grown without olaparib, and the clones were continuously grown in selection. (B) The 
histograms plot relative expression of the different proteins in each clone relative to the ES-2 
parent. Protein levels are corrected for differences in loading control. The first two ES-2 clones 
shown in green (ES-2 OLA_25:5 and ES-2 OLA_25:6) are resistant to 25µM olaparib. The 
following ES-2 clone shown in blue (ES-2 OLA_50:1) is resistant to 50µM AZD1775. Blots 
were carried out and analysed at AstraZeneca in the laboratory of Dr. Elisabetta Leo.  
                                                 ------------------------------------- 
The OVCAR8 parent cell line and four derived clones were also analysed for 
known changes involved in olaparib resistance (Figure 5.13). Elevated levels of 
γH2AX were again seen in all olaparib resistant clones. Two clones (OVCAR8 
OLA_12:4 and OVCAR8 OLA_12:5) showed major reductions in PARG levels. The 
same two clones also showed major reduction in levels of RIF1 and modest reduction 
in 53BP1, while clone OVCAR8 OLA_12:1 also showed a modest reduction in levels 
of RIF1. No changes associated with resistance were seen in the 
EZH2/H3K27Me3/MUS81 replication fork stabilisation pathway. Similar to ES-2, 
there was no evidence of MDR1 upregulation in OVCAR8 olaparib resistant clones.  
An additional change associated with olaparib resistance and particular to 
OVCAR8 was also seen. The OVCAR8 parent showed lower levels of BRCA1 than 
its ES-2 equivalent, presumably as a consequence of the reported BRCA1 gene 
methylation (Stordal et al., 2013). All clones analysed, especially clone OVCAR8 
OLA_12:3, showed increased levels of BRCA1. 
Thus, a number of mechanisms previously reported to result in olaparib 
resistance were seen in both ES-2 and OVCAR8 clones, with examples in both cell 
types of multiple changes in the same resistant clone. 
 



















Figure 5.13: Changes in protein expression in OVCAR8 derived olaparib resistant 
clones. (A)  Western blots of 53BP1 (predicted mol. wt. 220kDa), BRCA1 (mol. wt. 220kDa), 
RIF1 (mol. wt. 265kDa),  PARP1 (mol. wt. 116kDa), PARG (mol. wt. 111kDa), MDR1 (mol. 
wt. 170kDa), MUS81 (mol. wt. 62kDa), REV7 (mol. wt. 24kDa), EZH2 (mol. wt. 85kDa), 
H3K27Me3 (mol. wt. 15kDa), γH2AX (mol. wt. 45kDa) for OVCAR8 and four olaparib 
resistant OVCAR8 derived clones reprobed for GAPDH (mol. wt. 37kDa) as loading control. 
OVCAR8 was grown without olaparib, and the clones were continuously grown in selection. 
(B) The histograms plot relative expression of the different proteins in each clone relative to 
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the OVCAR8 parent. Protein levels are corrected for differences in loading control. The four 
OVCAR8 clones are shown in dark pink (OVCAR8 OLA_12:1, OVCAR8 OLA_12:3, 
OVCAR8 OLA_12:4 and OVCAR8 OLA_12:5). Blots were carried out and analysed at 
AstraZeneca in the laboratory of Dr. Elisabetta Leo. 
5.12. Discussion 
A range of mechanisms may be the cause of resistance to chemotherapy (Chien 
and Moasser, 2008; Coley, 2008; Gatti and Zunino, 2005). These well studied 
mechanisms include active efflux of the drug from the tumour cell, mutant/modified 
drug targets, cell cycle checkpoint alterations and enhanced DNA repair mechanisms. 
No evidence was observed to suggest that one of the most obvious mechanisms of drug 
resistance, namely alteration in the coding region of the Wee1 kinase gene itself, was 
operating in any of the AZD1775 resistant clones. One or more such mechanism can 
cause resistance and may also confer cross resistance to other agents. An 
individual tumour cell may have inherited or evolved to acquire these changes that 
make it resistant. Thus, resistance to chemotherapy may be intrinsic or acquired. The 
primary and acquired resistance mechanisms studied in SCLC (Sen et al., 2017) 
showed overexpression of different surface receptors, which stimulated signalling 
pathways and ended at the same point with increased CHK1 activation and improved 
cell survival. The concentration of 100nM AZD1775 was chosen to define primary 
resistance and sensitive cell lines were made resistant to a concentration of 1000nM 
(Sen et al., 2017). The aim of studying mechanisms of resistance is to identify genetic 
groups of patients which may develop resistance early or may respond well to 
combination of drugs and so avoid acquiring resistance. In the case of AZD1775 
resistant SCLC co-targeting AXL or mTOR in vitro overcame primary resistance 
while simultaneous inhibition of AXL/MET or mTOR reversed acquired resistance. 
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No evidence was found to suggest that the same mechanisms of resistance to AZD1775 
found in SCLC were operating in HGSOC.  
A study done on acute myeloid leukaemia (AML) and acute lymphocytic 
leukaemia (ALL) observed that inhibition of Cdk1 alone or together with Cdk2 
increased viability in cells treated with combination of AZD1775 and Cytarabine (ara-
C) (Garcia et al., 2018). My results also suggests that the role of Wee1 kinase in cells 
with damaged DNA extends beyond regulation of Cdk1 and the G2/M checkpoint and 
highlights the importance of Wee1 kinase in mediating progression through the cell 
cycle. The decrease observed in expression of total Cdk1 in the AZD1775 resistant 
ES-2 clones suggests that a similar mechanism to that reported by Garcia et al. (2018) 
is operating here to evade the effects of Wee1 kinase inhibition. A similar Cdk1 
decrease in OVCAR8 derived AZD1775 resistant clones was not observed and instead 
a slight increase was seen in Wee1 kinase expression. Increase in Wee1 kinase might 
enable cells to inactivate Cdk1-cyclin B complex and partially maintain G2 arrest in 
the presence of AZD1775. These findings suggest that the two cell lines might have 
acquired resistance through different pathways that each help the cells to survive.  
In the western blot analysis for phosphorylated Wee1 kinase, a reduction in Cdk1 
Tyr15 phosphorylation levels in AZD1775 treated cell lines was observed, 
demonstrating target engagement.  Also, the results did not show any upregulation of 
MDR1 in the clones resistant to AZD1775 that might suggest increased export of drug 
from the cell was contributing to resistance. 
The cell cycle progression is also dependent on Cdc25 phosphatase activity 
which removes the inhibitory phosphorylations on Cdk1 and Cdk2 and thus allows the 
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cell to progress into the next phase (Figure1.7). Cdc25B/C function in G2 phase while 
Cdc25A operates in S-phase.  Inhibition of Cdc25 by CHK1 can lead to maintenance 
of inhibitory phosphorylations on Cdk1 and so block the cell from progressing to 
mitosis. A decrease in expression of Cdc25B/C would help the cells to maintain G2 
arrest and give time to repair DNA damage. Not enough support could be gathered to 
show a decrease in Cdc25 expression in the resistant clones. In retrospect, considering 
the developing focus on events in S phase as being important for the development of 
resistance, I should also have investigated possible alterations in levels of Cdc25A in 
resistant clones. 
The cell doubling times for AZD1775 resistant clones (Table 4.1) and cell cycle 
analysis (Section 4.5) also support the notion that the slower cell cycles in resistant 
clones enables them to overcome the effects of Wee1 kinase inhibition. Resistant 
clones also had reduced DNA damage responses to AZD1775 treatment as compared 
to their parents (Figure 5.6). These results suggest that slowing down the cell cycle, 
particularly S phase, reduces the amount of replicative DNA damage that can result 
from Wee1 inhibition. One of the suggested ways to slow the cycle is by reduction in 
total Cdk1 (Figure 5.2).  In sensitive parents Wee1 inhibition by AZD1775 blocks G2 
arrest leading to premature mitotic entry while in resistant clones low levels of total 
Cdk1 give the cells time for repair and thus avoid premature entry into mitosis with 
damaged DNA. Wee1 kinase inhibition also removes the S-phase checkpoint (Beck et 
al., 2012) and can lead to premature entry into mitosis (Aarts et al., 2012). DNA 
damage accumulation in S-phase caused by Wee1 silencing is reduced on treatment 
with the Cdk inhibitor, roscovotine (Beck et al., 2010).  Further analysis of Cdk2 and 
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Cdc25A might help in identification of changes occurring in S-phase that are involved 
in resistance to Wee1 kinase inhibition in the resistant clones. 
The Src family are structurally related non-receptor-type tyrosine kinases 
comprising of Src, Lyn, Fyn, Yes, Fgr, Hck, Lck and Blk (Brown and Cooper, 1996; 
Thomas and Brugge, 1997). Previously described targets of AZD1775 are Wee1 and 
to a lesser extent PKMYT1, but also YES1 (Hirai et al., 2009). Src inhibitors also 
prolonged G2/M arrest (Fukumoto et al.,   2014). Reduction in activity of Src family 
kinases could be a possible way to slow cell cycle. Another interesting link between 
Src family and Wee1 kinase is through Lyn and Cdk1 interaction.  Lyn is known to 
catalyse inhibitory phosphorylation of Cdk1 (Uckun et al., 1996; Kharbanda et al., 
1996) and Cdk2 (Yuan et al., 1996) on Y15 in response to DNA damage. In the kinome 
analysis using the PamGene platform, a strong reduction in activity of Src family 
kinases, including YES, was observed in AZD1775 resistant ES-2 clones. This could 
be due to affinity of AZD1775 for Src family members. However, the effect on 
different Src family members was inconsistent and varied between clones. This 
suggests that interpretation of the kinome analysis may be compromised by poor 
quantitation of the peptide signals.  
In summary, the resistant cells showed different changes they had gathered that 

















Figure 5.14: Summary of changes in protein expression observed that could contribute 
to mechanisms of resistance to AZD1775 in ES-2 and OVCAR8.  Based on Figure 1.9 
which showed postulated mechanisms of resistance to AZD1775 to be investigated as aims of 
the thesis. Pink ticks and crosses are for presence or absence of a change in ES-2 clones, blue 
ticks and crosses for OVCAR8 clones. ? indicates that no information was obtained about this 
postulated change. 
                                                         ------------------------------------ 
Turning to olaparib resistance, previous studies using in vitro and in vivo 
models, have described HR dependent (reversion of BRCA defect, loss of 53BP1 and 
REV7/MAD2L2) and independent (export of PARPi, PARP1 loss) ways to acquire 
resistance to PARPi in BRCA mutant cells (Lord and Ashworth, 2017; Kais et 
al.,  2016; Murai et al., 2016; Wang et al.,  2016; Drost et al., 2016; Guillemette et al., 
2015; Xu et al., 2015; Wang et al., 2014; Barber et al., 2013; Bunting et al., 2010). 
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PARG enzymatically degrades PAR chains that are added by PARP enzyme at 
the single stranded DNA breaks. PARG depletion is known to cause PARPi resistance 
in BRCA2-deficient tumours. Loss of PARG activity can help in restoration of 
PARylation and rescue downstream signalling of PARP1 (Gogola et al., 2018). In the 
HR proficient and deficient cells lines studied in this project, a marked decrease in 
PARG expression was observed. This suggests that PARG downregulation, 
independent of the HR status of the cell lines, is an important mechanism for cells to 
overcome PARP inhibition.  
 Loss of 53BP1 is known to cause resistance to PARP inhibition in BRCA1-
deficient mouse mammary tumours (Jaspers et al., 2012). In vitro studies also show 
that 53BP1 loss in BRCA1-deficient cells increases resistance to DNA-damaging 
agents and partially restores HR activity (Bouwman et al. 2010; Bunting et al. 2010). 
53BP1 loss promotes end resection of DNA DSBs in the absence of BRCA1, recruiting 
RAD51 and promoting HR (Bunting et al. 2010). Loss of RIF1 and REV7 are also 
known to restore HR pathway (Francica et al., 2016). In all the ES-2 derived olaparib 
resistant clones, a decrease in expression of 53BP1 and RIF1 but not REV7 was 
observed. Three of the four OVCAR8 derived clones also showed reduced expression 
of RIF1, of which two also showed a reduction in 53BP1. 
Stabilization of stalled DNA replication forks was recently identified as a 
PARPi-resistance mechanism that promotes genomic stability in BRCA1/2-deficient 
cancers (Chaudhuri et al., 2016). EZH2 localizes at stalled forks and methylates Lys27 
on histone 3 (H3K27me3), to recruit MUS81 nuclease. Low EZH2 levels reduce 
H3K27 methylation, prevent MUS81 recruitment at stalled forks and stabilize and 
protect the replication fork (Rondinelli et al., 2017). Thus, loss of function of the 
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EZH2/MUS81 axis can help cells to acquire resistance to PARP inhibition. Two of the 
ES-2 clones showed a reduced expression of EZH2 and H3K27Me, but MUS81 
expression was unchanged. I did not see changes in the EZH2/MUS81 axis in 
OVCAR8.   
Multiple mechanisms of olaparib resistance appear to be operating in both ES-2 
and OVCAR8 clones. I am not aware that this has been reported previously, although 
this could simply be because only individual resistance mechanisms were being 
investigated. In the HR deficient OVCAR8 HGSOC cell line, restoration of HR 
activity by increased levels of BRCA1 was seen in all four clones, while in the two 
clones with the smallest increases in BRCA1 (OVCAR8 OLA_12:4 and OVCAR8 
OLA_12:5), HR was likely further boosted by reduced levels of RIF1 and 53BP1. 
These same two clones also showed major reductions in levels of PARG to stimulate 
the DNA damage response. Whereas in the HR proficient ES-2, major reduction in 
PARG levels appeared to be the main driver of resistance in all clones analysed, 
supplemented by reduced levels of 53BP1 or RIF1 to boost HR. 
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Chapter 6 
Changes in the Transcriptome of AZD1775 Resistant Clones 
6.1. Introduction 
To further understand the differences between the parental cell lines and clones 
resistant to AZD1775, RNA sequencing was carried out on selected clones and 
parental cell lines. The aim of this chapter was to analyse the changes in transcriptome 
of the AZD1775 resistant clones relative to their sensitive ES-2 and OVCAR8 parental 
cell lines and identify mechanisms of resistance. I wanted to investigate changes taking 
place in different pathways that could provide a survival advantage to the resistant 
clones.  
6.2. RNASeq experiment 
The first experiment was done with ES and ES-2 derived resistant clones. The 
experiment included untreated and treated (with 100nM of AZD1775 for 24 hours) 
parent cell line, and four resistant clones maintained in AZD1775: two clones resistant 
to 1000nM AZD1775, ES-2 AZ_1000:2_250:3 and ES-2 AZ_1000:2_250:7, and their 
predecessors resistant to 250nM AZD1775, ES-2 AZ_250:3 and ES-2 AZ_250:7. The 
clones for the experiment were chosen on the basis of changes observed in the protein 
expression in western blot analysis. The clones resistant to 250nM AZD1775 were the 
predecessors of the 1000nM AZD1775 resistant clones so as to identify changes that 
occurred sequentially.  Also, to keep the cost of the sequencing down, only four clones 
in total were chosen. The experiment was run on two flow cells with triplicates from 
all clones, and two replicates of treated and untreated parent - 16 samples in all. 
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Experiment 1 included samples MKG1-16, each flow cell with 8 samples (MKG1-8 
on flow cell 1, and MKG9-16 on flow cell 2). Two of the four ES-2 parent samples, 
MKG1 and MKG9, were treated with 100nM AZD1775 for 24 hours before RNA 
extraction. All clones were grown in AZD1775 selection.  
The results from the ES-2 experiment (see later) did not show large differences 
between treated and untreated parent, so to keep sequencing costs down for the second 
experiment with OVCAR8 and derived clones, untreated parent samples were 
excluded. This second experiment had triplicates from three OVCAR8 derived clones, 
OVCAR8 AZ_300:2, OVCAR8 AZ_300:3 and OVCAR8 AZ_300:4, and treated 
parent -12 samples in all. Experiment 2 including samples MKG101-112 were run on 
a single flow cell. OVCAR8 parent samples MKG101-103 were treated with 100nM 
AZD1775 for 24 hours before extracting RNA, sample MKG103 was a technical 
replicate of MKG102. All OVCAR8 clones were grown in AZD1775 selection.   
6.3. Preliminary analysis of altered gene expression in resistant clones 
The log fold changes (LFC) in expression for all the genes in the ES-2 data set 
were initially searched manually for expression changes between resistant clones and 
the ES-2 parent. When the threshold was set at LFC >1.5 for increased or decreased 
expression between all four resistant clones and the treated parent, only a single gene 
was identified. This was the Src family member, Lyn, where expression was reduced 
in all resistant clones (Figure 6.1). Reduced kinase activity of Lyn and other Src family 
kinases in AZD1775 resistant ES-2 clones was previously identified by the PamGene 
analysis (Chapter 5). Lyn has also been reported to carry out inhibitory 
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phosphorylation of Cdk1, the target of Wee1 kinase (Uckun et al., 1996; Kharbanda 









Figure 6.1: Reduced expression of Lyn in AZD1775 resistant ES-2 clones. Gene expression 
counts are shown on a log2 scale for untreated and AZD1775 treated ES-2 and treated 
AZD1775 resistant clones (ES-2 AZ_250:7, ES-2 AZ_1000:2_250:7, ES-2 AZ_250:3 and ES-
2 AZ_1000:2_250:3). Plots show mean expression, interquartile range and 1.5 x the 
interquartile range to identify outliers. All ES-2 derived clones show >4-fold reduced Lyn 
expression compared to the ES-2 parent, with the greatest reduction in clones resistant to 
1000nM AZD1775.  
                                                    --------------------------------------- 
It was clear from this initial analysis that more specialised bioinformatics 
analysis would be essential to extract the information required to identify possible 
resistance mechanisms.  Consequently all RNASeq data passing quality assurance 
were analysed with the assistance of Dr. John P. Thomson (IGMM).  
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6.4. Altered expression of cell cycle and related pathway genes in resistant clones  
The AZD1775 resistant ES-2 clones were compared to AZD1775 treated ES-2 
to identify genes that showed up or down regulation of expression. These genes were 
then assigned to a pathway by using KEGG pathway terms taken from DAVID. After 
this preliminary analysis, those specific pathways were studied to investigate changes 
in expression patterns using the z scores of the genes (it is important to note that only 
genes with 2-fold changes [LFC>1] and p <0.01 were visualised by z-scores).  
A comparison of expression patterns for cell cycle, TGF signalling pathway 
and apoptosis genes between ES-2 and AZD1775 resistant ES-2 clones is shown in 
Figure 6.2. Expression of each gene was quantified as the number of gene reads per 
kilobase of gene per million total reads (RPKM). Expression differences are displayed 
as z-scores on a colour scale. Blue indicates reduced expression, yellow indicates 
increased expression. The z-score shows the number of standard deviations that an 
expression value for a particular gene in a specific sample is away from the mean of 
all the expression values for the same gene in all the samples in the group. The z-score 
normalises expression for every gene and so allows expression differences between 
samples for genes with different baseline expression levels to be displayed together in 
order to observe expression patterns. 
The heat map for cell cycle control genes in ES-2 and ES-2 derived AZD1775 
resistant clones is shown in Figure 6.2 A. There was a clear shift in expression pattern 
between ES-2 and the two clones resistant to 1000nM AZD1775, with many genes 
which were highly expressed in the parent showing reduced expression in the clones, 
and vice versa. The two clones resistant to 250nM AZD1775, which are the 
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progenitors of the 1000nM clones, showed an intermediate expression pattern. Similar 
expression pattern shifts were seen for TGFβ pathway (Figure 6.2 B) and apoptosis 
(Figure 6.2 C) genes, but not for a similar size set of randomly selected genes (Figure 
6.2 D). The gene lists used for the z-score plots are shown in Appendix Table 2.  
Figure 6.3 shows the z-score heat map for cell cycle control genes in OVCAR8 
and derived clones. Two of the OVCAR8 clones, OVCAR8 AZ_300:2 and OVCAR8 
AZ_300:3, showed a similar expression pattern shift compared to the OVCAR8 parent 
as seen with the 1000nM ES-2 clones. The same expression pattern shift was not seen 







Figure 6.2: Comparison of expression patterns for cell cycle and related pathway genes 
between ES-2 and AZD1775 resistant ES-2 clones. Shown are z-scores on a colour scale 
(blue indicates reduced expression, yellow indicates increased expression) for ES-2 (untreated 
and treated), ES-2 AZ_250:3, ES-2 AZ_250:7, ES-2 AZ_1000:2_250:3 and ES-2 
AZ_1000:2_250:7. (A) Cell cycle, (B) TGF pathway, (C) apoptosis, (D) random genes. (See 
Appendix Table 2 for the gene lists). Note the clear shift in expression pattern for cell cycle, 
TGF pathway and apoptosis genes between ES-2 parent and 1000nM AZD1775 clones, with 
250nM AZD1775 clones in between. No such transition was seen for the random genes. 
(Figure on the next page)  
























































Figure 6.3: Comparison of cell cycle gene expression pattern between OVCAR8 and 
AZD1775 resistant OVCAR8 clones. Shown are z-scores on a colour scale (blue indicates 
reduced expression, yellow indicates increased expression) for OVCAR8 (treated), OVCAR8 
AZ_300:2, OVCAR8 AZ_300:3 and OVCAR8 AZ_300:4. (See Appendix Table 2 for the gene 
list). Note the clear shift in cell cycle expression pattern between OVCAR8 parent and clones 
OVCAR8 AZ_300:2 and OVCAR8 AZ_300:3. Clone OVCAR8 AZ_300:4 does not show the 
same shift.  
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6.5. Detailed analysis of altered cell cycle gene expression in resistant clones 
Cell cycle progression is positively regulated by the family of Cdks that are 
activated on binding with specific cyclins during distinct phases of the cell cycle. Cell 
cycle progression is also controlled by cyclin dependent kinase inhibitors (CDKNs) 
that inhibit the action of specific Cdks. Cdk inhibitors, including p21 (CDKN1A), p27 
(CDKN1B) and p57 (CDKN1C), interact with cyclin-Cdk complexes and inhibit their 
kinase activities (Morgan 1997; Murray 2004). Although the TP53 gene is mutant in 
almost all HGSOCs, including ES-2 and OVCAR8 as described in Chapter 3, an 
effective DNA damage response can still be initiated by ATM and ATR signalling 
through CHK2 and CHK1. This leads to inhibition of Cdc25 which blocks activation 
of Cdks and also to activation of Wee1 that inhibits Cdk1 leading to G2 arrest. 
TGFβ pathway signalling initiates on ligand binding that brings TGFβ type II 
receptor and TGFβ type I receptor together to form a complex. Complex formation 
results in auto phosphorylation of the receptors, allowing the activation of SMAD 
proteins through phosphorylation. Activated SMADs then translocate into the nucleus 
and function with other proteins to regulate the expression of particular target genes 
(Derynck and Zhang 2003; Shi and Massagué 2003). Induction of expression of the 
Cdk inhibitors p21 (CDKN1A) (Datto et al., 1995; Reynisdottir et al., 1995) and p15 
(CDKN2B) (Hannon and Beach 1994) by TGFβ signalling plays an important role in 
cell cycle arrest.  
Figures 6.4 – 6.6 adapt the KEGG pathway for cell cycle control to show all 
genes for which expression data were obtained from the RNASeq experiments. For 
each gene in Figure 6.4 the fold change in expression (measured as average reads for 
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each gene per kilobase per million total reads) between untreated and treated ES-2 
parent is shown on a linear colour scale. Blue indicates reduced expression in untreated 
ES-2, yellow indicates increased expression. As expected for untreated actively 
cycling cells, Figure 6.4 showed increased expression of a number of cyclins (CCNE 
and CCNA) and Cdk2 and reduced expression of Cdk inhibitors (most notably 
CDKN2B  and CDKN1A) compared to the AZD1775 treated parent. There was 
reduced expression of the TGFβ pathway in untreated compared to the treated parent, 
reflected in low expression of SMADs 2-4 which act to induce expression of CDKN2B  
and CDKN1A.  Surprisingly, expression of DNA damage response genes (ATM, ATR, 
CHK2, and CHK1) was largely unchanged between untreated and treated parent. 
SKP2 (S-Phase Kinase-Associated Protein 2) expression was strongly increased in 
untreated compared to treated parent. This gene encodes an E3 ubiquitin protein ligase 
that mediates the degradation of p21 (CDKN1A), p27 (CDKN1B) and p57 
(CDKN1C). 
 
Figure 6.4: Cell cycle gene expression changes in untreated ES-2 compared to AZD1775 
treated ES-2. For each gene the fold change in expression (measured as average reads for 
each gene per kilobase per million total reads) between untreated and treated ES-2 parent is 
shown on a linear colour scale. Blue indicates reduced expression in untreated ES-2, yellow 
indicates increased expression. This figure and the next two are adapted from the KEGG 
pathway for the cell cycle and show all genes for which expression data were obtained. Arrows 
indicate that the action of the gene at the tail of the arrow causes increased expression of the 
target gene at the arrowhead, or increased activity of its encoded protein. Lines with bars at 
the end indicate that the action of the gene at the start of the line causes decreased expression 
of the target gene at the bar, or decreased activity of its encoded protein. Arrows initiating 
from the TP53 gene are dashed to denote that these pathways are non-functional in ES-2 and 
OVCAR8 cells. (Figure on the next page) 
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Figure 6.5: Cell cycle gene expression changes in AZD1775 resistant ES-2 clones 
compared to AZD1775 treated ES-2. For each gene the fold change in expression (measured 
as average reads per kilobase per million total reads) between AZD1775 resistant clone and 
treated ES-2 parent is shown on a linear colour scale. Blue indicates reduced expression in the 
resistant clone, yellow indicates increased expression. Left side of each gene expression box 
ES-2 AZ_1000:2_250:3, right side ES-2 AZ_1000:2_250:7.  
 
Figure 6.6: Cell cycle gene expression changes in AZD1775 resistant OVCAR8 clones 
compared to AZD1775 treated OVCAR8. For each gene the fold change in expression 
(measured as average reads per kilobase per million total reads) between AZD1775 resistant 
clone and treated OVCAR8 parent is shown on a linear colour scale. Blue indicates reduced 
expression in the resistant clone, yellow indicates increased expression. Left side of each gene 
expression box OVCAR8 AZ_300:2, middle OVCAR8 AZ_300:3, right side OVCAR8 
AZ_300:4. 
                                              ---------------------------------------------- 
Figure 6.5 shows cell cycle control gene expression changes between AZD1775 
resistant clones, ES-2 AZ_1000:2_250:3 and ES-2 AZ_1000:2_250:7, maintained 
under selection and the treated ES-2 parent. Here the picture was very different, with 
decreased expression of many of the genes involved in active cycling, growth and cell 
division in the resistant clones (see Figure 6.7 for comparison). In addition to 
decreased expression of most cyclin and Cdk genes, expression of genes involved in 
DNA replication (ORC genes) and chromosome segregation (MCM genes) was also 
strongly downregulated. Opposite to the untreated parent, both clones showed 
activation of the TGFβ pathway. Although note that the mechanism appears different 
in the two clones. ES-2 AZ_1000:2_250:3 has increased expression of the TGFβR1 
receptor, while ES-2 AZ_1000:2_250:7 has increased expression of the TGFβ ligand. 
The other striking change was the increased expression of most of the CDKN 
inhibitors, with CDKN1A and CDKN2B being particularly strongly induced in both 
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resistant clones. SMAD3/4 are known to efficiently induce the expression of the 
CDKN1A and CDKN2B genes (Gomis et al., 2006). Increased expression of SMAD3 
was most pronounced in ES-2 AZ_1000:2_250:3. The increased expression of CDKN 
inhibitors is consistent with the decreased expression of the cyclins and Cdks. The 
clones showed no evidence for the involvement in resistance of increased expression 
of Wee1 kinase or PKMYT1 expression, but note the previously described reduced 
expression of LYN in both clones. Nor was any evidence found for increased 
expression of Cdc14A in resistant clones, another possible mechanism of resistance 
postulated in aims of the thesis. Some increased expression of DNA damage response 
pathway genes in the clones was indicated by the reduced expression of Cdc25A-C 
and the increased expression of TP53. Note that the normal ability of TP53 to inhibit 
CDKN1A and activate GAD45A and B as part of the damage response is inoperative 
because of TP53 mutation (dashed lines in the figure), but that the observed increased 
activity through the TGFβ pathway fulfils the same function. 
Figure 6.6 shows cell cycle control gene expression changes in OVCAR8 
derived resistant clones, OVCAR8 AZ_300:2, OVCAR8 AZ_300:3 and OVCAR8 
AZ_300:4, compared to the treated OVCAR8 parent. The expression changes were 
less marked and there was more heterogeneity between clones than observed for the 
ES-2 clones (see Figure 6.7 for comparison). Although decreased expression of most 
cyclin and Cdk genes was again observed, there was increased expression of Cdk6 and 
cyclins E1 and E2 in clones OVCAR8 AZ_300:2 and OVCAR8 AZ_300:3. Instead of 
expression of genes involved in DNA replication (ORC genes) and chromosome 
segregation (MCM genes) being strongly downregulated compared to treated parent, 
as seen in the ES-2 clones, expression was increased in the resistant OVCAR8 clones. 
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Expression of the TGFβ pathway was again elevated, with increased expression of 
TGFβ2 and TGFβR1 prominent in OVCAR8 AZ_300:4 and increased SMAD3 and 4 
expression in clones OVCAR8 AZ_300:2 and OVCAR8 AZ_300:3. However, the 
strong increased expression of CDKN1A and CDKN2B driven by the TGFβ pathway, 
as seen in ES-2 clones, was not observed in any of the OVCAR8 clones. Contrary to 
the situation in ES-2 clones, all OVCAR8 clones showed increased expression of 
Wee1 kinase and OVCAR8 AZ_300:2 and OVCAR8 AZ_300:3 also showed 
increased PKMYT1 expression, suggesting a possible involvement in resistance. 
Similar to ES-2 no change was observed for Cdc14A.  Increased expression of DNA 
damage response pathway genes (TP53 and GAD45A) was evident in clones 








Figure 6.7: Side by side comparison of cell cycle gene expression changes in AZD1775 
resistant clones and parents. The Figure is a composite of Figures 6.4, 6.5 and 6.6 
shown side by side for easier comparison. The red boxes highlight changes in cyclins 
and Cdks, cell cycle inhibitors and TGFβ pathway. (Figure on the next page)  
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6.6. Additional gene expression changes in AZD1775 resistant clones  
Figure 6.8 shows genes with an increase or decrease in expression of more than 
2-fold between AZD1775 resistant clones (ES-2 AZ_1000:2_250:3, ES-2 
AZ_1000:2_250:7, OVCAR8 AZ_300:2, OVCAR8 AZ_300:3 and OVCAR8 
AZ_300:4) and their respective AZD1775 treated ES-2 or OVCAR8 parent. Results 
of genes that showed more than 2-fold changes (p<0.01) in transcription are shown 
using z-scores on a colour scale, with red indicating reduced expression and green 
indicating increased expression in AZD1775 resistant clones. The gene lists are 
ordered so that genes involved in pathways of interest (Cell cycle, TGFβ signalling, 
Ras signalling, TNF signalling, PI3K-AKT signalling, ERBB signalling, Wnt 
signalling, NF-B pathway and transcriptional misregulation in cancer) appear 
together at the top (indicated by the black bar). This section of each array comparison 
is expanded to the right so that the z-scores for individual genes in these pathways can 
be seen. The gene list for each expanded comparison is shown in Appendix Table 3 
and 4. 
Figure 6.8A shows treated and untreated ES-2 parent and ES-2 derived clones, 
ES-2 AZ_250:3 and ES-2 AZ_1000:2_250:3. The z-scores of 1312 genes were 
increased or decreased by more than 2-fold in ES-2 AZ_1000:2_250:3 compared to 
the treated parent. ES-2 AZ_1000:2_250:3 showed increased expression of genes 
involved in the linked TNF signalling and NF-B pathway that together act to promote 
survival over apoptosis (Ting and Bertrand, 2016). There was decreased expression of 
genes involved in cell cycle, TGFβ signalling and genes involved in transcriptional 
misregulation in cancer. Some genes in the PI3K-AKT signalling pathway were 
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increased, while others were decreased. Just as in Figure 6.2, progenitor clone ES-2 
AZ_250:3 showed an intermediate expression pattern. Note that there is no 
inconsistency between the decreased expression in Figure 6.8A of five genes in TGFβ 
signalling in ES-2 AZ_1000:2_250:3 and the increased expression of TGFβ signalling 
into the cell cycle control pathway reported for ES-2 AZ_1000:2_250:3 and shown in 
Figure 6.5. The five TGFβ signalling genes shown downregulated in Figure 6.8A are 
not involved in TGFβ signalling into the cell cycle control pathway, but are instead 
involve in different aspects of TGFβ signalling. 
Figure 6.8B shows treated and untreated ES-2 parent and ES-2 derived clones, 
ES-2 AZ_250:7 and ES-2 AZ_1000:2_250:7. The z-scores of 1623 genes were 
increased or decreased by more than 2-fold in ES-2 AZ_1000:2_250:7 compared to 
the treated parent. Unlike ES-2 AZ_1000:2_250:3, ES-2 AZ_1000:2_250:7 did not 
show increased expression of genes involved in the TNF signalling and NF-B 
pathway. Like ES-2 AZ_1000:2_250:3, there was decreased expression of genes 
involved in cell cycle and TGFβ signalling, but also in ERBB, Ras and Wnt signalling. 
Some genes in the PI3K-AKT signalling pathway and involved in transcriptional 
misregulation in cancer were increased, while others were decreased. Progenitor clone 
ES-2 AZ_250:7 again showed an intermediate expression pattern. 
The number of genes with expression z-scores increased or decreased by more 
than 2-fold was reduced for OVCAR8 clones compared to the treated OVCAR8 
parent. Figure 6.8C shows OVCAR8 derived clone OVCAR8 AZ_300:2, where the z-
scores of 409 genes were changed by more than 2-fold.  As with ES-2 
AZ_1000:2_250:3, there was increased expression of genes in the linked TNF 
signalling NF-B pathway.  There was also increased or decreased expression of genes 
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involved in transcriptional misregulation in cancer. A very similar result was observed 
in Figure 6.8D for OVCAR8 AZ_300:3, where the z-scores of 441 genes were changed 
by more than 2-fold.  
A different pattern was seen in OVCAR8 AZ_300:4, where the z-scores of just 
332 genes were changed by more than 2-fold (Figure 6.8E).  There was no change in 
expression of genes in the linked TNF signalling NF-B pathway.  Instead there was 
increased and decreased expression of a very small number of genes in the PI3K-AKT 









Figure 6.8: Gene expression changes in AZD1775 resistant clones. Shown are z-scores on 
a colour scale (red indicates reduced expression, green indicates increased expression) for 
AZD1775 resistant clones compared to their respective ES-2 or OVCAR8 parent. Each panel 
shows the z-score profile for all the genes (N= gives the number) whose expression is 
increased or decreased by more than two fold between resistant clone and parent. Genes in 
pathways of interest with altered expression are grouped together at the top of each panel 
(indicated by the black bar). This section of each array comparison is expanded to the right so 
that the z-scores for individual genes in these pathways can be seen. (See Appendix Table 3 
and 4 for the gene lists in these pathways of interest).  (A) ES-2 treated, ES-2 untreated, 
AZ_250:3, ES-2 AZ_1000:2_250:3. (B) ES-2 treated, ES-2 untreated, ES-2 AZ_250:7, ES-2 
AZ_1000:2_250:7. (C) OVCAR8 treated, OVCAR8 AZ_300:2. (D) OVCAR8 treated, 
OVCAR8 AZ_300:3. (E) OVCAR8 treated, OVCAR8 AZ_300:4. (Figure on the next page) 
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Table 6.1 lists genes with >2-fold increased expression in the linked TNF 
signalling NF-B pathway in clones ES-2 AZ_1000:2_250:3, OVCAR8 AZ_300:2 
and OVCAR8 AZ_300:3. There is extensive gene overlap between the resistant clones. 
The action of all of the genes listed in Table 6.1 is expected to upregulate activity of 
the TNF and NF-B signalling pathway to provide a survival advantage to resistant 
cells, and help them in evading apoptosis.  
The significance of these and the other gene expression changes described in this 
Chapter are considered in the discussion section at the end of the Chapter. 
OVCAR8 AZ_300:2 OVCAR8 AZ_300:3 ES-2 AZ_1000:2_250:3 
TNF signalling 
IL1B IL1B IL1B 
CCL20 CCL20  
IL1A   
IL6 IL6  
CXCL1 CXCL1 CXCL1 
EDN1 EDN1  
BIRC3 BIRC3 BIRC3 
CXCL2 CXCL2  
TNFAIP3 TNFAIP3 TNFAIP3 
TNF TNF  
ICAM1 ICAM1 ICAM1 
TNFAIP2 TNFAIP2  
 CXCL3 CXCL3 
 BIRC2  
  RPS6KA5 
NF-κB pathway 
CXCL8 CXCL8  
NFKB1 NFKB1  
NFKBIA NFKBIA NFKBIA 
RELB RELB  
 TRIM25  
 BCL2A1  
  PLAU 
 
Table 6.1: Gene lists supporting Figure 6.8. Genes with two-fold or more increased 
expression in TNF signalling and NF-κB pathway in AZD1775 resistant OVCAR8 and ES-2 
clones compared to their respective parents. The lists are aligned to show that increased 
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expression of the same genes often occurs in different clones. Increased expression of all the 
genes shown here indicates increased activity of the TNF signalling or NF-κB pathways. i.e. 
None of the genes act as pathway inhibitors, nor would be expected to have increased 
expression if the pathways are down regulated.                   
6.7. Comparison of kinome analysis and RNASeq data 
I wished to investigate the extent to which the data from the kinome analysis, 
which detects kinase activity, supported the conclusions from the RNASeq analysis 
where gene expression data were obtained. Src family members were well represented 
in both data sets. Figure 6.9A shows the loss of kinase activity observed in all ES-2 
and OVCAR8 AZD1775 resistant clones compared to their respective parent. Figure 
6.9B shows a good correlation with the RNASeq expression data for Lyn, Src and Yes 
kinases, where there was consistent reduced expression in almost all clones. There was 
poor correlation with RNASeq data for the remaining family members. Possible 




Figure 6.9: Comparison of Src family kinase activity and gene expression between 
resistant clones and treated parental controls. (A) Kinase activity changes in resistant 
clones relative to treated parent determined from the PamGene platform. (B) Log fold gene 
expression changes in resistant clones relative to treated parent from RNASeq. Data are for 
ES-2 derived (ES-2 AZ_250:3, ES-2 AZ_1000:2_250:3, ES-2 AZ_250:7 and ES-2 
AZ_1000:2_250:7) and OVCAR8 derived (OVCAR8 AZ_300:2, OVCAR8 AZ_300:3 and 
OVCAR8 AZ_300:4) clones as compared to treated parent. The figure compares the results 
from RNASeq (B) and Kinome analysis (A). Although kinase activity is not a measure of 
transcription or vice versa, a comparison was made to see if similar directions of change in 
kinase activity and RNA levels were observed. (Figure on the next page) 





















6.8. Overcoming resistance to AZD1775 
Based on the results from the RNASeq experiments, three pathways were 
identified with increased activity in most of the resistant ES-2 and OVCAR8 where it 
was postulated that targeted inhibitor blockade could overcome AZD1775 resistance: 
TGFβ signalling, TNF signalling and the NF-B pathway. Four inhibitors with good 
specificity and potency against their targets were selected: RepSox (TGFβ receptor 1 
inhibitor), SIS3HCl (SMAD 3 inhibitor), Pomalidomide (TNF inhibitor) and ML120B 
(NF-B inhibitor). RepSox inhibits TGF-β with an IC50 of 18 nM in vitro (Gellibert et 
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al., 2004) while SIS3HCl inhibits Smad3 activation at a concentration of 10 μM in 
AML 12 cell line (Leiting et al., 2016). Pomalidomide inhibits TNFα release and is 
known to significantly decrease cell proliferation and DNA synthesis on exposure  to 
9.14 - 146 μM for 48 hours in cells from hematopoietic origin in vitro (Hernandez-
Ilizaliturri et al., 2005). ML120B is a potent and selective IKKβ inhibitor and can 
block NF-B pathway with an IC50 of 1.1 μM (Wen et al., 2016).  Growth assays were 
performed with a range of concentrations for the four inhibitors with highest 
concentration of 64 μM.  
Figure 6.10 shows growth curves where ES-2 was compared with resistant 
clones ES-2 AZ_1000:2_250:3 and ES-2 AZ_1000:2_250:7 in the presence of the four 
inhibitors individually. No differential sensitivity between parent and clones was seen 
with SIS3HCl (Figure 6.10B). ES-2 AZ_1000:2_250:7 was more sensitive to 
Pomalidomide (Figure 6.10C) and both ES-2 AZ_1000:2_250:3 and ES-2 
AZ_1000:2_250:7 were more sensitive to ML120B (Figure 6.10D) at the highest 
concentrations of each used. However, IC50 determinations for ES-2 
AZ_1000:2_250:3 showed a 20-fold increased sensitivity to RepSox (TGFβ receptor 
1 inhibitor) as compared to both ES-2 parent and ES-2 AZ_1000:2_250:7 (Figure 
6.10A).  
Figure 6.11 shows the equivalent assays for OVCAR8 with resistant clones 
OVCAR8 AZ_300:3 and OVCAR8 AZ_300:4. Neither of the OVCAR8 clones 
showed any increase in sensitivity to the inhibitors as compared to their parent.  
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Figure 6.10: Sensitivity to inhibitors for upregulated pathways in ES-2 derived AZD1775 
resistant clones. Figure shows growth curves for four different inhibitors in ES-2, ES-2 
AZ_1000:2_250:3 and ES-2 AZ_1000:2_250:7. (A) RepSox (TGF receptor inhibitor); (B) 
SIS3HCl (SMAD3 inhibitor); (C) Pomalidomide (TNF inhibitor); (D) ML120B (NF-B 
inhibitor). IC50 determinations could only be made for the RepSox growth curves. Note the 
20-fold increased sensitivity to RepSox for ES-2 AZ_1000:2_250:3, which shows 
upregulation of the TGF receptor (see Figure 6.5). 
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Figure 6.11: Sensitivity to inhibitors for upregulated pathways in OVCAR8 derived 
AZD1775 resistant clones. Figure shows growth curves for four different inhibitors in 
OVCAR8, OVCAR8 AZ_300:3 and OVCAR8 AZ_300:4. (A) RepSox (TGF receptor 
inhibitor); (B) SIS3HCl (SMAD3 inhibitor); (C) Pomalidomide (TNF inhibitor); (D) ML120B 
(NF-B inhibitor). 
6.9. Discussion  
 To understand the transcriptional changes in resistant clones as compared to the 
parental cells, RNA Sequencing was employed. Differences in expression between 
resistant and sensitive cells can help in understanding the mechanisms of resistance. 
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To be able to rely on the data generated by RNASeq, it was passed through different 
quality control steps. The principal component analysis done for experiment 2 revealed 
an outlier in the RNASeq samples, OVCAR8 AZ_300:2 (MKG106).  This same 
sample also showed a very low exonic mapping rate compared to all the other samples 
run on the same flow cell, which were all well in excess of the minimum quality 
threshold level (Appendix Figure 4B). Failure of this sample to pass QC was unlikely 
due to extensive DNA contamination because there was no evidence of this in the QC. 
The more likely explanation is incomplete or failed ribo-depletion of the RNA prior to 
construction of the library, resulting in excessive sequencing reads from rRNA rather 
than mRNA. 
As previously mentioned in Chapter 5, Lyn has been reported to be able to carry 
out the same inhibitory Tyr15 phosphorylation of Cdk1 as Wee1 kinase itself (Uckun 
et al., 1996; Kharbanda et al., 1996). From the initial manual search for expression 
changes in ES-2 derived resistant clones, Lyn was the only gene found with a large 
reduction in expression (LFC >1.5) in all four resistant clones compared to the 
AZD1775 treated ES-2 parent. Kinase activity analysis, discussed in Chapter 5, also 
showed a consistent reduction for Src family members, especially Lyn, in ES-2 clones. 
Although, as discussed in Chapter 5, interpretation of the kinome analysis may be 
compromised by poor quantitation of the peptide signals, it is interesting to see a 
reduction in Lyn expression to support reduced Lyn kinase activity. However, it is 
important to note that a reduced level of Lyn transcripts might not necessarily lead to 
a lower level of Lyn kinase activity. The activity of kinases can be dependent on many 
factors other than the level of transcription of the kinase encoding gene itself, most 
notably activating and inhibitory phosphorylation and dephosphorylation. Whether the 
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reduced level of Lyn expression could be involved in resistance to AZD1775 will be 
considered again in Chapter 7 (Conclusion). 
To understand differences of expression patterns between the clones, z-score 
based heatmaps have been used for visualization. z-scores were used instead of 
absolute expression because z-score normalisation helps in comparisons where base 
line expression levels are variable. Instead of normalising data for all the genes, data 
are normalised on an individual gene basis.  With the use of these heatmaps the change 
of expression pattern from parental cell lines to resistant clones could be observed 
(Figures 6.2 and 6.3). For ES-2 derived resistant clones, the clones resistant to 250nM 
AZD1775 showed an intermediate expression pattern shift, while the clones resistant 
to 1000nM AZD1775 showed a bigger expression pattern shift compared to parental 
cells. This is consistent with at least some elements of the altered expression pattern 
being involved in the mechanism of resistance.  
The number of differentially expressed genes between the ES-2 parent and 
clones resistant to 1000nM AZD1775 was much greater than the number of 
differentially expressed genes between the OVCAR8 parent and clones resistant to 
300nM AZD1775. This could possibly be explained by different requirements for 
resistance between the two parental cell lines, but more likely reflects the second round 
of selection employed in ES-2 to achieve the higher level of drug resistance. Looking 
back, a second round of selection to derive OVCAR8 clones resistant to a higher level 
of AZD1775 could provide a better understanding of the relationship between altered 
expression pattern and resistance. 
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Studying the detailed changes in the expression of cell cycle genes, ES-2 parental 
cells showed high expression of Cdks and cyclins in the absence of AZD1775 
treatment (Figure 6.4). There was a striking decrease in expression of the Cdks and 
cyclins in AZD1775 resistant clones compared to AZD1775 treated ES-2 parental cells 
(Figure 6.5). Cyclins along with Cdks are fundamental positive regulators of the cell 
cycle and a reduction in expression of either implies a slower cell cycle. Such a 
decrease was supported by the reduced growth rates of resistant clones compared to 
their parental cells described in Chapter 4. This decrease of cyclin and Cdk expression 
was more apparent in ES-2 derived clones than in OVCAR8 clones (Figure 6.6).  
Figures 6.4-6.6 (see Figure 6.7 for comparison) include all RNASeq data available on 
genes in the KEGG cell cycle control pathway, no KEGG cell cycle control gene data 
were excluded. The best way to visualise the changes of expression observed is by 
moving between the three superimposed figures on screen. The effects of the gene 
expression differences between resistant clones and treated parental cells observed are 
consistent with a slowing of the cell cycle control pathway and the conclusion that the 
differences are involved in the resistance mechanism. The generally good agreement 
between replicates also argues against the differences observed between resistant 
clones and their respective parents being simply random gene expression changes. 
Ideally a treated and untreated OVCAR8 comparison should also have been carried 
out to confirm that OVCAR8 parental cells also showed high expression of Cdks and 
cyclins in the absence of AZD1775 treatment.  
The analysis of RNASeq data also reinforces the heterogeneity among the clones 
that was originally described for differences in the DNA damage response in Chapters 
4 and 5. For instance, although there was a consistent increase in TGF signalling into 
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the cell cycle control pathway in both ES-2 derived resistant clones (Figure 6.5), the 
clones showed different changes in the TGF pathway.  ES-2 AZ_1000:2_250:3 has 
increased expression of the receptor, while ES-2 AZ_1000:2_250:7 shows an increase 
in the ligand expression. While for the three OVCAR8 clones analysed, OVCAR8 
AZ_300:4 showed both increased expression of both the TGF receptor and ligand, 
while the other two clones instead had increased expression of SMADs 3 and 4. 
In Figure 6.8 altered expression of a number of genes in pathways of interest that 
could potentially be involved in resistance to AZD1775 was observed in both ES-2 
and OVCAR8-derived resistant clones. The direction of expression changes for genes 
in the PI3K-AKT, Ras and Wnt signalling pathways would be expected to have 
conflicting effects on the overall activity of these pathways and so were considered 
unlikely to have a role in AZD1775 resistance. However, increased expression of a 
number of genes was observed in two of the OVCAR8 clones and one of the ES-2 
clones analysed that would all be expected to result in increased activity through the 
TNF and NF-κB pathways. The TNF and NF-B pathways are connected. TNF 
induces rapid transcription of genes that regulate inflammation, cell survival, 
proliferation and differentiation, through activation of the NF-κB pathway.  TNF 
pathway on activation, allows the release of NF-B to move to the nucleus and lead to 
transcription of anti-apoptotic genes that support survival (Vanden Berghe et al., 
2014). There was considerable overlap between the three clones in the TNF and NF-
κB pathway genes showing increased expression (Table 6.1), strengthening the case 
for the possible involvement of increased expression of these pathways in resistance. 
In clinical setting, patients who stop responding to AZD1775 will need a new 
inhibitor to control cancer cell growth. Based on my interpretation of the expression 
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differences in the RNASeq data, four inhibitors were selected to be checked as a means 
to overcome resistance to AZD1775. Two of these were for the TGFβ signalling 
pathway because an increase in TGFβ signalling into the cell cycle control pathway 
(albeit for different reasons) was observed in all ES-2 and OVCAR8 resistant clones. 
The other two inhibitors were directed against the TNF and NF-κB pathways that show 
increased expression in two of the OVCAR8 clones and one of the ES-2 clones. With 
one very clear exception, no clinically useful differences in sensitivity were observed 
for any of the inhibitors in any of the resistant clones.  The exception was the TGFβ 
receptor inhibitor sensitivity in ES-2 AZ_1000:2_250:3, the clone with the strongest 
increase in expression of TGFβR1 and the downstream SMAD3. Here there was a 20-
fold reduction in the IC50 for the inhibitor as compared to the ES-2 parent, suggesting 
that this could be a realistic way to overcome resistance to AZD1775 in some 
circumstances.  




7.1. HGSOC cell line responses to different chemotherapeutic agents 
HGSOC subtypes with HR defects are more likely to respond to DNA damaging 
agents as discussed in Chapter 3. As expected, it was observed that in the panel of cell 
lines tested, HR defective cell lines were found to be more sensitive to olaparib and 
cisplatin than cell lines with an intact HR pathway. However, the same sensitivity 
association with Wee1 kinase inhibitor AZD1775 was not found.  It is important to 
note here that some cell lines had slower growth rates than the rest which complicated 
the interpretation of the results.  
7.2. Resistance in HGSOC 
Based on the results from the sensitivity assays for the panel of cell lines, faster 
growth rate and their ability to form clones when plated at low densities, two cell lines 
were chosen to be used as parental cell lines for generation of clones resistant to 
AZD1775 and olaparib, which were further studied to understand mechanisms of 
resistance. ES-2 represents the HR proficient HGSOC and OVCAR8 represents HR 
deficient HGSOC.  
Since HGSOC is characterised by genetic heterogeneity (Hoogstraat et al., 
2014), it was also expected that HGSOC cell lines would harbour different genetic 
sub-populations of cells. For this reason and to be able to focus on genetic changes 
involved in resistance, individual resistant clones were isolated. Each colony obtained 
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by thinly plating and treating parental cells was considered an individual population. 
Step-wise dose escalation of AZD1775 was used to isolate clones from ES-2 that 
showed a high level of resistance (IC50 for clones resistant to 1000nM AZD1775 was 
>6-fold higher than the parent). Given more time, the same strategy for OVCAR8 
would have helped in generating clones with a higher level of resistance (OVCAR8 
derived clones resistant to 300nM AZD1775 were only ~2-fold more resistant than 
their parent).  
7.3. Mechanisms of resistance 
7.3.1. Olaparib resistance  
Previous studies using in vitro and in vivo models, have described HR dependent 
and independent ways to acquire resistance to PARPi in BRCA mutant cells (discussed 
in Chapter 5). Several mechanisms of olaparib resistance appear to be operating 
together in both ES-2 and OVCAR8 clones. I am not aware that multiple mechanisms 
of resistance in individual olaparib resistant clones has been reported previously. In all 
the ES-2 derived olaparib resistant clones, a decrease in expression of 53BP1 and RIF1 
was observed, thus promoting DNA repair by HR. Some of the OVCAR8 derived 
clones also showed reduced expression of RIF1 and 53BP1. A reduction of expression 
of EZH2 and H3K27Me3 was observed in some ES-2 derived clones but MUS81 
expression, which can lead to replication fork destabilisation, was unchanged. 
OVCAR8 derived clones did not show any changes in the EZH2/MUS81 axis.  In 
clones derived from both cell lines, a marked decrease in PARG expression was seen 
which can help in maintaining PARylation at the break site and so boosting repair. In 
OVCAR8 derived clones restoration of HR activity by increased levels of BRCA1 was 
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seen in all four clones. All these previously described mechanisms, separately or in 
conjunction, could be driving olaparib resistance in ES-2 and OVCAR8 clones. 
7.3.2. AZD1775 resistance  
During the course of the project, another study was published on primary and 
acquired resistance to AZD1775 in SCLC (Sen et al., 2017). This study showed 
overexpression of different surface receptors signalling down to cause increased 
activation of CHK1 and resulting in cell survival. In the case of AZD1775 resistant 
SCLC, co-targeting of AXL or mTOR in vitro resulted in overcoming primary 
resistance while acquired resistance was overcome by simultaneous inhibition of 
AXL/MET or mTOR. These mechanisms were also investigated in my resistant clones 
derived from ES-2 and OVCAR8. The same mechanisms of resistance to AZD1775 
were not found in HGSOC.  
7.3.2.1. Changes in the AZD1775 targeted pathways 
It was postulated that resistance to AZD1775 in HGSOC could occur through a 
number of different changes in the DNA damage response and cell cycle control 
pathways (shown in Figure 1.9). One of the main aims of the thesis was to investigate 
the possible involvement of these different changes in resistance. 
7.3.2.2. Wee1 kinase  
It is already known that changes in inhibitor targets are a common mechanism 
to gain resistance. For example, reversion mutations in BRCA genes restoring the 
reading frame leads to acquired resistance in platinum and PARP inhibitor sensitive 
patients (Cheng et al., 2018; Carneiro et al., 2018; Quigley et al., 2017; Wang et al., 
2016; Edwards et al., 2008; Perrin-Vidoz et al., 2002). It was hypothesized that a 
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mutation in the Wee1 kinase gene that makes it unavailable to the inhibitor might 
contribute towards resistance (Figure 7.1).  No alterations in the coding sequence of 
the Wee1 gene were found in any ES-2 or OVCAR8 clones resistant clones. A single 
intronic mutation was present in some ES-2 clones, but there was no evidence that it 
would affect gene function (Chapter 4). It was concluded that mutation of the coding 
region of the Wee1 kinase gene was not involved in the development of resistance in 
the studied HGSOC cell lines.  
Increased Wee1 kinase expression could also overcome the effects of the 
inhibitor (Figure 7.1). Western blot protein expression data did not show any increase 
in ES-2 clones, but some OVCAR8 clones showed an increase as compared to their 
parental cells. This result was supported by RNASeq data, where increased numbers 
of Wee1 kinase gene transcripts were observed in all three OVCAR8 clones, but not 
in ES-2. So increased expression of Wee1 kinase could contribute to resistance in 
OVCAR8 clones, but not in ES-2.   
7.3.2.3. PKMYT1 
Increase in PKMYT1 might also play a role in enabling cells to inactivate Cdk1-
cyclin B complex and maintain G2 arrest. PKMYT1 can phosphorylate Cdk1 on Y15 
as well as T14 (Mueller et al., 1995). In this way PKMYT1 could take over the role of 
AZD1775 inhibited Wee1 kinase to maintain the ability of the cell to undergo G2 arrest 
in presence of DNA damage (Figure 7.1). I did not find any change in PKMYT1 
expression in ES-2 derived clones, but OVCAR8 derived AZD1775 resistant clones 
(OVCAR8 AZ_300:6 and OVCAR8 AZ_300:7) showed an increase in PKMYT1 
expression in the western blot analysis. RNASeq analysis of clones OVCAR8 
AZ_300:2 and OVCAR8 AZ_300:3 also showed an increase in PKMYT1 transcript 
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levels compared to OVCAR8. This increase in PKMYT1 could also contribute to 









Figure 7.1: Role of Wee1 kinase at G2. Based on Figure 1.9 which showed postulated 
mechanisms of resistance to AZD1775 to be investigated as aims of the thesis. Shown here is 
Wee1 kinase function and overlap of PKMYT1 kinase function to phosphorylate Cdk1- 
cyclinB complex. Three possible mechanisms of resistance are shown on the schematic 
diagram and discussed in the text (in section 7.3.2.2 to 7.3.2.4).  Pink ticks and crosses are for 
presence or absence of a change in ES-2 clones, blue ticks and crosses for OVCAR8 clones.  
 
7.3.2.4. Cdk1  
Cells might also gain resistance to AZD1775 by reducing levels of total Cdk1 
expression or activity. Cdk1 is phosphorylated on Thr14 and Tyr15 by PKMYT1 and 
Wee1 kinase. These phosphorylations lead to inactivation of the Cdk1-cyclinB 
complex and G2 arrest (see Figure 7.1).  The suggestion here is that in the absence of 
Wee1 kinase inhibition of Cdk1, as a result of the inhibition of Wee1 kinase by 
AZD1775, lower levels of total Cdk1 would result in less active Cdk1 being available 
to drive cells into premature mitosis.  
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I found that most ES-2 clones tested did indeed have reduced levels of total Cdk1 
protein, but the same was not observed for OVCAR8 clones. Perhaps reduced levels 
of Cdk1 are not necessary for resistance in OVCAR8 clones because of the increased 
levels observed of Wee1 kinase and PKMYT1. A separate study on acute myeloid 
leukemia (AML) and acute lymphocytic leukemia (ALL) supported my hypothesis for 
low levels of Cdk1 resulting in resistance to AZD1775. In this study inhibition of Cdk1 
alone or together with Cdk2 increased the viability of cells treated with a combination 
of AZD1775 and Cytarabine (Garcia et al., 2018). Thus, reduced Cdk1 levels could 
also contribute to AZD1775 resistance.  
7.3.2.5. Cdc25 
The cell cycle progression is also dependent on Cdc25 phosphatase activity 
which removes the inhibitory phosphorylations on Cdk1 and Cdk2 and thus allows the 
cell to progress into the next phase (Figure 7.2). By decreased expression of Cdc25 
phosphatase the Cdk1-cyclinB complex stays in an inactive state and thus cells are 
able to arrest in G2 to give time for them to overcome any DNA damaging effects of 
AZD1775 before proceeding into mitosis (Figure 7.2). Cdc25B/C function in G2 phase 
while Cdc25A operates in S-phase.  Inhibition of Cdc25 by CHK1 in response to DNA 
damage can lead to maintenance of inhibitory phosphorylations on Cdk1 and so block 
the cell from progressing to mitosis. I could not gather enough support to show a 
decrease in Cdc25C expression through western blots. However, from the RNASeq 
data (Chapter 6), a decrease in Cdc25A/B/C transcripts in both ES-2 derived clones 
was found, but not all Cdc25 isoforms had reduced levels of transcripts in OVCAR8 
derived clones. Decreased transcripts were observed for Cdc25B in OVCAR8 
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AZ_300:2 only and for Cdc25C in OVCAR8 AZ_300:2 and OVCAR8 AZ_300:3. The 
observed decrease in Cdc25 isoforms could also contribute to AZD1775 resistance.  
7.3.2.6. Cdc14A 
Cdc14A stabilises Wee1 kinase (Ovejero et al., 2012) and also inhibits Cdc25 
(Sacristán et al., 2011) (Figure 7.2). I did not find any changes in transcript levels for 
Cdc14A from the RNASeq data for any of the cell lines. Retrospectively, better 
analysis of Cdc14A protein expression by western blotting might have given more 











Figure 7.2: Role of Cdc25 and Cdc14A at G2. Based on Figure 1.9 which showed 
postulated mechanisms of resistance to AZD1775 to be investigated as aims of the thesis. 
Shown here is dephosphorylation of Cdk1 - cyclinB complex mediated by Cdc25 to help the 
cell transition into mitosis. Cdc14A stabilises Wee1 kinase and inhibits Cdc25, thus helping 
the cells maintain G2. Two further possible mechanisms of resistance are shown on the 
schematic and discussed in the text (in section 7.3.2.5 and 7.3.2.6). Pink ticks and crosses are 
for presence or absence of a change in ES-2 clones, blue ticks and crosses for OVCAR8 clones. 
Where a tick and cross are superimposed, the change was not found in all the resistant clones 
from that cell line  
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7.3.2.7. Drug pumps  
Increased expression of drug transporters in the cell membrane has been reported 
to cause resistance to different drugs in vitro (Thomas and Coley, 2003; Goldman, 
2003). I did not find any previous reports of involvement of increased drug transporters 
in AZD1775 resistance, but the most common transporter (MDR1) that shows 
increased expression in other drug resistant cells was investigated.  I did not find any 
evidence to suggest overexpression of the drug transporter in any of the AZD1775 
resistant clones. This was supported by the western blot analysis of phosphorylated 
Cdk1. A reduction in Cdk1 Tyr15 phosphorylation levels in AZD1775 treated cell 
lines was observed, demonstrating target engagement. This could only occur if levels 
of AZD1775 sufficient to inhibit Wee1 kinase were being maintained in the cells. This 
extends support to the drug not being exported out of the cell at an elevated rate.   
7.3.3. A reduced growth rate is an important component of AZD1775 resistance  
Wee1 kinase also plays a role in S-phase of the cell cycle by phosphorylating 
Cdk2 at Tyr15 and causing its inhibition. This phosphorylation can be removed by 
Cdc25A to push the cells through S-phase.  Inhibition of Wee1 kinase by AZD1775 
would thus remove the S-phase checkpoint (Beck et al., 2012), resulting in faster 
progression of cells through S-phase and likely increasing the amount of replication 
associated DNA damage, such as stalled replication forks, single and double strand 
DNA breaks and regions of single stranded DNA. In the cell cycle analysis (Chapter 
4), highly dysregulated profiles for parental ES-2 on treatment with AZD1775 were 
observed. These profiles showed an abnormal S-phase with no clear transition between 
S and G2 phases and continued replication in the absence of cell division. While, in 
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stark contrast, AZD1775 resistant ES-2 clones show normal profiles with lower 
number of cells in S-phase. This indicates that that the resistant cells are able to 
overcome the detrimental effects of Wee1 kinase inhibition on S-phase. It can be 
inferred from these results that the resistance to AZD1775 in ES-2 clones could be due 
to the ability of the cells to overcome the effects of AZD1775 in rushing cells through 
the S-phase.   
The cell doubling times for AZD1775 resistant clones (Chapter 4) also support 
the idea that slower cell cycles in resistant clones enable them to overcome the effects 
of Wee1 kinase inhibition. The role of reduced levels of Cdk1 in slower growth has 
been discussed above (7.3.2.4.).  Another example in support of my argument comes 
from the western blotting for the mitotic marker phosphorylated histone H3 (Chapter 
5). This mitotic marker was highly elevated in both AZD1775 treated parental lines, 
reflecting the role of AZD1775 in preventing G2 arrest and leading to premature 
mitosis. While levels of the mitotic marker were much reduced in both ES-2 and 
OVCAR8 AZD1775 treated clones, again suggesting that slowing the cell cycle could 
be an important component of the resistance mechanism.  
A key prediction of the model for resistance is that resistant clones should show 
lower levels of replication associated DNA damage when treated with AZD1775 than 
similarly treated parental cells. Western blotting in Chapter 5 provided strong support 
for the model. Compared to the ES-2 parent, all AZD1775 resistant ES-2 clones 
showed a much reduced level of the chromatin marker for double strand DNA breaks, 
H2AX, and of activated DNA-PK, involved in the repair of ds DNA breaks by NHEJ. 
Levels of activated RPA, a marker for regions of single stranded DNA (Vassin et al., 
2009), and of DNA damage response proteins ATM and CHK2, were much lower in 
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all ES-2 treated clones and lower in most OVCAR8 treated clones than the treated 
parents. 
Although the reduced levels of these DNA repair and DNA damage response 
proteins provide support for the model that resistant clones have lower levels of 
replication associated DNA damage, further work to study DNA replication itself in 
resistant clones would be necessary to confirm the model. Further support for my 
model comes from the report that DNA damage caused by Wee1 silencing is reduced 
when cells are treated with Cdk inhibitor roscovotine (Beck et al., 2010). 
7.3.4. Involvement in resistance of changes in other pathways  
7.3.4.1. Src family member Lyn 
One interesting finding in the analysis was reduced activity and expression of 
Src-family tyrosine kinases, particularly Lyn, in resistant clones.  Could the reduced 
level of Lyn be involved in resistance to AZD1775? Src inhibitors have been reported 
to lead to prolonged G2/M arrest (Fukumoto et al.,   2014). Although the mechanism 
is unclear, reduction in activity/expression of Lyn could be another possible route to a 
slower cell cycle and so to resistance to AZD1775. This could be tested by 
overexpressing Lyn in resistant clones and observing whether resistance was 
overcome. 
7.3.4.2. Expression of many genes is altered in resistant clones 
More than 1000 genes showed >2 fold alterations in expression between ES-2 
clones resistant to 1000nM AZD1775 and the ES-2 parent. Whereas, OVCAR8 clones 
resistant to 300nM AZD1775, which had only been through a single round of selection, 
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showed less than 500 expression alterations of the same magnitude. The cellular stress 
associated with prolonged exposure to AZD1775, particularly on DNA replication, 
could result in a number of epigenetic and genetic alterations in gene expression. Some 
of the many changes actually observed involve genes encoding transcription factors or 
proteins involved in chromatin biology, which could then lead to altered expression of 
large numbers of genes as observed in the resistant clones. If some of this large number 
of random gene expression changes occurred in pathways favouring survival in the 
presence of AZD1775 then the cells with these changes, together with the many other 
neutral changes, would be selected for. 
7.3.5 AZD1775 resistance summary 
In conclusion, AZD1775 resistant clones had the following changes that could 
be contributing to resistance in ES-2 and/or OVCAR8 derived resistant clones (Figure 
7.3).  
 Increased Wee1 kinase expression in OVCAR8 derived clones 
 Increased expression of PKMYT1 in OVCAR8 derived clones 
 Altered expression of cell cycle control pathway genes 
 Reduced expression of total Cdk1 in ES-2 clones 
 Reduced expression of Cdc25 in ES-2 and some OVCAR8 derived clones 
 Reduced DNA damage in ES-2 and OVCAR8 derived clones 
 A slower cell cycle 
 Upregulated TGFβ, TNF and NF-B signalling in some of the ES-2 and 
OVCAR8 derived clones 
 





















Figure 7.3: AZD1775 resistance mechanisms operating in ES-2 and OVCAR8 derived 
clones. Based on Figure 1.9 which showed postulated numbered mechanisms of resistance to 
AZD1775 to be investigated as aims of the thesis. The numbering is continued for additional 
changes in the resistant clones that were identified during the course of the thesis. A tick 
indicates a change that was observed. A cross indicates a change that was not seen. Pink ticks 
and crosses are for presence or absence of a change in ES-2 clones, blue ticks and crosses for 
OVCAR8 clones.  Where a tick and cross are superimposed, the change was not found in all 
the resistant clones from that cell line.  
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7.4. Overcoming resistance to AZD1775 
Most of the above mentioned changes that contribute to the slower growth rate 
of the resistant cells that I believe is essential for survival, involve increased or 
decreased expression of many genes in the cell cycle control pathway. It was not 
feasible in the time available to attempt to overcome resistance to AZD1775 by 
individually restoring the expression of these individual genes to the parental level. 
Instead I focussed on pathways apparently upregulated in resistant cells to investigate 
whether resistance could be overcome by inhibiting these pathways. These pathways 
were TGFβ signalling into the cell cycle control pathway and the linked TNF and NF-
B pathway that promotes survival and proliferation over apoptosis. 
One of the inhibitors used, a TGFβR1 inhibitor, showed a striking difference in 
IC50 values between one of the 1000nM AZD1775 resistant clones and parental ES-2 
cells. ES-2 AZ_1000:2_250:3, the resistant clone with the highest expression of the 
TGFβR1 receptor, was twenty times more sensitive to the inhibitor than parent ES-2 
cells.  
7.5. Limitations of the project 
In hindsight, if there were no financial or time constraints, I would have done 
the following things differently;  
1. I would have used one of the two sensitivity assays to analyse 
sensitivity of the cell lines. Either only SRB for continuous and sequential exposure or 
Alamar blue for both conditions because using two different assays makes it difficult 
to compare sensitivities for two different treatment methods.   
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2. I would have generated resistant clones from more HR+ and HR- cell 
lines. This would help to clarify whether the differences observed from protein and 
RNA analysis were due to their different HR status or simply because these are two 
genetically different cell lines.   
3. I would have used the same loading controls for all western blot assays 
to reduce variability.  
4. I would have used more clones to study the differences by both western 
blotting and RNA sequencing.   
7.6. Future prospects 
TGFβ pathway has been targeted through the administration of small-molecule 
inhibitors of the kinase domains and soluble-protein or antisense-compound 
inhibitors (Fisher Colbrie et al., 1997). TGFβ is one of the main inducers of EMT in 
vitro and in vivo and is known to induce EMT in ovarian adenosarcoma 
cells (Kitagawa et al., 1996), mouse NMuMG breast epithelial tumour cells (Piek et 
al., 1999) and human lung adenocarcinoma cell line A549 (Keshamouni et al., 2006). 
Also, interestingly, TGFβ blocking led to impaired tumour growth with a decrease in 
cell proliferation and angiogenesis in ovarian carcinoma models. It also almost 
completely stopped ascites formation (Liao et al., 2011). Similarly, Repsox (TGFβR1 
inhibitor) has also been shown to prevent seizures (Weissberg et al., 2015) making 
TGF signalling a good target for therapeutic intervention for epilepsy. 
Going forward, it would be important to see how effective RepSox is in 
overcoming AZD1775 resistance in the rest of the many resistant ES-2 and OVCAR8 
clones that were isolated. The strong result observed for the TGFβR1 inhibitor needs 
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to be validated in more clones for it to be translated into clinic. The importance of the 
individual expression/activity differences that I believe are contributing to resistance 
could be dissected by introducing constructs into resistant clones to increase or silence 
the expression of individual genes in the cell cycle control and DNA damage response 
pathway and determine their effect on resistance to AZD1775. 
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Appendix Table 1: Mutations in genes commonly mutated in cancers that are found in the HGSOC cell line panel.  The table displays mutation 
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Appendix Figure 1: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 
1000nM AZD1775. Untreated parent cell line ES-2, resistant clones ES-2 AZ_1000:4_250:7, 
ES-2 AZ_1000:1_250:3, ES-2 AZ_1000:3_250:3, ES-2 AZ_1000:4_250:3, ES-2 
AZ_1000:6_250:3 and ES-2 AZ_1000:8_250:3, and cell lines treated for 24 hours with 
1000nM AZD1775, were fixed and stained with propidium iodide to display their DNA 
content and so their cell cycle status. Intensity of propidium iodide staining (DNA content) on 
the x axis, frequency (count) on the y axis. The percentage of cells with sub G1, G1, S, G2/M, 
and >4n DNA content, is indicated across the top of each profile. Sample cell number counts: 
highest, 20,000; lowest, 2,800. ES-2 cells treated for 24 hours with 1000nM AZD1775 show 
an abnormal profile, while resistant clones appear normal. 
 
 






















Appendix Figure 2: Cell cycle analysis by flow cytometry of ES-2 clones resistant to 
800nM CDDP and 100nM AZD1775. Untreated parent cell line ES-2, resistant clones ES-2 
AZ_100_CP800:1 and ES-2 AZ_100_CP800:4, and cell lines treated for 72 hours with 250nM 
AZD1775, were fixed and stained with propidium iodide to display their DNA content and so 
their cell cycle status. Intensity of propidium iodide staining (DNA content) on the x axis, 
frequency (count) on the y axis. The percentage of cells with sub G1, G1, S, G2/M, and >4n 
DNA content, is indicated across the top of each profile. Sample cell number counts: highest, 
20,000; lowest, 5,000. ES-2 cells treated for 72 hours with 250nM AZD1775 show an 



































Appendix Figure 3: Quality control steps for RNASeq experiment 1 (ES-2). The figure 
shows reports for (A) total reads, (B) exon mapping rate, (C) count density and (D) principal 
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Appendix Figure 4: Quality control steps for RNASeq experiment 2 (OVCAR8). The 
figure shows reports for (A) total reads, (B) exon mapping rate, (C) count density and (D) 
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principal component analysis. For A and B, the quality threshold level is indicated by the 
dashed vertical lines. Note the single failed sample in (B). 
 











SMAD3 THBS1 SEP4 IL21R-AS1 E2F2 
CDC6 SMURF2 CTSV ZNRF2P2 TGFB3 
TP53 SMAD3 CTSS CAMLG E2F1 
ANAPC11 AMH CASP10 MED7 MCM6 
TGFB1 TGFB1 TUBA8 DAPK3 TP53 
TTK TGFBR1 TUBA4A LINC01585 TGFB2 
CDKN2B CDKN2B BIRC3 AC113192.2 CDK6 
ORC4 ROCK1 TP53AIP1 ZNF233 GADD45A 
HDAC2 TGFB2 CTSF SMIM27 CCNE1 
TGFB2 MAPK3 NGF GLIPR1L2 CDKN1A 
SMAD4 SMAD4 TNF HMGN2P17 ABL1 
MCM6 BMPR2 TUBA1A PACSIN1 WEE1 
MCM3 LTBP1 TUBAL3 SOD2 MDM2 
ORC3 ID2 CTSB NCCRP1 MCM5 
GADD45B BAMBI NFKBIA AC134772.1 CDKN1C 
CDKN1A BMP4 TNFSF10 LINC00630 CCNE2 
ATM SMAD7 MAP3K14 SLC5A8 PKMYT1 
CDKN2C NOG EIF2AK3 RN7SL107P SMAD3 
E2F2 SMAD2 IL3 CD24 RBL2 
SMAD2 TGFB3 TP53 KRT18P31 E2F3 
TGFB3 ACVR1C TRAF1 AC009065.5 MCM3 
CCNB3 DCN PIK3R2 CCDC9B CDC45 
CDC14B MINOS1-NBL1 APAF1 AL645568.1 MCM2 
WEE2 GDF5 ITPR2 RNU6-1016P PCNA 
GADD45G INHBB CFLAR CRAMP1 GSK3B 
CCND2 LEFTY2 PRF1 AC116535.1 ORC1 
CDKN1C TNF PIDD1 ARPC4-TTLL3 BUB3 
RB1 INHBC MAP3K5 KRR1 MYC 
CDC27 GDF7 CTSD ATF6 ORC5 
SFN ID4 HRK ZC3H7B CDC16 
ORC2 BMP5 ERN1 RPL38P3 YWHAB 
CCNA1 AMHR2 IKBKB CYYR1-AS1 SMC1B 
CDK6 BMP7 AKT3 TLK1 CDKN2C 
E2F3 BMP8A GADD45B DCAF17 CDKN1B 
ESPL1 GDF6 CTSH IPP CDC6 
CCNE1 BMP8B MAPK3 AC005632.2 MCM7 
Appendix                                                                                                                               258 
 
RBL1 LEFTY1 CTSO AL138689.1 ANAPC2 
CHEK2 ACVR1B PIK3CD NETO2 ANAPC5 
WEE1 EP300 FOS CYP4F30P TFDP1 
CDKN2D CHRD ITPR3 RIC8A TFDP2 
GSK3B BMP6 HTRA2 VWA5B1 SMAD4 
RBL2 ACVR2A TNFRSF10B PRDM14 CREBBP 
E2F1 BMPR1B TRADD AF131216.1 RB1 
CDC45 SMAD6 BAD CDC25B E2F4 
ATR SMURF1 ATM AL596257.1 STAG2 
ORC1 PITX2 SPTAN1 AC104966.1 ORC3 
CDC25C PPP2R1B RIPK1 ISCA2 ORC6 
CCND3 SMAD9 MAPK10 ENTPD7 CDC7 
BUB1B NBL1 ITPR1 AC007422.2 CDK4 
CDKN1B RBL1 CASP2 HNRNPA1P66 STAG1 
CHEK1 ACVR1 CASP9 SNORD71 YWHAE 
STAG1 ACVR2B FASLG SLC27A6 CDC25A 
ORC5 SMAD1 BIRC2 HSPA1L YWHAH 
CDC16 INHBE PARP2 FUT2 SMAD2 
CDC7 TGIF2 DIABLO AC116158.2 ATM 
TFDP2 ZFYVE16 CTSZ MKRN9P MCM4 
CDK2 RPS6KB1 PTPN13 RN7SL716P ANAPC4 
CDC23 CUL1 BID AL138756.1 CDC14B 
CREBBP SP1 CTSW AC211486.2 ANAPC1 
MDM2 RPS6KB2 RELA AC024257.1 SKP2 
E2F5 PPP2CB FADD SNCB CDK2 
CCNE2 CREBBP BCL2 CAPN10-AS1 ZBTB17 
CDC26 E2F5 CASP8 LINC00934 BUB1B 
BUB1 ZFYVE9 CAPN1 GMCL1 ANAPC11 
CDKN2A BMP2 FAS IFIT2 RBL1 
DBF4 BMPR1A BIRC5 AL445363.1 SMC3 
CDC25B SMAD5 CAPN2 PARN YWHAG 
FZR1 MAPK1 PIK3CB AP003392.6 CDC23 
CDC25A INHBA CASP6 PDGFD CHEK2 
RBX1 TGFBR2 TNFRSF10A ILVBL HDAC2 
CCNH RBX1 MAP2K2 LMLN2 MAD1L1 
STAG2 PPP2R1A PDPK1 LILRB3 CDK7 
HDAC1 ID3 PIK3CA LINC01514 ANAPC7 
SKP2 TGIF1 AIFM1 ZNF812P CHEK1 
CCND1 ID1 MAP2K1 CEP135 PRKDC 
ABL1 E2F4 MAPK1 SEC61G RBX1 
CDK7 PPP2CA PIK3R3 POLR2KP1 CDKN2A 
MCM2 TFDP1 TNFRSF1A ZNF37CP TTK 
GADD45A MYC XIAP AL391840.1 MAD2L2 
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CCNA2 RHOA PARP4 INAVA ORC2 
SMC1A SKP1 DAB2IP ABCC13 CDC27 
PRKDC FST DAXX AC013731.1 ATR 
ORC6 
 
PARP1 GAS7 CDC20 
PLK1 
 
GADD45A ZNF705E CCND3 
CCNB2 
 
BCL2L1 MXI1 CCNB2 
SMC3 
 
BAX AC005339.1 FZR1 
E2F4 
 
MAPK9 MIR3132 HDAC1 
TFDP1 
 
ACTG1 MIR1-1HG CDK1 
MCM5 
 
BCL2L11 AC098818.2 DBF4 
MAD2L1 
 
PIK3R1 PDCL3 TGFB1 
MYC 
 
DFFA PFN1P1 ESPL1 
RAD21 
 
CTSL HEXIM2 RAD21 
MCM7 
 
EIF2S1 RPS26P21 CCNH 
CDK4 
 
PMAIP1 SMARCAL1 CUL1 
MCM4 
 
JUN CCNT2-AS1 BUB1B 
PCNA 
 
AKT1 FN3K CDC25B 
SKP1 
 
CASP7 GCNT3 SKP1 
CDK1 
 
AKT2 ERI2 ANAPC10  
PTTG1 
 
KRAS C1D GADD45B 
CDC20 
 















































































































Appendix table 3: Gene lists supporting Figure 6.7 (A and B) 
ES-2 AZ_1000:2_250:3 ES-2 AZ_1000:2_250:7 
Gene Pathway Gen Pathway 



















































PLAU NF-B COL4A2 
NFKBIA COL5A1 




















INHBE TGF EIF4EBP1 
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  MMP2 
  PTGER4 
  BCL2A1 
  CEBPB 
  COMMD3-BMI1 
  JMJD1C 
  MMP3 
  NUPR1 
  PPARG 
  TFE3 
  HBEGF ERRB 
   SRC 















  ELK1 
  FGF1 
  FGF2 
  GNG10 
  GNG4 
  KITLG 
  MAPK8 
  NGFR 
  PAK3 
  PDGFC 
  PLCE1 
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  RASAL2  
 
 
  RASGRF2 
  RASSF1 
  VEGFC 




















  CAMK2G 
  DKK1 
  FRAT2 
  NFATC4 
  PPP3CB 
  PRICKLE1 
  SIAH1 
  WNT5B 
  CAMK2G 
  DKK1 
  FRAT2 
  NFATC4 
  PPP3CB 
  PRICKLE1 
  SIAH1 
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Appendix table 4: Gene lists supporting Figure 6.7 (C-E) 
OVCAR8 AZ_300:2 OVCAR8 AZ_300:3 OVCAR8 AZ_300:4  






 CCL20 BIRC3 SGK1 
IL1A CCL20 FGF2 
IL6 CXCL1 LAMC2 
CXCL1 CXCL2 EPAS1 Transcriptional 
misregulation 
in cancer 
EDN1 CXCL3 SLC2A1 
BIRC3 EDN1 MMP1 














NFKBIA BCL2A1 NF-B 
  
RELB CXCL8 
  
NFKB1 NFKB1 
  
HMGA2 Transcriptional 
misregulation 
in cancer 
NFKBIA 
  
PAX8 RELB 
  
NFKBIZ TRIM25 
  
MEF2C HMGA2 Transcriptiona
l 
misregulation 
in cancer 
  
  
NFKBIZ 
  
  
PAX8 
  
  
MEF2C 
  
 
 
 
 
 
 
 
 
